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Cancer immunotherapy has emerged as an effective treatment to provide benefits to cancer 
patients. One of the main treatment modalities of cancer immunotherapy is the adoptive 
transfer of T cells with genetically engineered receptors known as chimeric antigen receptor 
(CAR), which has recently emerged as a promising approach for haematological cancers. 
Although some success has been achieved in treating leukaemia, treatment of solid tumours by 
this approach is limited mainly due to poor infiltration of cancer targeting lymphocytes and 
their inhibition by immunosuppressive tumour microenvironment (TME) created by hypoxia, 
low pH, and immunosuppressive metabolites within solid tumours. 
In this thesis, we attempted to exploit immunosuppressive metabolites (e.g. adenosine and low 
pH) in solid TME to reduce their suppressive effect on T cells by designing chimeric receptors 
with CXCR3 signalling domain fused to the extracellular metabolite sensing receptor. 
Functionality of these chimeric receptors were assessed using calcium flux assay, ERK 
phosphorylation assay and migration assays. While the assays were effective at assessing signal 
transduction via non-modified CXCR3 in response to the cognate ligand, CXCL11, signalling 
via chimeric receptors was not detected in the presence of respective stimuli. 
Immunosuppressive molecules in TME also activate protein kinase A (PKA) in T cells which 
results in the localization of the PKA regulatory subunit 1A (PRKAR1A) to the immune 
synapse inhibiting several central proteins involved in the T-cell signalling cascade and leading 
to T cell inactivation. While research have targeted PRKAR1A using peptides to supress its 
activity, we used a different approach by overexpressing microRNAs (miRNAs) to 
downregulate PRKAR1A expression. Overexpression of either miR96/183 or miR155 
significantly downregulated PRKAR1A expression in HEK293 cells at both mRNA and 
protein level. We further validated PRKAR1A 3' UTR as a direct target of both miRNAs using 
luciferase assay. Additionally, miR96/183 and miR155 were found to target other inhibitory 
proteins of TCR signalling such as TET2, FOXO3 and PTPN2 which might have additional 
advantage to enhance T cell activation. Consistently, overexpression of miRNA96/183 
enhanced IL-2 production while overexpression of miR155 enhanced both IL-2 production and 
CD69 expression on Jurkat T cells following anti-CD3/CD28 stimulation compared to controls 
with normal expression of respective microRNAs. 
II 
 
We revisited the tetracycline-inducible sleeping beauty system to expand miRNA 
overexpression approach in CAR T cell therapy and generated a vector to induce 
miRNA/coding gene overexpression in the presence of tetracycline while constitutively 
expressing second generation HER2 CAR. To study the effect of miRNA overexpression in 
HER2 CAR in primary human T cells, a third-generation lentiviral system was also optimised 
by exploring both single and dual promoter systems to co-express non-coding (miRNA) and 
coding genes (HER2-CAR and GFP) from the same vector. Although cytokine production (IL-
2 and IFN-γ) and CD69 expression were similar between HER2 CAR±miRNA transduced T 
cells when co-cultured with HER2 positive MCF-7 cells, the profile of phenotypic marker 
expression was different.  
Overall, this thesis demonstrates that the miRNA overexpression in T cells could be a useful 
approach to combat intrinsic inhibitory molecules. The modified sleeping beauty vector and 
the lentiviral vectors developed in this study can be utilized to combine CAR T cell therapy 
with other approaches to enhance the efficacy of the treatment in cancer immunotherapy. 
Therefore, this thesis provides useful resource for the development of various strategies in 
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Chapter 1: Introduction 
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1.1 The immune system and T cells  
The immune system comprises of a complex network of cells that are involved in conferring 
innate or adaptive immune response against invading pathogen, toxin or allergens that bypass 
the structural (skin and mucous membrane) and chemical barriers [1]. Innate immune response 
is the primary response of the body and comprises of rapidly responding cells such as myeloid 
cells (macrophages and neutrophils), dendritic cells (DCs), natural killer (NK) cells that rely 
on pattern recognition receptors (PRR) to sense pathogen associated molecular patterns 
(PAMPS) on the invading pathogen.  This recognition induces release of inflammatory 
cytokines such as tumour necrosis factor, interleukins (IL) and chemokines which result in the 
recruitment of other innate immune cells to the sites of infection [2]. Some innate cells such as 
macrophages, neutrophils, and DCs can phagocytose microbes and kill them using bactericidal 
pathways [3]. Additionally, these cells are also involved in activating adaptive immune 
response by acting as an antigen presenting cells (APCs) following lysis of foreign pathogen. 
APC expresses cell surface glycoproteins that bind and display processed fragments of antigen 
or peptides on the major histocompatibility complex (MHC) or human leukocyte associated 
antigen (HLA) in class I (MHC I) or class II (MHC II) molecule [4]. The slower adaptive 
immune system involves recognition of antigens by specific cell surface receptors expressed 
on T cells and B cells. B cells recognise antigen through unique antibody expressed on their 
surface and with the appropriate signals, differentiate into antibody-producing plasma cells. 
CD4 T helper cells (discussed below) and key cytokines are normally required for B cells to 
mature to plasma cells. Other 'innate-like' B cells termed B1 B cells can form plasma cells 
when antigen is recognised in the context of TLR signalling. Antibodies bind to the soluble or 
membrane bound antigens, or flag microbes for destruction by complement activation, as well 
as promote phagocytosis by neutrophils and macrophages [5].  
T cells are derived from hematopoietic stem cells in bone marrow and migrate to thymus for 
maturation. In thymus, precursor T cells, called thymocytes, undergo rigorous selection process 
to detect and eliminate thymocytes possessing strong T cell receptor (TCR) with high affinity 
to MHC bound to self-peptide in order to avoid autoimmune responses [6]. A mature T cell 
expresses a single type of TCR following an extensive V (variable), D (diversity) and J 
(joining) gene segments recombination during the selection process against a specific antigen 
and consists of either α and β (in αβ TCR) or γ and δ (in γδ TCR) chains [7]. T cells are abundant 
in peripheral blood, lymph node, tissues and majority of T cells use α β TCR (90-95%). The 
bulk T cell compartment is further classified into helper CD4 and cytotoxic CD8 T cells based 
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on the expression of the co-receptor, CD4 or CD8 [8]. During T cell activation, the CD4 and 
CD8 co-receptor interacts with MHC class II molecule and MHC class I molecule, respectively 
(Figure 1.1). 
 
Figure 1.1 MHC antigen presentation and T cell activation. MHC class I and II are highly 
polymorphic molecule expressed on APCs which presents the antigen to the TCR. During T cell 
activation, MHC molecule interacts with the TCR along with other T cell co-receptors CD4 or CD8; 
MHC II interacts with the CD4 co-receptor molecules whereas MHC class I molecule liaise with CD8 
co-receptor. Following activation, CD4 T cells predominantly produce cytokines such as IL-2, IL-4 and 
IFN-γ which supports function of other immune cells, while CD8 T cells mainly produce cytotoxic 
molecules such as granzymes and perforin and kill the infected cells. 
The interaction of TCR and MHC-antigen complex causes signal transduction by stimulating 
CD3 complex (consisting of CD3γε heterodimer, CD3δε heterodimer and CD3ζ homodimer) 
resulting in partial activation of T cells. The interaction between co-stimulatory molecule, 
CD28 on T cells and CD80 (B7.1) or CD86 (B7.2) on APC causes full activation of T cells [9]. 
Following the TCR interaction, the immunoreceptor tyrosine based activation motifs (ITAM) 
in the cytoplasmic portion of CD3 are phosphorylated by the kinases; Src family protein 
tyrosine kinases (PTK), LCK and FYN which then recruits Syc-family kinase ζ-associated 
protein ZAP-70 via its SH2 domains that binds to phospho-tyrosine residues in the ITAM [10]. 
ZAP-70 phosphorylation leads to recruitment of adaptors (linker for the activation of T cells 
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(LAT) and SH2 containing leukocyte phosphoprotein of 76 kDa (SLP-76)) and 
phosphorylation/activation of other proteins (phospho lipase C γ1 (PLC γ1), protein kinase C 
(PKC), mitogen associated protein kinases (MAPK) including ERK, NFκB, NFAT and AP-1) 
leading to secretion of cytokines, T cell proliferation and differentiation (Figure 1.2) [11, 12]. 
Helper CD4 T cells gain the potential of helping various immune cells via cytokine secretion 
such as IL-2, IL-4 and IFN-γ whereas cytotoxic CD8 T cells express cytotoxic granules such 
as perforin and granzymes that can lyse the infected cells (Figure 1.1) [13]. 
 
Figure 1.2 TCR signaling. Recognition of the MHC-peptide complex by the TCR triggers CD3 
complex stimulation. This initiates the phosphorylation of ITAM in the cytoplasmic portion of CD3 by 
the kinases namely PTK, LCK and FYN leading to the recruitment of Syc-family kinase ζ-associated 
protein ZAP-70. Phosphorylated ZAP-70 further recruits LAT and SLP-76 which results into a cascade 
of phosphorylation/activation of PLC γ1, PKC, ERK and activation of nuclear transcription factors 
NFκB, NFAT and AP-1. 
After a period of activation, most T cells (~90%) form or develop effector function and 
eventually undergo apoptosis while a subset of antigen stimulated T cells differentiate into long 
lived memory cells [14]. Naïve and antigen experienced T cells can be differentiated based on 
the expression of different isoform of CD45, a major leukocyte transmembrane protein-
tyrosine phosphatase present on the surface of leukocytes. Naïve cells express high molecular 
weight isoform, CD45RA while memory cells lose expression of this exon to form low 
- 5 - 
 
molecular weight isoform, CD45RO through alternative splicing [15]. Memory cells can be 
further classified into effector memory (TEM) and central memory (TCM) based on the 
differential expression of CD62L (L-selectin); which is required for extravasation of cells from 
endothelial venules to  secondary lymphoid organs such as spleen and tonsils, and chemokine 
receptor 7, CCR7; a lymph node homing receptor [16]. High expression of CD62L/CCR7 in 
TCM facilitates homing to secondary lymphoid organs while TEM expressing low 
CD62L/CCR7 produce effector molecules (e.g. IFN-γ, IL-4, perforin and granzyme) and 
express integrins and chemokine receptors necessary for localisation to inflamed tissues [17, 
18]. However, memory T cells may not be confined to only CD45RO positive T cell 
compartment but may also be present in the CD45RA T cell compartment expressing CD27 
and exhibiting CD44lowCD62Lhigh phenotype which also co-express high amount of stem cell 
antigen-1 (SCA-1), the memory marker interleukin-2 receptor β (IL-2Rβ), CD95 (Apo-1/Fas 
receptor), CCR7, chemokine C-X-C motif receptor 3 (CXCR3) and are called stem memory T 
cells (TSCM) [19, 20]. TSCM cells demonstrate stem cell-like ability to self-renew and the 
multipotent capacity to differentiate into any memory and effector T cell subset [21]. Similarly, 
TEM cells that re-expresses CD45RA can be divided into terminally differentiated effector 
memory cells (TEMRA) which is characterised by decreased expression of CD27/CD28 and 
increased expression of CD57 and effector molecules such as perforins and granzyme B [22, 
23]. 
1.2 Cancer  
Cancers are caused by abnormal cell growth resulting from altered gene expression. The major 
hallmarks of cancer are classified as sustaining proliferative signaling, evading growth 
suppressors, activating invasion and metastasis, enabling replicative immortality, inducing 
angiogenesis, and resisting cell death. Recently, two general hallmarks have been added to the 
list: manipulation/reprogramming of energy metabolism and evading immune destruction [24]. 
Cancer is the second leading cause of death globally, with 18.1 million new cases and 9.6 
million deaths in 2018. According to International agency for research on cancer (IARC, 2018), 
the most common types of cancer in men are lung, prostate, colorectal, stomach and liver cancer 
while in women the most common are breast, colorectal, lung, cervical and thyroid cancer. 
Cancers may be treated with traditional methods such as surgery, chemotherapy, or radiation 
therapy. Approaches that physically or chemically remove the tumour bulk may still leave 
traces of tumour cells. Surgical excision induces the post-operative wound healing that can 
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stimulate the growth and metastasis of the primary tumour [25]. Although the methods of 
chemotherapy and radiation therapy has been improved lately, these are still associated with 
side effects mainly, being the damage of healthy tissues and tend to induce tolerance as well as 
recurrence of tumour cells [26-29]. 
Immunotherapy has emerged as a new avenue of cancer therapy and as a promising and 
potentially safer method compared to other traditional treatments [30]. Additionally, a better 
understanding of the organization of complexity of cancer, its traits and hallmarks in recent 
years has opened new doors for the development of more effective anti-cancer therapies [24].  
1.3 Solid tumour and tumour microenvironment 
Cancer arises either in hematopoietic compartment leading to haematological tumours 
involving blood cells such as lymphoma or leukemia, or tissues other than haematological 
systems leading to localised solid tumours such as breast cancer, pancreatic cancer. Compared 
to haematological cancers, solid tumours exhibit additional complexity due to the presence of 
both malignant and infiltrating non-transformed cells. The interaction between these cells 
creates the tumour microenvironment (TME), an associated trait of solid tumours, that aids 
tumour growth and/or protects cancer cells from immune attack (Figure 1.3) [24]. During 
tumour development, cancer and other infiltrating cells have limited access to nutrients and 
oxygen because of which a permanent or transient hypoxic regions is established around solid 
tumours  [31]. Hypoxic TME is immunosuppressive and it protects the tumour cells from the 
infiltrating immune  cells and limits the efficacy of immunotherapies [32]. On top of this, 
cancer cells as well as stromal cells in the TME display enhanced glycolysis (Warburg effect) 
resulting lactic acid accumulation which contributes to low pH in the TME and further impedes 
the function of immune cells [33, 34]. The non-transformed cells in the tumour 
microenvironment which are cancer associated fibroblast (CAFs), adipocytes, endothelial cells, 
pericytes composing tumour vascularate, immune and inflammatory cells, bone marrow 
derived cells and the extracellular matrix (ECM) also play a key role in tumour progression 
directly or indirectly [35, 36]. For example, cells of the immune system such as lymphocytes, 
NK cells and natural killer T (NKT) cells in TME, which fail to destroy tumour because of 
immunosuppression posed by different factors of TME, help in tumourigenesis [37, 38].  The 
immune cells are supressed by T regulatory cells (Tregs) present at the TME via the production 
of IL-10 and transforming growth factor beta (TGFβ) around TME [39]. Also, the antigen 
presenting cells in TME e.g. DCs are impaired and may suppress T cell function [40]. Tumour 
- 7 - 
 
associated macrophages (TAMs) which are abundant in the TM can contribute to tumour 
angiogenesis and play important role in migration, invasion as well as metastases of malignant 
cells [41]. Some tumours exhibit dense cancer associated fibroblasts (CAFs) that surround the 
malignant cells restricting the infiltration of anti-cancer immune cells or the delivery of drugs 
to the target malignant cell [42]. Hypoxia in the TME leads to accumulation of 
immunosuppressive molecules such as adenosine, prostaglandin that directly act on tumour 
cells to promote their growth and survival [43], as well as suppress activation of T cells [44]. 
Unlike the immunotherapy of lymphoma and leukemia which have shown satisfactory clinical 
outcomes, the treatment of solid tumours have been disappointing presumably due to the 
restrictions posed by the immunosuppressive TME. However, common features such as 
hypoxia and low pH can be found in TME of many types of tumour and recent studies have 
been carried out to explore and target components of the tumour microenvironment to enhance 
cancer immunotherapy [45]. Alternatively, various strategies to armor immune cells against 
the hostile TME to enhance the efficacy of immunotherapy approaches is also widespread and 
are discussed in next section [46].  
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Figure 1.3 A schematic diagram of the tumour microenvironment and its components.  Established 
tumours are surrounded by a wide array of stromal cells (e.g. CAFs, endothelial cells, pericytes) and 
infiltrating immune cells (e.g. Tumour associated macrophages; TAM, dendritic cells, lymphocytes) 
which eventually creates immunosuppressive tumour microenvironment that enables cancer cells to 
establish and evade immune surveillance and destruction. 
1.4 Immunotherapy 
The role of the immune system in cancer regression was evident as early as 18th century but 
there was no scientific evidence to support it. A series of procedures performed in the mid-18th 
to late-19th century using bacterial toxins for cancer treatment shed some light on the ability of 
the body to fight cancer [47, 48]. William B. Coley, the retrospective father of immunotherapy 
was an orthopaedic surgeon who observed that some patients with postoperative wound 
infection exhibited regression of their unresected tumours. He developed a cocktail of live and 
inactivated bacteria, called Coley’s toxin and succeeded in achieving durable remission of 
several types of malignancies [48]. However, the risk of septicaemia in patients injected with 
Coley’s toxin and lack of mechanistic explanation for Coley’s toxin mediated tumour 
regression diverted oncologists to implement surgery or radiotherapy as an alternative 
treatment [49]. 
The concept of immunosurveillance emerged in 1957 suggesting the significance of 
lymphocytes in identifying and eliminating cancerous somatic cells, but there was insufficient 
evidence on the existence of tumour associated antigens [50]. With the identification of 
Interleukin 2 (IL-2) in 1976, in vitro culture of T cells became possible and this led to studies 
involving infusion of high dose of recombinant IL-2 together with adoptive transfer of tumour 
infiltrating lymphocytes (TILs) or lymphokine activated killer cells (LAKs) to treat patients 
with metastatic melanoma and renal cell cancer [51, 52]. Among many cytokines, interferon 
(IFN) alpha (IFN-α) was the first to be approved by the US food and drug administration (FDA) 
to treat hairy cell leukemia in 1986. Subsequently, the use of IL-2 as an immunotherapeutic 
agent was approved by FDA to treat renal cell cancer in 1991 and metastatic melanoma in 1998 
which drew further attraction to cytokine therapy. Various cytokines such as Granulocyte-
macrophage colony stimulating factors (GMCSF), IL12, IL15 and IL21 were evaluated 
clinically, whereas some are still part of the investigation [53].  
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1.4.1 Antibody therapy 
The use of antibody for infectious diseases began in the late 18th century with the discovery of 
sheep antiserum being useful against diphtheria toxin infection [54]. The use of antitoxins 
against tetanus and botulism is still common now [55]. Later the development of antibody 
secreting hybridoma [56] and phage display technology helped boost the antibody based 
therapeutic approaches. Antibodies kill or inhibit tumour development either by targeting 
specific components such as growth factor receptors (e.g. human epidermal growth factor 
receptor; EGFR2) or by activating death receptor pathway following binding [57, 58]. 
Monoclonal antibodies (MAbs) have become popular following the FDA approval of 
muromonab-CD3 developed to treat kidney allograft rejection in 1986 [59]. Several humanized 
MAbs have been approved recently by FDA to target and kill cancer cells. VEGF inhibitors 
such as bevacizumab that binds to VEGF receptor on cancer cells inhibiting the formation and 
growth of blood vessels in tumour have been approved by FDA for the treatment of metastatic 
tumours (e.g. metastatic renal cell carcinoma or metastatic colorectal cancer) [60]. Similarly, 
rituximab binds to surface CD20 on immature malignant B cells facilitating their elimination 
by complement mediated destruction and phagocytosis and was approved by FDA in 1997 for 
the treatment of non-Hodgkin’s lymphoma and lymphocytic leukemia [61]. 
Herceptin/Trastuzumab MAb used in treatment of patients with human epidermal growth factor 
receptor 2 (HER2) positive breast cancer and metastatic gastrointestinal cancers, binds to 
EGFR2/HER2 ectodomain (p185HER2) blocking its activity and facilitating destruction of 
cancer cells by the immune systems [62]. 
MAbs have also been employed to deliver radioisotopes to cancer cells to study the extent of 
cancer metastasis. Also, MAbs such as rituximab together with yttrium 90 labelled 
ibritumomab tiuxetan when used in patients with previously treated non-Hodgkin’s lymphoma 
demonstrated durable treatment response [63-65]. New therapeutic combinations involving 
chemotherapy together with MAbs for cancer treatment are being explored to improve 
therapeutic responsiveness and reduce side effects [66]. 
1.4.2 Vaccines 
Research have been carried out to determine the potential of a vaccine to enhance anti-
melanoma immunity in humans. Vaccination aims to use antigenic signals to stimulate both B 
cells (plasma) and T cell responsiveness. This results in enhanced production of antibodies by 
B cells and cytokines by cytotoxic T cells to destroy tumour cells [67, 68]. Various types of 
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vaccines against cancer have been developed and tested before their potential to become 
clinically successful to resist cancer recurrence for long duration [69]. However, the antigens 
used to develop vaccines can be categorised into two classes; tumour associated antigens 
(TAAs) and tumour derived antigens (TDAs). TAAs are self-antigens that are abnormally 
expressed in tumour cells, but healthy cells may also express TAA at low level. Cancer 
vaccines loaded with TAA needs an extra boost to overcome the tolerance (peripheral and 
central tolerance) generated by self-antigen while minimising on-target off-tumour toxicity 
[70]. Some of the TAA used to develop vaccine to date are NY-ESO-1 (metastatic prostate 
cancer), gp100 (melanoma), MAGE-A3 and MUC1 (non-small cell lung cancer, NSCLC), 
HER2 (breast cancer) [71-75]. Vaccines based on TDAs involves the use of oncogenic viral 
antigens and neoantigens which are derived from tumour. Vaccines loaded with HBV and HPV 
surface antigens have been shown to be effective to reduce the occurrence of hepatocellular 
and cervical cancer respectively [76, 77]. Various therapeutic vaccines have been developed 
recently which have displayed strong immunological response such as VGX-3100, GX-188E 
targeting HPV-16 and HPV-18 (E6 and E7 proteins), pNGVL4a-CRT-E7 targeting HPV-16 
E7 protein for patients with cervical intraepithelial neoplasia (CIN) [78-80]. Since these 
vaccines are designed to prevent viral entry (prophylactic), their potential to treat established 
tumours have not been established, and they may lack the potency to induce cell mediated anti-
tumour response. Neoantigens are generated by mutation in the tumour cell genome and may 
vary among patients [81-83]. With the development of affordable and convenient high-
throughput sequencing technology, the interest in developing and testing vaccines targeting 
neoantigens has significantly increased with successful immunogenic response in clinical 
setting [84-86]. Additionally, cellular vaccines that uses either whole cells or cell lysates have 
also been developed such as DCs based vaccines that delivers antigens to DCs ex vivo [87]. 
GVAX vaccine is designed to deliver whole tumour cell modified to secrete granulocyte-
macrophage colony-stimulating factor (GM-CSF) to stimulate antigen presentation, activation 
and survival of DCs [88]. Similarly, other different types of vaccines such as peptide and naked 
nucleic acid vaccines (DNA and RNA) are also being tested to induce strong immune response 
[89, 90]. Although many of these vaccines have been shown to elicit immune response to 
certain level in vitro and/or in vivo, many failed to show significant response in clinical setting. 
Further intensive investigation has been suggested to understand the mechanism of action of 
cancer vaccines, number and quality of tumour infiltrating or peripheral antigen specific T cells 
and antigen affinity to achieve consistent outcome [91].   
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1.4.3 Immune checkpoint inhibitors  
With the advancement of antibody therapy, immune checkpoint inhibitors (ICI) therapy was 
developed that involve the use of monoclonal antibody to disrupt signaling pathways involved 
in the suppression of effector immune cells [92]. Unlike targeted therapies, ICI therapy 
enhances the immune response irrespective of the type of tumour and has already been 
implicated for the treatment of various types of cancers such as melanoma, renal cell cancer, 
gastric cancer and colorectal cancer [93]. 
The cytotoxic T-lymphocyte-associated antigen (CTLA-4 / CD142) and programmed cell 
death (PD)-1 immune checkpoints are major negative regulators of T cell function that play 
important role in immune modulation and self-tolerance [94]. CTLA-4 is a homolog of CD28 
and has higher affinity towards CD80 (or B7-1) and CD86 (B7-2). Activation of T cells 
upregulates and translocates CTLA-4 to the cellular membrane [95]. The exposure of CTLA-
4 at the cell membrane causes disruption of CD28-B7 interaction and forms CTLA-4-B7 
interaction, thus reducing the T cell activation [96, 97]. PD-1 is a member of B7/CD28 
costimulatory receptors expressed on the surface of activated T cells, B cells, macrophages, 
NK cells and subsets of DCs [98, 99] and plays an important role in maintaining peripheral 
immune tolerance [100]. When tumour specific T cells infiltrate the tumour, TCR-mediated 
activation is triggered by recognition of antigen presented in MHC complex which then results 
in the release of inflammatory cytokines including IFN-γ. This triggers the expression of PD-
1 ligands; PD-L1 and PD-L2, on the surface of macrophages or tumour cells [101]. The 
interaction of PD-1 and PD-L1 suppresses the T cell response including T cell proliferation, 
survival and release of cytokines such as IFN-γ and IL-2 [102, 103]. Tasuko Honjo and 
colleagues first studied PD-1 in 1992 [104] which was followed by the discovery of CTLA-4 
in 1996 by James Allison and colleagues [105]. They were both awarded with Nobel Prize in 
physiology and medicine in 2018 for the discover of PD-1 and CTLA-4 and their implication 
in cancer treatment. Anti-CTLA-4 monoclonal antibody, ipilimumab was granted FDA 
approval in 2011 for the treatment of advanced and unresectable melanoma, after which anti-
PD-1 monoclonal antibodies; pembrolizumab and nivolumab were also approved by FDA in 
2014 for treatment of patients with BRAF WT metastatic and unresectable melanoma. [106]. 
Following this, several inhibitors targeting CTLA-4, PD-1 and PD-L1 have been developed 
and tested clinically in the treatment of various types of malignancies [107]. As of the time of 
writing, there are around 120 monoclonal antibodies in clinical studies targeting checkpoint 
molecules such as LAG-3, TIM-3, CD40, TIGIT, GITR, OX40 together with CTLA-4, PD-1 
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and PDL-1 [108]. However, research is also being carried out to amend the side effect of 
immune checkpoint blockade such as immune related adverse events (irAEs) (e.g. colitis, 
diarrhoea or hypophytis) that occurs due to excessive activation of immune system as seen with 
anti-CTLA-4 and anti-PD1 therapies [109].  
1.5 Adoptive T cell therapies 
Adoptive T cell therapy (ACT) involves the infusion of autologous or allogenic T cells to treat 
the cancer. Rosenberg and colleagues in 1986 established a method for the isolation of tumour 
infiltrating lymphocytes (TILs) from variety of human tumours which were then successfully 
expanded in vitro with the use of IL-2 and transferred clinically for cancer treatment [51, 110]. 
Similar studies were carried out by incorporating lymphodepletion prior to ACT in patients 
with metastatic melanoma which was found to mediate durable anti-tumour response in 
patients [52]. Another approach of ACT utilises tumour lysate that includes multiple tumour 
antigen to stimulate T cells. For example, antigen presenting cells such as dendritic cells 
exposed to tumour cell lysate were used to activate and induce proliferation of tumour specific 
T cells demonstrating effective tumour regression [111]. Although, expansion and infusion of 
TILs ex vivo emerged as an effective treatment for melanoma, it suffers several disadvantages; 
(i) TILs recognize antigen expressed on tumour cells (TAA) which may also be expressed on 
self-tissue and results in immune tolerance [112] (ii) tumour cells may escape immune 
surveillance by downregulating MHC on the surface and / or inducing tolerance via common 
autoantigens [110] (iii) ATC is personalized treatment and hence is expensive [113] (iv) TILs 
are low in number and therefore may not always  be expanded sufficiently for infusion. 
To further enhance the effectiveness of ACT and redirect the T cells to tumour, genetic 
approaches were adopted utilising the knowledge of gene therapy [114, 115]. Genetically 
engineered T cells expressing anti-MART-1 TCR (TCR specific for melanoma antigen) was 
shown to confer high avidity and tumour reactivity for the treatment of melanoma following 
lymphodepletion [116]. Another study carried out similar approach by transducing mouse 
splenocytes with a retrovirus encoding anti-melanoma TCR which resulted in successful 
tumour regression in vivo [52, 117]. Also, the use of TCR-transgenic (Tg) T cells has been 
successful for the treatment of several advanced cancers [118]. The sensitivity of the TCR-T 
cells to detect intracellular antigens through the MHC system has been shown to be more 
effective clinically in the treatment of metastatic melanoma and colorectal cancer which may 
display a high mutational burden [119, 120]. TCR-Tg-T cells against New York esophageal 
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squamous cell carcinoma (NY-ESO-1 or CTAG1A) showed positive outcome with no severe 
toxicity in 80% of the patient with metastatic melanoma. However, one should consider the 
probabilities of on target / off tumour toxicity when developing genetically modified T cells 
and strategies should be explored to promptly ablate such T cells if necessary [121]. 
1.6 Chimeric antigen receptor T cells  
The outpouring interest and extensive knowledge in immune cells led to the introduction of 
chimeric antigen receptor (CAR) T cells in cancer immunotherapy. CAR T cells are T cells 
engineered to express recombinant receptor that recognizes diverse tumour antigens in a HLA-
independent manner [114, 122]. A CAR consists of antigen-binding scFv domain 
(ectodomain), a spacer linked to the transmembrane domain, a co-stimulation domain (as signal 
2) and cluster of differentiation 3 (CD3) ζ signaling tail (as signal 1) (Figure 1.4) [123]. CAR 
T cells are designed to function independently without the need of MHC presentation and cell 
surface bound co-stimulatory signals. CAR acts like an antibody that detects unprocessed target 
antigen and can undergo potent activation. Briefly, CD3 activation mediates calcium influx 
and translocation of NFAT to the nucleus. Co-stimulatory domain in CAR (e.g. CD28 and 4-
1BB) recruits phosphatidylinositol 3-kinase (PI3K) and TNF receptor associated factors 
(TRAFs) to enhance activation and transcription of cytokines and cytotoxic granules 
(granzymes and perforins) as well as genes involved in cell survival by translocating Ap-1, NF-
κB to the nucleus [124]. Therefore, CAR T cell approach is useful to target tumour that escapes 
immune surveillance [114, 125]. Furthermore, targeting expressed antigen on surface of 
tumour overcomes the limited tumour antigen presentation by MHC [122, 126]. Among CAR 
T cells designed against CD19, CD20, CD30 to treat hematological malignancies such as acute 
lymphoblastic leukemia (ALL), chronic lymphoblastic leukemia (CLL), lymphoma and 
multiple melanoma respectively, CD19 CAR has efficiently worked in patients to treat B cell 
lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) and has been 
given FDA approval in 2019 [35, 127, 128]. The first clinical use of CAR T cell in solid tumour 
was reported utilising CAR T cells recognising carbonic anhydrase IX (CAIX) for the treatment 
of metastatic renal cell carcinoma [121]. Although a number of solid tumour antigen targeting 
CAR are in clinical trials, e.g. fibroblast activation protein (FAP) (for malignant pleural 
mesothelioma), di-ganglioside GD2 (for neuroblastoma), carcinoembryonic antigen (CEA) 
(for colorectal adenocarcinoma), human epidermal growth factor receptor 2 (HER2) (for 
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HER2-positive sarcoma), mesothelin (for pancreatic, ovarian, lung cancer), majority of these 
are still far to be ready in terms of safety and efficacy [129, 130].  
There exists multiple generations of CAR T cells. Although the antigen recognition domain 
together with the co-stimulatory domain and an activation domain remains the same in between 
these different generations, the structure evolved in terms of flexibility and controllability 
(Figure 1.4). The first generation of CAR consisted of an antigen recognition domain and T 
cell signaling domain, CD3ζ [131]. The second generation of CAR was designed by combining 
a co-stimulatory domain; either CD28 or 4-1BB (CD137) with the signaling domain and is the 
most used CAR design in clinical studies [132]. Incorporation of CD28 or 4-1BB as co-
stimulatory signal have been shown to be beneficial for CAR T cell therapy as demonstrated 
by in vivo study in mice; CD28  enhanced proliferation of CAR T cells while 4-1BB enhanced 
persistence [133, 134]. Additionally, activation domains such as OX40 (CD134), ICOS and 
CD27 have also been tested [135, 136]. The third generation of CAR T cells were designed to 
achieve greater degree of activation by addition of a third intracellular co-stimulatory domain 
such as 4-1BB or OX40 to CAR antigen recognition domain and CD28 co-stimulatory signal 
[137]. The fourth generation of CAR also referred as T cells redirected for universal cytokine-
mediated killing (TRUCKS) is similar to second generation CAR with additional signal e.g. 
IL-12 that is produced constitutively or induced upon CAR activation.  This generation of CAR 
has already been shown to be highly efficient in elimination of solid tumour in preclinical 
models [138]. Similar to IL-12, TRUCKS secreting IL-18 has also been designed and tested 
against solid tumours [139]. A second generation CAR with an additional truncated 
cytoplasmic domain of IL2-Rβ together with STAT3 binding motif was also developed which 
enhanced the efficacy of CAR T cells [140].  
 




Figure 1.4 Different generation of CAR T cells. Basic CAR design consists of antigen recognition 
domain (scFv) derived from single chain antibody separated with the transmembrane domain via spacer. 
The transmembrane domain is followed by costimulatory domain (CD28 or 4-1BB) and signaling 
domain (CD3ζ). First generation CAR consists of scFv and CD3ζ. Second generation CAR also contains 
a co-stimulatory domain (CD28 or 41BB). Third generation CAR contains two co-stimulatory domains 
(CD28 and 4-1BB). Fourth generation CAR consists of a co-stimulatory domain (CD28 or 41BB) and 
cytokine genes (IL-12) under the control of NFAT-responsive promoter. 
Although various CAR designs have been developed and tested to expand the capability and 
flexibility of CAR T cells, this approach is also limited due to the CAR being only able to 
recognize one, or two target antigens in the case of dual CARs [141] or tandem CARs [142]. 
Therefore, studies are being done to design a universal CAR T cell. Lohmueller JJ et al 
designed an anti-tag (AT) CAR T cell  that expresses monomeric streptavidin 2 (mSA2) biotin-
binding domain that binds to cancer cells coated with biotinylated antibodies and subsequently 
mediates cancer cell lysis [143]. Another group designed SUPRA CAR (split, universal and 
programmable) that could be used to target multiple antigens with improved precision and 
tenability [144]. SUPRA CAR was designed with a universal signaling domain (zipCAR) with 
a leucine zipper that can bind to its cognate leucine zipper linked to scFv specific for a tumour 
antigen (zipFv). Trafficking of CAR T cells to the tumour is important for effective treatment. 
Several CARs have been designed to co-express a chemokine receptor to enhance migration 
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towards chemokine-producing tumour masses. For example, anti-GD2 CAR co-expressing 
CCR2B receptor and anti-CD30 CAR expressing CCR4 demonstrated enhanced migration to 
CCL2 secreting neuroblastoma cells and CCL17 secreting Hodgkin lymphoma respectively 
[145, 146]. Another major challenge with CAR T cell therapy is the off tumour / on target 
activity as TAAs that are expressed on solid tumours may also be expressed in healthy tissues 
at low level and lead to life-threatening toxicity, cytokine release syndrome (CRS) [65, 147, 
148]. For example, anti-GD2 CAR led to fatal encephalitis in preclinical study of 
neuroblastoma model because of low level of GD2 expression in the brain [149]. Inducible 
caspase 9 (iCasp9) and safety switches such as suicide switches and ON switches have been 
incorporated into CAR T cells for its clearance in the case of adverse effect [150]. Inhibitory 
CAR (iCAR) co-expressing conventional CAR and inhibitory CAR are also developed to 
restrict T cell response to cancer cells [151]. Dual-targeting CAR (on-switch CARs) may be 
able to control the expression of the CAR by exogenously added drugs such as rapamycin 
[152]. CAR T cell efficiency is also compromised by the poor quality of T cells that is obtained 
from the patient, hence the concept of universal off-the-shelf CAR T cells is also being 
developed to benefit patients from whom good quality T cells cannot be isolated adequately 
[153].  
1.6.1 HER2 CAR 
HER2 is a member of epidermal growth factor receptor (EGFR) family of tyrosine kinases. 
There are four types of HER (1-4) that plays an important role in proliferation and maintenance 
of normal epithelial surfaces. Unlike HER2 which is ligand independent, other receptor 
tyrosine kinases are activated upon binding of ligand such as EGF and undergo either 
homodimerisation or heterodimerisation leading to phosphorylation and activation of 
downstream signaling pathways important for cellular replication [154, 155]. HER2 on the 
other hand has been found to act as an oncogenic driver in breast cancer and is therefore well-
established as a therapeutic target (e.g. Trastuzumab, commercial MAb targeting HER2 
expressing cancer). It is overexpressed in a variety of cancers such as breast, gastric, ovary, 
colon, cervix, uterine, head and neck, bladder, lung, esophageal cancer [156]. The first human 
HER2 CAR was generated with HER2 specific scFv and CD3 zeta chain (first generation CAR) 
which resulted in regression of medulloblastomas in mice without causing immunogenicity 
[157]. However, significant resurgence of tumour was observed in all treated animals. Another 
study with first generation HER2 CAR to treat pulmonary micrometastasis and 
macrometastasis also failed to demonstrate satisfactory outcome [158]. The use of second and 
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third generation HER2 CAR T cells have been shown to improve efficacy both in preclinical 
and clinical settings against HER2 positive tumour (such as breast cancer, gastric cancer, 
osteosarcoma or glioblastoma)  [159, 160]. Infusion of third generation HER2 CAR T cells 
with trastuzumab based antigen recognition exodomain and CD28.41BB.CD3ζ endodomain to 
treat metastatic colon cancer caused on target / off tumour toxicity as the CAR T cells attacked 
the lung tissue which weakly expresses HER2 antigen [161]. To address the safety concern 
posed by toxicity, second generation HER2 CAR with FRP5 based exodomain and CD28.CD3ζ 
endodomain in lower dose was infused without affecting the efficacy [162]. FRP5 based CAR 
has lower affinity and recognizes the HER2 protein distal from the cell membrane, which may 
finetune the activation and reduce CAR associated toxicity [163]. To enhance the persistence 
of HER2 CAR, Nakazawa et al. developed HER2 CAR Epstein-Barr virus-specific cytotoxic 
T lymphocytes (EBV-CTLs) using a transposon system which enhanced survival of mice 
bearing sarcoma (HER2 positive) [164]. Similar results were obtained when tested in 
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Table 1.1 Different types of HER2 CAR constructs used against HER2 positive tumours in 
clinical trials (Data obtained from https://clinicaltrials.gov) 
Cancer Type of CAR Clinical trials Phase 
Advanced sarcoma CD28-CD3ζ NCT00902044 I 
GBM CD28-CD3ζ NCT01109095 I 
HER2+ advanced solid tumour 41BB-CD3ζ NCT01935843 I/II 
GBM CD28-CD3ζ NCT02442297 I 
Breast cancer CD28-CD3ζ NCT02547961 I/II 
Ovarian cancer CD28-CD3ζ NCT02713984 I/II 





Pancreatic cancer CD28-CD3ζ  NCT03267173 I 
Glioma 41BB-CD3ζ NCT03389230 I 
HER2+ CNS tumours CD28-CD3ζ NCT03500991 I 
Breast cancer 41BB-CD3ζ NCT03696030 I 
HER2+ malignancy CD28-CD3ζ NCT03740256 I 
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1.7 PKA regulatory subunit 1 A (PRKAR1A)  
PKA signaling plays a vital role in inhibition of T cell function in tumours [166, 167]. In this 
thesis, we downregulated one of the regulatory subunits of PKA to overcome such 
immunosuppression. PKA is a heterotetrametric holoenzyme that consists of two regulatory 
subunits (R), type I PKA and type II PKA and two catalytic subunit (C) that can further be 
divided into Cα and Cβ, with number of variants and isoforms [168]. Type I PKA and Type II 
PKA has two isoforms RIA and RIB, and RIIA and RIIB, respectively. Type I PKA is highly 
expressed in the immune cells whereas Type II PKA is expressed in other cellular structures 
and organelles [167]. PKA is activated when exogenous signals binds to a G-protein coupled 
receptor and stimulates adenyl cyclase (AC) which causes conversion of adenosine 
triphosphate (ATP) to cyclic AMP (cAMP) leading to the accumulation of cAMP in the cytosol 
[169]. Binding of four molecules of cAMP to the R subunit leads to conformational changes 
and dissociation of the two C subunits (Figure 1.5). The C subunits are involved in catalytic 
activation and phosphorylation of several downstream targets in the cytoplasm and nucleus 
[170]. The R subunit interacts with a kinase anchoring proteins (AKAP) and are confined to 
specific subcellular compartments [171, 172]. In T cells, ~80% of total PKA activity is 
associated with Type I PKA isoform whereas only 20% is associated with Type II PKA isoform 
[173]. The predominant type I PKA isoform is anchored close to TCR and is involved in 
maintaining T cell function at multiple levels as well as T cell homeostasis [174]. Upon 
activation of T cells, PRKAR1A (labelled as PKA R1A in Figure 1.5) localizes to the immune 
synapse where it anchors to Ezrin-ERM-binding phosphoprotein [174]. PKA type I 
phosphorylates protein tyrosine kinase (PTK) Csk on serine 364 that negatively regulates Lck 
by phosphorylating a C-terminal tyrosine residue Y505 and stabilizing Lck in an inactive 
conformation which leads to disruption of T cell signaling [170, 175]. Besides T cells, Type I 
PKA also inhibits the activation and proliferation of B cells as well as cytotoxicity of natural 
killer cells [176, 177]. 
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Figure 1.5 Regulation of T cell activation by type I regulatory subunit of PKA. Protein Kinase A 
is a heterotetrameric holoenzyme made up of two catalytic and two regulatory subunits. PKA signaling 
is activated when cAMP binds to the regulatory subunit of PKA leading to its dissociation from catalytic 
subunit. In T cells, type I PKA regulatory subunit localizes to the immune synapse inhibiting T cell 
activation by phosphorylating Csk on serine 364 that leads to phosphorylation of a C-terminal tyrosine 
residue, Y505 stabilizing Lck in an inactive conformation which inhibits T cell activation. 
Studies have shown that loss of both alleles of PRKAR1A in mice produces an embryonic lethal 
defect with several developmental abnormalities [178]. However, mice containing an antisense 
transgene targeted to R1A demonstrated normal development, but the mice developed 
neoplastic lesions as they aged [179]. Downregulation of PRKAR1A have been shown to 
protect cells from apoptosis induced by endoplasmic reticulum (ER) stress and promote cell 
survival [180]. Increase in PKA activity associated with downregulation of PRKAR1A in 
diverse cell types has also been shown to promote apoptosis by causing upregulation of 
proapoptotic B-cell lymphoma-2 (BCL-2) family members [181, 182].  
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1.8 Interfering RNA (RNAi) approach in cancer therapy 
A study done by Andrew Fire and Craig Mello in 1998 revolutionized the field of non-coding 
RNAs by identifying the role of double stranded RNA in potent and specific RNA interference 
in Caenorhabditis elegans [183]. Later studies showed that 21-22 nucleotide (nt) double 
stranded RNA containing complementary sequence to a specific gene are involved in inducing 
post-transcriptional gene regulation in different eukaryotic species [184]. RNAi consists of 
microRNAs (miRNAs), small interfering RNAs (siRNAs) or small/short hairpin RNAs 
(shRNAs) that can target specific messenger RNAs (mRNAs) in sequence specific manner 
(Figure 1.6) [185]. RNAi have received considerable attention as an effective therapeutic 
approach for cancer and other diseases because of their ease of use [186, 187]. More recently, 
studies are carried out to combine cell-based therapies (e.g. DC-based vaccine) with RNAi 
approach to downregulate inhibitory targets (e.g. IDO; indoleamine 2, 3-dioxygenase) and have 
shown success in triggering anti-cancer T cell immunity in cancer therapy [188, 189]. 
1.8.1 MicroRNAs 
MicroRNAs (miRNAs, miRs) are small non-coding RNAs (~22 nucleotides in size) that 
regulate gene expression in a variety of organisms [190]. Since the discovery of the first 
miRNA, lin-4, thousands of miRNAs have been identified [191]. The biogenesis of miRNA 
involves multi-step process starting in the nucleus and ending in the cytoplasm (Figure 1.6). 
First, the miRNAs are transcribed from DNA sequence by RNA polymerase II or III into long 
primary miRNA (pri-miRNA) bearing a local hairpin structure. The pri-miRNA hairpin RNA 
structure is recognized and cleaved by RNAse III enzyme, Drosha and DGCR8 to shorter 
hairpin of about 70 nucleotide length called the pre-miRNA [192]. The pri-miRNA is then 
exported to the cytoplasm through Exportin-5 and is cleaved by another RNase III enzyme, 
Dicer, generating the double stranded mature miRNA duplex [193]. The mature miRNA duplex 
is loaded onto an Argounate (AGO) protein to form RNA-induced silencing complex (RISC). 
One of the strand of the duplex (passenger strand) is immediately cleaved, or is unwound and 
removed by the endonuclease while the other strand (guide strand) binds to a specific sequence 
called miRNA response element (MREs) located at the 3ꞌ UTR of the target mRNA and thus 
regulates gene expression either by translational repression or by mRNA deadenylation and 
decapping [190]. The modulation of gene expression following binding of miRNA to the 5ꞌ 
UTR and the coding region has also been reported [194, 195]. 
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About 60% of the human genes are regulated by miRNAs and majority of them are tumour 
associated genes [196, 197]. MiRNAs are expressed abnormally in tumour cells and affect 
tumour development as they can act either as tumour inducer genes (oncogenes) or tumour 
suppressor genes or both [198, 199]. The identification of disease specific miRNAs have also 
helped to understand underlying molecular pathways involved in disease progression and have 
provided evidence to generate therapeutic strategies [200]. Moreover, miRNAs are also 
involved in regulating development, homeostasis, differentiation and function of cells of both 
innate and adaptive immune system [201-205]. Additionally, miRNAs regulate cell cycle, 
cytokine release, expression of membrane receptors (CTLA-4 or PD-1), and various signaling 
molecules (kinases and phosphatases) in immune cells [206]. The miRNAs used in this study 
are discussed in next section. 
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Figure 1.6 Mechanism of gene silencing by miRNA and shRNA. miRNA is transcribed in the nucleus 
forming pri-miRNA and is processed to form pre-miRNA by Drosha. The pre-miRNA is transported 
by exportin 5 to the cytoplasm and is processed by Dicer into mature miRNA. The guide strand is loaded 
into RISC and the miRISC targets the mRNA through partially complementary binding inhibiting the 
target via translation repression, degradation, and cleavage. Similar to miRNA processing, double 
stranded shRNA is also transcribed in the nucleus and exported from the nucleus via exportin 5 to the 
cytoplasm which is processed by Dicer to form siRNA and loaded into the RISC. The guide strand then 
targets the mRNA by full complementary binding and leads to cleavage of mRNA. 
1.8.1.1 miR96 and miR183 
The miR96/183/182 is a highly conserved polycistronic, paralogous miRNA cluster comprised 
of miR96, miR183 and miR182 within 5kb in the genome of both human and mice [207, 208]. 
The miR182 and miR183 were first identified as a cluster that is co-expressed in murine retina 
and later miR96 was found to be part of the same cluster, required for sensory organs function 
[208-210]. The miR96/183/182 family are considered to be oncogene and is highly upregulated 
in several types of tumours (e.g. colon and  pancreatic cancer) and their function may differ in 
different tumour types [211]. In addition to its use as a diagnostic marker in different types of 
cancers such as bladder cancer, prostate cancer, urothelial carcinoma, the cluster has been 
shown to regulate cell survival, proliferation, and migration of tumour cells [212-216]. Most 
breast cancers overexpress miR96/183/182 cluster plays a role in tumorigenesis and metastasis 
[217, 218].  
The conserved miR96/183/182 cluster plays an important role in the inflammatory response of 
macrophage against Pseudomonas aeruginosa and lipopolysaccharide (LPS) [201]. In T cells, 
miR96/183/182 cluster have been found to assist T helper (Th) 17 cells to gain pathogenicity 
both in vitro and in vivo by downregulating transcription factor, foxo1 [203]. Also, miR96/183 
was found to be upregulated in mouse CD4+ T cells where it was shown to enhance Akt 
signaling pathways and negatively modulate EGR-1 and PTEN expression resulting in 
enhanced activation and proliferation [219].  
1.8.1.2 miR155  
miR155 was first identified within the proto-oncogene B-cell integration cluster (bic) that was 
originally described as a common site of viral DNA integration causing lymphomas in chicken. 
Later miR155 was found to be an active non-coding transcript of bic [220]. Studies suggest 
miR155 is overexpressed in activated B and T lymphocytes as well as dendritic cells and acts 
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as a central regulator of immune system homeostasis and plays important role in inflammatory 
response to pathogen and cancer [221-223].  MiR155 has been shown to be important in 
differentiation of plasma cells and antibody production, differentiation of dendritic cells, 
development of Tregs and regulation of Th1/Th17 lineage commitment [222, 224-226]. 
Additionally, miR155 plays a vital role in immunoglobulin class switching by downregulating 
expression of activation-induced cytidine deaminases (AID) and the transcription factor PU.1 
[224, 227]. In miR155 deficient mice, B cells exhibited reduced extrafollicular and germinal 
center response as well as failed to produce high affinity antibodies suggesting important role 
of miR155 in B cell function [224, 228]. Similarly, adoptively transferred tumour specific 
miR155-/- CD8+ T cells showed poor anti-tumour response compared to wild type, confirming 
impaired T cell function in the absence of miR155 and highlighting significant role of miR155 
in T cell function as well [229-231]. Deficiency of miR155 in DCs have been shown to inhibit 
their potential to activate T cells as well as impair their cytokine producing ability [232]. 
Consistently, overexpression of miR155 in DCs promoted T cell activation and suppressed 
tumour growth in a murine model of breast cancer [233]. MiR155 inhibits the expression of 
the suppressor of cytokine signaling molecule (SOCS1) which results in the inhibition of 
JAK/STAT pathway and Src homology-2 domain-containing insositol 5-phosphatase 1 (Ship1) 
leading to the enhancement of STAT5 (but not STAT3) and AKT signaling respectively, thus 
enhancing T cell responsiveness [234-236]. Moreover, overexpression of miR155 have been 
shown to promote expansion and long-term persistence of exhausted T cells during viral 
infection [237, 238]. Several studies have reported the upregulation of miR155 in malignant 
cells suggesting its role as an oncogene that regulates cell survival pathways and contributing 
pathogenesis of many human cancers [35, 239-241].  
1.8.2 Small or short hairpin RNAs (shRNAs)  
Soon after the discovery of siRNAs, DNA vectors that could transcribe short RNA molecules 
known as shRNAs capable of entering the RNAi pathway were developed [242, 243]. The 
shRNAs are processed by the same RNAi machinery as described for miRNAs (Figure 1.6). 
Unlike siRNAs, long-term knockdown of stable proteins is possible with low copy number of 
shRNA by incorporating shRNA expression cassettes into viral vector systems which permit 
stable integration of shRNA into the host genome [244]. The vector consists of antibiotic 
selection markers and fluorescent protein markers to select stably transfected cells and track 
transfected cells, respectively which will allow isolation of pure population of transfected cells. 
Additionally, vector based shRNAs can be regulated by using inducible promoters. 
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Structurally, miRNAs have bulges in the secondary structure as a result of internal mismatches 
whereas shRNAs have complete internal base pairing [185]. shRNAs have also been utilized 
in therapeutic approaches to treat cancer and infectious diseases. For example, shRNA 
mediated inhibition of IL-6 receptor (IL-6R) expression reduced the severe CRS incidence 
without compromising the efficacy of the anti-CD19 CAR T cells [245]. Additionally, studies 
have highlighted the possibility of using combinatorial RNAi approach involving the 
expression of multiple shRNA combinations targeting HIV-1 strains as potential novel therapy 
against all currently known variants of HIV-1 subtypes [246]. 
1.9 G protein-coupled receptors 
G protein-coupled receptors (GPCRs) are the largest family of membrane proteins that are 
characterised by the presence of seven transmembrane helices. The seven transmembrane 
helices consist of  N terminus, three extracellular loops (ECL1-ECL3), seven transmembrane 
α-helices (TM1-TM7), three intracellular loops (ICL1-ICL3) and the C terminus [247]. In 
general, the extracellular region binds to the ligand and, TM region transduces the signal to the 
intracellular region by conformational changes, and intracellular region interacts with cytosolic 
signaling proteins [248]. Based on sequence and structural similarity, GPCRs can be classified 
into five families; rhodopsin (Class A), secretin (Class B), metabotropic gultamate (Class C), 
fungal mating pheromone (Class D), cAMP receptors (Class E), and frizzled/Taste receptors 
(Class F) [249]. Most GPCRs mediate cellular responses to wide variety of endogenous as well 
as exogenous ligands and stimuli (e.g. hormones, proteins/peptides, neurotransmitters) within 
the human body by interacting with different isoforms of G proteins downstream; Gs, Gq/11, Gi 
and G12/13, resulting in the activation of a number of signaling cascades [250]. GPCR mediated 
cellular response are also regulated by their interaction with GPCR kinases (GRKs), regulators 
of G protein signaling (RGS) and arrestins that are widely expressed in various tissues and 
organs. The GPCR-GRK interaction leads to the phosphorylation of the receptor terminating 
its interaction with G protein and initiating its interaction with arrestins which leads to receptor 
endocytosis via clathrin-coated pits [251, 252]. The process of degradation and recycling of 
the receptors ultimately determines the level of receptor expression on the cell surface [253]. 
GPCRs are expressed in diverse organs and systems such as sensory organs, respiratory and 
digestive tract, central nervous system, immune cells where it mediates key physiological 
processes and have been shown to play role in many human diseases such as heart failure, 
diabetes and hypertension [254]. 
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GPCRs are highly expressed on cancer cells and plays an important role in regulating various 
cellular functions such as proliferation, apoptosis, metabolism and migration [24, 255]. GPCRs 
are also expressed by the cells of the TME including vascular cells, immune cells, 
inflammatory cells and cancer-associated fibroblasts [256]. In T cells, a large variety of GPCRs 
have been found to be involved in T cell activation, homeostasis and function [257]. For 
example, prostaglandin receptors such as EP1, EP2, EP3 and EP4 are involved in regulating T 
cell immune response; activation of EP1 enhances Th1-mediated immune response while 
EP2/EP4 inhibits T cell activation and regulates Th17 differentiation [258, 259]. Similarly, 
expression of chemokine receptors such as CXCR3, CXCR4, CCR5 on the surface of T cells 
have been shown to regulate their migration and function [260-262]. Some of the GPCRs 
utilised in this study are discussed below. 
1.9.1 CXCR3   
CXCR3 (GPR9/CD183) is a chemokine receptor. Chemokines are divided into four families 
based on the relative position of the two N-terminal cysteine (C) residue in mature protein viz. 
C, CC, CXC and CXXC. Human CXCR3 has three splice variants; CXCR3-A, CXCR3-B and 
CXCR3-alt while mice have a single variant of CXCR3 receptor [263]. CXCR3 is highly 
expressed on activated T cells as well as NK cells, dendritic cells, macrophages and subsets of 
B cells [264, 265]. CXCR3 receptor can bind to three different IFN--induced chemokines, 
CXCL9 (MIG, monokine induced gamma interferon), CXCL10 (IP-10, interferon induced 
protein) and CXCL11 (I-TAC, interferon induced T cell alpha chemoattractant) and induces 
migration of the activated T cells to sites of inflammation [266, 267]. Among the three 
chemokines, CXCL11 is the most potent chemokine that binds to the CXCR3 receptor with the 
highest affinity [268]. Chemokine interaction with Gi protein-coupled CXCR3 activates 
multiple pathways; MAPK, phosphatidylinositol-3-kinase (PI3)/AKT pathways, calcium flux, 
phosphorylation of tyrosines on ZAP-70, LAT and PLCγ1 [269, 270].  
It has been reported that CXCR3 receptor plays an important role in stimulation and 
coordination of several inflammatory disorders such as atherosclerosis, autoimmune diseases 
and transplant rejection as well as suppressive T cell response [260, 271-273]. It was also found 
to play an important role in tumour development by promoting angiogenesis and cancer 
metastasis [274]. Furthermore, expression of CXCR3 has been suggested as a marker of 
polarization of the T helper subset towards a Th1 phenotype and their recruitment to inflamed 
tissue [260, 275]. CXCR3 expression is rapidly upregulated following T cell activation and 
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controls the fate of CD8 T cells by generating short-lived effector and memory T cells [276, 
277]. Adoptive transfer of T cells isolated from CXCR3 knockdown mice demonstrated poor 
migration to tumour site compared to T cells isolated from wild type mice [267, 278, 279]. 
Similarly, expression of CXCR3 has been found to be important to enhance anti-tumour 
response of CD8 T cell following PD-1 blockade (anti-PD-1therapy) highlighting the potential 
role of CXCR3 for immunotherapeutic approach [279].  
1.9.2 Adenosine receptors (A1 and A2A) 
Adenosine receptors (ARs) comprise a family of GPCRs with four different sub-types namely, 
A1 AR, A2A AR, A2B AR, and A3 AR. These receptors are shown to be involved in various 
critical physiological functions such as vasodilation, pain, sleep, and inflammation [280]. The 
activation of A1 AR and A3 AR receptor causes inhibition of adenyl cyclase, thereby 
decreasing intracellular cAMP level while A2A AR and A2B AR activation stimulates adenyl 
cyclase increasing cAMP level [281]. These adenosine receptors and adenosine are found to 
be upregulated in various tumour cells and TME respectively which suggest the role of these 
receptors in tumour progression [282]. Among the four known types of adenosine receptors, 
A1 and A2A receptor have been extensively studied to explore their pathophysiological role in 
multiple neurodegenerative diseases as these receptors are predominantly expressed in the 
brain [283]. Additionally, A1 AR signaling have been shown to play both pro- and anti-
inflammatory role in disease development [284]. Studies have also highlighted the role of A1 
AR signaling on microglial cells to reduce tumour size [285]. The A2A AR has been shown to 
negatively regulate the immune response [286]. A2A AR signaling has been shown to limit the 
effector functions of macrophages, dendritic cells and T cells [287-289]. Interestingly, A2A 
AR is the predominant adenosine receptor on lymphocytes and have been reported to suppress 
both CD4 and CD8 T cell function by inhibiting the expression of proinflammatory cytokines, 
and selectively enhancing upregulation of checkpoint inhibitors; PD-1 and CTLA-4, and 
generating LAG-3 and Foxp3+ regulatory T cells [290]. Therefore, studies carried out by 
inhibiting A2A AR signaling using specific inhibitors have demonstrated improvements in the 
anti-tumour response [43, 291]. 
1.9.3 T-cell death-associated gene 8  
T-cell death-associated gene 8 (TDAG8), also known as GPR65, is an extracellular pH sensing 
GPCR which is expressed on various immune cells, tumours and tumour cell lines and is 
activated by histidine protonation [292-294]. TDAG8 couples to multiple G proteins. Coupling 
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to Gαs results in adenylate cyclase activation resulting in cAMP accumulation and coupling to 
Gα12/13 leads to activation of downstream Rho protein [295]. 
TDAG8 expression has been associated with the regulation of inflammatory and immune 
responses; it has been shown to inhibit inflammatory cytokine production in macrophages, 
inhibit superoxide anion production in neutrophils and increase viability of eosinophils in 
response to extracellular acidification [296-299]. Self-reactive immature thymocytes were 
shown to have enhanced TDAG8 expression during TCR-mediated cell death, indicating its 
role in negative selection of thymocytes [89]. ChIP-seq analysis suggested binding of the Th17 
master transcription factor, RORγt, to the promoter region of TDAG8 and promoting Th17 cell 
pathogenicity [300]. Moreover, TDAG8 plays a vital role in maintaining lysosomal function 
which is required for pathogen defence and autophagy [301]. 
In some tumours (e.g. hematological malignancies), expression of TDAG8 has been shown to 
have pro-oncogenic and anti-oncogenic function by enhancing glucocorticoid induced 
apoptosis of lymphocytes and inhibiting c-myc expression respectively [292, 302, 303]. 
Furthermore, overexpression of TDAG8 in tumour cells was shown to promote cell survival 
and proliferation by conferring resistance to acidic environment [295, 304, 305]. However, 
activation of TDAG8 receptor on the surface of T cells can reduce activation and regulate 
cytokine production [306]. Hence, modulating TDAG8 expression on anti-tumour T cells could 
be one of many strategies to combat the inhibitory effect of TME during cancer 
immunotherapy. 
1.10 Gene transfer  
The method of introducing CAR into T cells has become an area of interest with the 
advancement in CAR T cell therapy. Viral vectors have evolved to become highly efficient at 
delivering nucleic acid to a diverse range of cells without provoking host response. Although 
viral transduction of T cells to deliver the CAR gene is already adopted clinically, the 
possibility of random integration of the retroviral and lentiviral vectors into the genome poses 
safety concerns [307]. In order to minimize random integration to achieve more targeted 
integration, other approaches such as zinc finger nucleases (ZFNs), transcription activator-like 
effector nucleases (TALENS) and clustered regularly interspaced short palindromic repeats 
(CRISPR) have been investigated [308, 309]. Simultaneously, the non-viral gene delivery 
methods using transposons such as sleeping beauty and piggy bac are also being explored as 
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an alternative to viral vectors [164, 310]. This thesis has utilized both sleeping beauty system 
and lentiviral vectors which are further discussed below. 
1.10.1 Sleeping beauty system  
The Sleeping beauty system (SB) consists of a transposon containing the gene expression 
cassette and a plasmid which codes the transposase enzyme. The transposon, which is 
generated from the sequence of inactive transposon (Tc1/mariner) found in salmonids, consists 
of inverted terminal repeats (ITRs) to which transposase binds and mediates insertion of GOI 
placed in between the ITRs into a new DNA locus by cut and paste mechanism [311, 312]. 
This property makes transposon system a simple and natural DNA delivery method  which can 
be useful for various genetic engineering applications [313]. The first successful human 
application of SB system was carried out to generate clinical grade second generation CD19 
CAR against multiply relapsed ALL [314, 315]. 
The SB system have been revised periodically to enhance the transposition efficiency in 
primary cells. For example, screening of a number of hyperactive variants by Lajos et al led to 
the discovery of new SB100X that possessed ~100-fold higher degree of transposition 
compared to the original SB transposase system [316] and showed enhanced gene transfer 
efficiency both in cell lines and transgenic animals [317, 318]. SB system have also been 
revisited recently to add fluorescent proteins (GFP or RFP) to trace transfected cells, selection 
markers (puromycin, blasticidin) to select stably transfected cells and SfiI restriction sites with 
different overhang to allow cloning of correctly oriented gene [319]. Two new types of SB 
vectors were also introduced for the expression of GOI: constitutive (pSBbi-GP, pSBbi-RP, 
pSBbi-bla) and tetracycline or doxycycline inducible vectors (pSBtet-GP). Sixteen different 
variants of SB including both constitutive and inducible vectors are available now in addgene. 
The constitutive system consists of dual promoters, EF-1α and synthetic RPBSA fused in 
divergent orientation, while the inducible system consists of tetracycline inducible promoter 
(TCE) and RPBSA placed in the same direction. The SB system has become attractive tool of 
gene delivery in recent years because of safety reasons as the system poses low genotoxicity 
compared to viral vectors and can reduce manufacturing cost to meet GMP guidelines. The 
cargo size in sleeping beauty system is limited, yet greater cargo capacity (5kb) has also been 
used, however, the efficiency of transposition decreases with increasing cargo load [320]. 
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1.10.2 Lentiviral vectors  
The use of lentivirus for gene therapy have become increasingly popular because of the natural 
ability of the viruses to efficiently transduce both non-dividing and dividing cells and stably 
transfer genetic material by the virus derived reverse transcriptase (RT) and integrase (IN) (CE 
Thomas, 2003). The majority of lentiviral vectors are based on HIV-1 virus that consists single-
stranded positive-sense RNA genome which encodes three structural proteins (Gag, Pol and 
Env), two regulatory proteins (Tat and Rev), and four accessory proteins (Vif, Vpr, Vpu and 
Nef) flanked by long terminal repeats (LTRs) [321]. Each LTR contains three regions: U3 (acts 
as enhancer/promoter), R (acts as polyadenylation signal) and U5 [322]. The Gag and Pol gene 
encodes core proteins and enzymes for viral replication (protease, RT and IN) respectively to 
make up the core structure of the infectious viral particle called virion. Env gene encodes the 
viral surface glycoprotein called gp160 which gets cleaved by proteases into gp120 (surface 
subunit) and gp41 (transmembrane subunit) that undergoes conformational changes to facilitate 
viral entry into the cells [323]. The virion is encapsulated and consists of tat to activate viral 
transcription, rev to facilitate nuclear export of the viral transcript and accessory proteins: vif, 
vpr, vpu, nef to assist in viral replication [324]. Briefly, once the virion enters the cells, 
uncoating of the capsid proteins occurs releasing RNA genome and viral enzymes. The positive 
sense RNA is then converted into double stranded DNA in the cytoplasm and imported into 
the nucleus thus integrating it into the host genome [325, 326]. The viral mRNA is later 
synthesized via transcription and exported to the cytoplasm where all the viral genome and 
proteins are assembled to create mature infectious virion that are released from the cells. 
Lentiviral vectors have gone through multiple stages of optimization for improved safety and 
infectivity. First generation lentiviral vector consists of three separate plasmids; (i) a packaging 
vector that expresses gag, pol and regulatory/accessory proteins, (ii) env vector that expresses 
viral attachment protein VSV-G (instead of env) to improve the viral titre and increase its target 
cell range and (iii) a transfer vector that expresses transgenes and contains cis acting elements 
such as LTRs, psi (packaging signal) and reverse response element (RRE). Like first 
generation, second generation lentiviral vectors incorporate three separate plasmids but the 
accessory proteins vif, vpu, vpr and nef are excluded from the packaging plasmid. To further 
increase the safety, third generation lentiviral system was generated to decrease the chances of 
recombination. The third-generation lentiviral system consists of four separate plasmids; (i) a 
packaging construct consisting of gag and pol genes, (ii) a plasmid containing Rev, (iii) a 
plasmid expressing VSV-G and (iv) a transfer plasmid with enhancer / promoter region in 5ꞌ 
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LTR replaced by a strong heterologous promoter (allows transcription of the full-length viral 
RNA in tat independent manner) and self-inactivating (SIN) property (disrupts 
promoter/enhancer activity in U3 region of 3ꞌ LTR). This prevents the possibility of 
packageable viral transcript formation in 5ꞌ LTR as U3 region of 3ꞌ LTR is copied and 
transferred to 5ꞌ LTR during reverse transcription and lowers the probability of replication 
competent lentivirus formation by reducing the chances of sequence homology with wild-type 
virus [327-329]. Although the lentiviral system confer additional advantages of high 
transduction efficiency, relatively shorter time of transduction and ease of large scale 
manufacturing because of established constitutive virus producer cells compared to traditional 
vectors, the vector can still pose a serious safety hazard if semi-random integration of the vector 
occurs near a proto-oncogene by triggering oncogenesis [137]. Additionally, the size of the 
cargo in lentiviral system is restricted because of the limited size of the viral capsid and its 
requirement to include viral packaging components. Moreover, the construction of good 
manufacturing practice (GMP) grade viral vectors is an expensive and labor demanding process 
which requires extensive validation. 
1.11 Aims of thesis 
CAR T cell therapy is one of the most promising approaches for the treatment of cancer. To 
date, FDA has approved only two CAR T cell products for the treatment of lymphoblastic 
leukaemia and B-cell lymphoma. However, data collected over years of research from CAR T 
cell therapy targeting solid tumour suggests that this approach is still preliminary and requires 
incorporation of additional measures to overcome the immunosuppressive tumour 
microenvironment. This research explores some strategies to fortify T cell function and expand 
CAR T cell approach in solid tumours with following aims: 
I. To exploit immunosuppressive metabolites abundantly present in TME by turning them 
into stimulatory signal to enhance the migration and/or activation of T cells. This aim 
was attempted by utilising CXCR3 intracellular signaling domain based chimeric 
receptor fused to extracellular metabolite sensing GPCR. (Chapter 3) 
II. To utilise RNAi tools (shRNA as well as miRNA) to supress the expression of 
inhibitory target, PRKAR1A and investigate its effect in T cell function using Jurkat-T 
cell as proof of concept. (Chapter 4) 
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▪ I further aim to revisit the tetracycline inducible sleeping beauty transposon 
system to incorporate expression of HER2 CAR downstream of constitutive 
promoter and an additional GOI under the control of inducible promoter.  
III. To optimize lentiviral system for the expression of miRNA, HER2 CAR and a reporter 
gene from the same vector by comparing different single promoter or dual promoter 
systems and to study the effect of miRNA overexpression on HER2 CAR T cells by 
assessing expression of cytokines and phenotypic markers on primary human T cells. 
(Chapter 5) 
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2.1 Cell culture 
2.1.1 Cell lines 
The adherent cell lines human kidney cell lines (HEK293; ATCC CRL-1573, HEK293T; 
ATCC CRL-3216), breast cancer cell lines (MDA-MB 231; ATCC HTB-26, MCF-7; ATCC 
HTB-22, SKBr3; ATCC HTB-30) and mouse melanoma cell line (B16-F10; ATCC CRL-
6475) were maintained at 37 °C with 5% CO2 in Dulbecco’s Modified Essential medium 
(DMEM, Thermo Fisher Scientific catalogue number (#) 10569010 or #12100061) 
supplemented with 10% fetal bovine serum (FBS; Pan-Biotech GmbH), 
Penicillin/Streptomycin (100 U/ml penicillin, 100 µg/mL streptomycin; Gibco #15140) and 2 
mg/mL sodium bicarbonate (Merck #1063290500). The cells were passaged when the 
confluency reached approximately 80%. Briefly, the cells were washed with PBS (Thermo 
Fischer Scientific, #18912014) and treated with a solution of PBS containing 1x Trypsin-
EDTA (Sigma #T1426, #E5134) for 2-5 minutes depending upon the cell line. PBS (10 mL) 
was then added, and the single cell suspension was centrifuged at 1500 rpm for 5 minutes. The 
cells were then diluted to 1:4 (cell to media) and transferred back into the original flask or new 
flasks. 
The non-adherent (in suspension) cell lines such as mouse EL4 T cells (ATCC TIB-39) and 
human Jurkat T cells (ATCC TIB-152) were cultured in Roswell Park Memorial Institute 
(RPMI) 1640 (Gibco #31800-022) supplemented with 10% fetal bovine serum, 
Penicillin/Streptomycin (100 U/mL penicillin, 100 µg/mL streptomycin) and sodium 
bicarbonate (2 mg/mL). The cells were diluted to 1:10 and passaged every 3 to 4 days. 
For long term storage, the cells were centrifuged at 1500 rpm for 5 minutes and were 
resuspended in medium containing 90% FBS and 10% DMSO (1 × 107/vial). Cells were stored 
at -80°C for 24 hours after which they were transferred to liquid nitrogen.  
2.1.2 Primary human cells 
Blood was taken from healthy donors with informed written consent approved by the 
University of Otago Human Ethics Committee (H18/089). Peripheral blood (50 mL) was taken 
by venipuncture from each donor in a 50 mL falcon tube containing 10 U/mL heparin. Blood 
was then diluted with 50 mL PBS at 1:1 ratio. 15 mL Histopaque-1077 (Sigma-Aldrich) was 
added to three 50 mL falcon tubes and blood was slowly layered over (by gravity) on top of 
the histopaque layer without mixing followed by centrifugation at 800 g (acceleration 5 and 
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deceleration 0) for 30 minutes. Following the density gradient centrifugation, the monolayer of 
peripheral blood mononuclear cells (PBMCs) from three falcon tubes were transferred into a 
fresh falcon tube and centrifuged. Collected PBMCs were then washed twice with PBS 
followed by centrifuging at 300 g for 10 minutes (acceleration 9 and deceleration 9) during 
each wash step. Finally, isolated PBMCs were counted by hemocytometer, resuspended in 
freezing medium (90% FBS and 10% DMSO) at a concentration of 1 × 107/vial and stored at -
80 °C for 24 hours which were then transferred to liquid nitrogen for long-term storage. 
Human T cells were isolated from PBMCs using EasySepTM human T cell isolation kit 
(Stemcell Technologies; #17951) according to the manufacturer's protocol. Cryopreserved 
PBMCs were thawed from liquid nitrogen and rested in CTSTM OptimizerTM T cell expansion 
SFM (TCE, Thermo Scientific; # A1048501) containing 1mM glutamine overnight. Next 
morning, PBMCs were washed and resuspended in PBS containing 2% FBS and 1 mM EDTA 
(T cell isolation buffer) at the concentration of 5 × 107 cells/mL (in 1 mL) in polystyrene round 
bottom tube. Isolation cocktail provided in the kit was then added (50 µL/mL) and mixed. 
Following 5 minutes incubation at room temperature (RT), 40 µL/mL RapidspheresTM 
(vortexed for 30 seconds prior to use) were added and mixed. The total volume of the mixture 
was made to 2.5 mL by adding T cell isolation buffer and was placed into the magnet for 3 
minutes at RT. After incubation, the magnet was inverted (in one continuous motion) and the 
cell suspension was poured into a new tube. The isolated T cells were centrifuged at 1500 rpm 
for 5 minutes and were cultured in TCE medium with 50 U IL-2 (PeproTech; # 200-02-100ug) 
at a concentration of 1 × 106 cells/mL. The cells were cultured with fresh medium every three 
days. 
2.2 Cloning  
2.2.1 Vectors used in this study 
Sleeping Beauty (SB) vectors (pSBbi-GP, pSBbi-RP, pSBbi-Bla, pSBtet-GP) and SB 
transposase vector (pCMVCATT7-SB100) were purchased from Addgene (USA). The 
pmiRGLO dual-luciferase miRNA target expression vector was purchased from In Vitro 
technologies (Australia, # PME1330). The lentiviral vectors including transfer vector pCCL-
Sin (p.CCL-Sin.PPT.hPGK.GFP), packaging vectors (pMDLg/pRRE and pRSV-Rev) and an 
envelope vector (pMD2.G) were a kind gift from Luigi Naldini (IRCCS San Raffaele Scientific 
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Institute, Italy). The restriction enzymes used in this study were bought from New England 
Biolabs (NEB, USA).  
2.2.2 Cloning CXCR3, chimeric receptors (A1-CXCR3, A2A-CXCR3, TDAG8-
CXCR3) and CXCL11 
The mouse CXCR3 and the chimeric constructs (A1-CXCR3 and A2A-CXCR3) encompassing 
extracellular A1 or A2A domains with intracellular murine CXCR3 were designed based on 
the amino acid sequences and tertiary structure models available at https://www.uniprot.org/ 
and http://gpcrdb.org/. The constructs were synthesized as gene blocks by IDT (Integrated 
DNA technologies, Iowa, USA) and cloned into sleeping beauty system (pSBbi-RP/ pSBbi-
GP) using the SfiI restriction sites. To monitor the surface expression of the chimeric receptors 
post transfection by flow cytometry, a c-myc tag (EQKLISEEDL) was added to the N-terminus 
of the constructs. The N-terminal c-myc tag of A1-CXCR3 or A2A-CXCR3 constructs were 
replaced with respective N-terminals without c-myc tag utilizing NotI and SalI restriction sites 
to use as controls without c-myc tag. Similarly, CXCL11-His and pelB-CXCL11-His were 
synthesized as gene blocks by IDT. CXCL11-His and pelB (periplasmic signal sequence)-
CXCL11-His were cloned into expression vector pQE80L utilizing restriction sites; BamHI-
HindIII and EcoRI-HindIII respectively to produce CXCL11. All sequences were confirmed 
by Sanger sequencing. 
2.2.3 Cloning shRNAs  
The short hairpin RNAs or small hairpin RNAs (shRNAs) were synthesized as single stranded 
oligos (sense and antisense) by IDT (Singapore) with SfiI overhangs. Oligos were reconstituted 
in nuclease free duplex buffer (IDT). For annealing, equal amount (10 µM) of both sense and 
antisense oligos were added to a tube and the final volume was made to 50 µL with nuclease 
free duplex buffer. The tube was incubated in a heat block at 95 °C for 5 minutes. The heat 
block was turned off and the tube was left in the heat block for an additional 5 to 6 hours. The 
annealed oligos were then phosphorylated using T4 polynucleotide kinase (PNK; New England 
Biolabs) and inserted into pSBtet-GP using SfiI restriction enzyme. The shRNA sequences are 
given in the Table 2.1. 
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2.2.4 Cloning miRNAs into pSBtet-GP 
Human genomic DNA was extracted from isolated PBMCs using QIAmp DNA mini kit 
(Qiagen). The miRNAs: miR96/183 and miR155, were PCR amplified from genomic DNA 
using primers shown in Table 2.2. The PCR products were then cut with restriction enzymes 
(NcoI and ClaI) and were cloned into tetracycline inducible sleeping beauty system (pSBtet-
GP) to generate pSBtet-miR96/183 and pSBtet-miR155.  
Table 2.2: Cloning primers for miR96/183 and miR155 
 
2.2.5 Cloning PRKAR1A 3ꞌ UTR into pmirGLO vector 
PRKAR1A 3' UTR was PCR amplified from human genomic DNA. The reporter plasmid, 
pmirGLO carrying PRKAR1A 3' UTR downstream of the firefly luciferase gene was generated 
using NheI and SalI restriction sites. The pmirGLO vector carrying mutation at miR96, miR183 
or miR155 binding region in PRKAR1A 3' UTR were also constructed. The splicing by overlap 
extension PCR (SOEing PCR) was utilized to insert the mutations. The primers are listed in 
the Table 2.3. 
  
Cloning primers Primer sequence 
miR96/183 Fwd ATGCCATGGTCCTTGAAGGTCATCTTGGGCT 
miR96/183 Rev TACCATCGATAGGCAGTGTAAGGCGATCT 
miR155 Fwd ATGCCATGGGATCAAAGTCTTCAAATATGCCTAAAGG 
miR155 Rev TACCATCGATTGAACAAGCCAAAACCTGC 
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Table 2.3: Primers used for cloning 3ꞌ UTR and various mutations 
Name Primer sequence 
3' UTR Fwd CCGCTCGAGCTCCTCTCCCCAATCCATGC 
3' UTR Rev ACGCGTCGACTGCTTGCAGTCACTCCCAAA 
miR96-mut Fwd TCGATGCGTAATTGATCAGATGC 
miR96-mut Rev CGCATCGATAGCTGGATAAAGGTC 
miR183-mut Fwd GGCAGTGGCCATTGTGCTTTTTGGTGAGGG 
miR183-mut Rev AAAAGCACAATGGCCACTGCCCAGGGTG 
miR155-mut Fwd AATTTGGGATGCCGGCTAAATGCTCATACAC 
miR155-mut Rev CATTTAGCCGGCATCCCAAATTGAAAATGG 
 
2.2.6 Modification of inducible sleeping beauty system (pSBtetGP) for the 
overexpression of miRNAs and HER2 CAR 
The sleeping beauty vector (pSBtet-GP) was modified to express either miR96/183 or miR155 
under tetracycline inducible TCE promoter and anti-FRP5 HER2 CAR under constitutive 
promoter. Briefly, a multiple cloning site with EcoRI and NotI was cloned into pSBtet-GP 
using Bsu361 and BstBI restriction site to remove GFP-P2A-rtTA-P2A-Puromycin under 
RPBSA promoter. GFP-P2A-HER2 and P2A-rtTA were PCR amplified and were spliced 
together to create GFP-P2A-HER2-P2A-rtTA using SOEing PCR. A G72V mutation (Glycine 
to Valine) was also introduced in the rtTA sequence using inverse PCR. The primers are listed 
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Table 2.4: SOEing PCR primers used for pSBtet-GP modification 












rtTA Rev CTCAGTTCGAACCCGGGGAGCATGTCAAGGTCAAAATC 
GFP Rev CAGCAGGCTGAAGTTAGTAGCGCCGGACCCCTTGTACAGCTCGTC
CATGCCGAGAGT 
2.3 Cloning miRNA into lentiviral system 
2.3.1 Inducible system 
The miR96/183 and miR155 were PCR amplified from pSBtet-miR96/183 and pSBtet-miR155 
respectively using forward primer with NcoI overhang and reverse primer with KpnI overhang 
to remove poly A sequence from the vector present at the end of the miRNAs. The miRNAs 
were then cloned back into pSBtet-GP utilising NcoI and KpnI restriction sites. Next, GFP-
P2A-HER2-P2A-rtTA-G72V was PCR amplified from modified pSBtet-GP from previous 
section and was cloned into pSBtet-GP plasmid bearing miRNA (either miR96/183 or miR155) 
without a poly A sequence. TCE forward and rtTA reverse primers were used to PCR amplify 
the whole construct containing miR96/183 or miR155 and cloned into lentiviral vector (pCCL-
Sin) utilising the EcoRV and SalI restriction sites. The primers are listed in the Table 2.5. 
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Table 2.5: Primers used for cloning inducible lentiviral system 
Name Primer sequence 
NcoI-miR96/183 Fwd  TTATTCCATGGAGGCAGTGTAAGGCGATCTGG 
KpnI-miR96/183 Rev  TTATTGGTACCTCCTTGAAGGTCATCTTGGGCTG 
NcoI-miR155 Fwd  TTATTCCATGGTCAAAGTCTTCAAATATGCCTAAAGG 
KpnI-miR155 Rev  TTATTGGTACCTGAACAAGCCAAAACCTGC 
EcoRV-TCE Fwd TCTAGACGAGTTTACTCCCTATCAG 
SalI-rtTA Rev TGATTGTCGACTCACCCGGGGAGCATGTCAAGGTC 
 
2.3.2 Single promoter constitutive system 
2.3.2.1 hPGK promoter  
The miR96/183 or miR155 sequences were PCR amplified from pSBtetGP-miR96/183 and 
pSBtetGP-miR155 (as described earlier). Similarly, HER2-P2A and GFP were PCR amplified 
using primers shown in the Table 2.6. The three fragments were cut with Sap I (type IIs) 
restriction enzyme and were ligated into pCCL-Sin utilising BamHI-SalI restriction sites. 
Ligation was done in two steps; the fragments miR96/183 or miR155 and GFP were ligated 
first to the backbone (pCCL-Sin), after which HER2-P2A fragment was added to the ligation 
mixture to clone miRNA-HER2 CAR-GFP downstream of human PGK promoter (hPGK). 
2.3.2.2 EF1 alpha promoter  
EF1 alpha promoter (EF1α or EF1) was cut with BamHI-SalI restriction enzymes from pSBbi-
GP vector, phosphorylated and ligated to a pCCL-Sin vector cut with the same set of restriction 
enzymes to create pCCL-Sin-EF1. GFP-P2A-HER2 CAR was then PCR amplified from the 
dual promoter constitutive system mentioned later in 2.3.3 utilizing primers with BamHI-SalI 
overhang and was ligated to pCCL-Sin-EF1 utilising BamHI-SalI restriction enzymes creating 
pCCL-Sin-EF1-GFP-P2A-HER2 CAR construct. This construct was used as HER2 CAR 
construct (control HER2 CAR) throughout the experiments involving human T cells. The 
construct was further digested with SalI restriction enzyme and was ligated with the miRNAs 
(miR96/183 or miR155) that were PCR amplified from dual promoter constitutive system 
mentioned in 2.3.3 using; SalI-SalI overhang primers (Table 2.6).  
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Table 2.6: Primers used for cloning single promoter constitutive system 
Name Primer sequence 
BamHI-miR96/183 Fwd TTGTGGATCCAGGCAGTGTAAGGCGATCTGG 
BamHI-miR155 Fwd TTGTGGATCCTCAAAGTCTTCAAATATGCCTAAAGG 
miR96/183 Rev CACCACAGCTCTTCGATCGATGGTATCCTTGAAGGTCA 







GFP-P2A Fwd CACCACAGCTCTTCGCCCATGTTGAGCAAGGGCGAGG 
SalI-GFP Rev ACAACAGTCGACTTACTTGTACAGCTCGTCCATGCCG 
P2A Rev AACAGCTCCTCGCCCTTGCTCAACATGGGGCCAGGATTCTCCT
CGACGTCACC 
BamHI-GFP Fwd TCTGCGGATCCCCACCATGTTGAGCAAGGGCGAGGAGC 
SalI-CD3 Rev TTATTGTCGACTTAGCGAGGGGGCAGGGCCTGCATG 
SalI-miR96/183 Fwd TTGTGTCGACAGGCAGTGTAAGGCGATCTGG 
SalI-miR96/183 Rev TTATTGTCGACTCCTTGAAGGTCATCTTGGGC 
SalI-miR155 Fwd TTGTGTCGACTCAAAGTCTTCAAATATGCCTAAAGG 
SalI-miR155 Rev AATAAGTCGACTGAACAAGCCAAAACCTGC 
 
2.3.3 Dual promoter constitutive system 
2.3.3.1 Uni-directional (hPGK and RPBSA) 
BamHI-miR96/183 forward or BamHI-miR155 forward primer in combination with SalI-CD3 
reverse primer was used to PCR amplify the fragment miRNA (either 96/183 or 155)-RPBSA-
GFP-P2A-HER2-CAR from the inducible lentiviral system. It was then cut with BamHI and 
SalI restriction enzymes and were cloned into the pCCL-Sin system using BamHI and SalI 
restriction site downstream of hPGK promoter. The primers are listed in the Table 2.7. 
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Table 2.7: Primers used for cloning uni-directional lentiviral system 
Dual promoter primers Primer sequence 
BamHI-miR96/183 Fwd TTGTGGATCCAGGCAGTGTAAGGCGATCTGG 
BamHI-miR155 Fwd TTGTGGATCCTCAAAGTCTTCAAATATGCCTAAAGG 
SalI-CD3 Rev TTATTGTCGACTTAGCGAGGGGGCAGGGCCTGCATG 
 
2.3.3.2 Bi-directional (hPGK and EF1)  
EF1-HER2 CAR construct (control HER2 CAR) was utilized to construct bi-directional 
system. The hPGK and miRNA (either miR96/183 or miR155) was PCR amplified from 
hPGK-single promoter system and was ligated to the EcoRV-ClaI digested EF1-HER2 CAR 
fragment creating miRNA-hPGK-EF1-GFP-P2A-HER2 CAR construct. The primers are listed 
in the Table 2.8. 
Table 2.8: Primers used for cloning bi-directional lentiviral system 
Name Primer sequence 
EcoRV-hPGK Fwd  TTATTGATATCGAATTCCCACGGGGTTG 
ClaI-miR96/183 Rev TTATTATCGATTCCTTGAAGGTCATCTTGGGC 
ClaI-miR155 Rev AATAAATCGATTGAACAAGCCAAAACCTGC 
 
2.4 Transfection 
2.4.1 Transfection of HEK293 cells  
HEK293 and HEK293T cells were transfected using lipofectamine 3000 (Invitrogen) 
according to the manufacture’s protocol. For transfection, 1 × 106 HEK293 cells were cultured 
in antibiotic free DMEM per well in a six-well plate. Next day, two tubes with 125 µL Opti-
MEM were prepared for cells in each well and labelled as tube 1 and tube 2. Lipofectamine 
3000 (7.5 µL) was added to the tube 1 and 2500 ng DNA (transposase: sleeping beauty plasmid 
at a ratio of 1:5) along with 5 µL p3000 reagent was added to the tube 2. Tube 2 was then 
mixed with tube 1 and incubated for 10-15 minutes. The mixture was then added to the cells 
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and the plate was incubated at 37 °C with 5% CO2. The media was changed with fresh medium 
the following day. The same procedure was followed for the transfection of EL4 T cells. 
2.4.2 Transfection of Jurkat T cells 
NeonTM tranfection system was used to transfect Jurkat T cells. Briefly, cells were washed with 
PBS and resuspended in R buffer at a concentration of 2 × 107 cells/mL. A mixture of 
transposase to sleeping beauty plasmid at a ratio of 1:5 (6 µg total) was added to the cells. Cells 
were electrolyzed following manufacturer’s electroporation parameters (1350 volts, 3 pulse for 
10 seconds) and cultured in a six well plate with pre-warmed 2 mL media (RPMI-10% FBS) 
per well at 37 °C with 5% CO2. After 24 hours fresh media containing 2 µg/mL of puromycin 
in the final volume was added to select the cells stably expressing the transfected constructs.  
2.5 Lentivirus production and titration to determine viral titre 
A total of 22.1 × 106 HEK293T cells in 32 mL media were seeded in a T175 flask. Next day, 
the cells were transfected using lipofectamine 3000 according to the manufacturer’s protocol 
for lentivirus production. For each flask, two falcon tubes were prepared with 4.6 mL Opti-
MEM and labelled as tube A and tube B. To the tube A, 129 µL lipofectamine 3000 was added. 
To the tube B, 41.4 µg of viral packaging vectors (pRSV-Rev, pMDLg/pRRE and pMD2.G) 
and 13.8 µg of pLenti-based expression vector (pCCL-Sin) was added along with 111 µL 
P3000 reagent. The contents of tube B was added to the tube A and was incubated at RT for 
15 minutes. The mixture was then added to T175 flask. Next morning, the media was replaced 
with pre-warmed packaging medium (Opti-MEM with 5% FBS and Penicillin/Streptomycin) 
and the flask was incubated at 37 °C with 5% CO2. The viral supernatant was collected in a 
polycarbonate tubes (Beckman Coulter, #355655) at both 48 and 72 hours after transfection 
and were centrifuged at 120,000 g for 2 hours (L80-XP). The supernatant was discarded, and 
remaining pellet was resuspended in TCE media. The virus was aliquoted into cryovials and 
stored at -80 °C. 
For titration, HEK293T cells were cultured in a 24-well plate at a density of 50,000 cells/well 
in 0.5mL DMEM with 10% FBS (Day 1). Next day, the cryopreserved virus was slowly thawed 
on ice. Serial dilution of the lentivirus was prepared from 1 × 10-1 to 1 × 10-5 in polybrene 
containing media (DMEM with 10 % FBS and polybrene at a final concentration of 8 µg/mL) 
and was added to the 24-well plate after removing the media. The plate was briefly centrifuged 
at 450 g for 20 minutes and incubated (Day 2). Next day, the virus containing media was 
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changed with fresh media (Day 3).  On day 6, the cells were washed with PBS and fixed with 
2% paraformaldehyde. Fixed cells were resuspended in 0.1% BSA/PBS/2 mM EDTA solution 
and acquired in flow cytometer to determine GFP expression. The viral titre was then calculated 
based on the GFP percentage using the formula given below. 
 
2.6 Transduction  
2.6.1 Transduction of T cells 
Cryopreserved PBMCs were thawed from liquid nitrogen and rested in TCE medium overnight. 
Next morning, T cells were isolated using EasySepTM human T cell isolation kit according to 
the manufacturer's protocol. Isolated T cells were resuspended at 1 × 106 cells/mL along with 
prewashed Dynabeads (Thermo Fischer Scientific #11132D) at 1:1 ratio. To prewash the 
Dynabeads, the beads were vortexed for at least 30 seconds and calculated amount of beads 
were transferred to a 5 mL polystyrene tubes containing 2 mL media. The beads were vortexed 
again and the tube was placed on a magnetic stand for two minutes. The media was carefully 
removed, and fresh media was added to the beads before mixing it to the T cell suspension. 
Next day, a 24-well plate was coated with 40 µg/mL retronectin (diluted in PBS; MediꞌRay 
#TKT100B) and was incubated at 4 °C for 24hrs. The plate was then blocked with 2% FBS (in 
PBS) for 30mins and washed with PBS. Lentivirus at a multiplicity of infection (MOI) of 45 
was added to the wells and the plate was centrifuged at 2000 g for 2 hours at RT. After two 
hours, virus was removed from the wells and activated T cells were transferred into the well at 
a concentration of 1 × 106 cells/mL in 0.5 mL media along with 50 U/mL of IL-2. The plate 
was again centrifuged at 800 g for 20 minutes. Next day, cell-bead complexes were pipetted 
slowly, and beads were removed from the cells using a magnet stand and the cells were cultured 
in fresh media with IL-2 into a new 24-well plate at concentration of 1 × 106 cells/mL.  
2.6.2 Transduction of HEK293T cells  
HEK293T cells were cultured in a 24-well plate at a density of 300,000 cells/well in 0.5 mL 
DMEM with 10% FBS. Next day, the cryopreserved virus was slowly thawed on ice and the 
media containing 8 µg/mL polybrene (Sigma-Aldrich # 28728-55-4) was prepared. The media 
in the 24-well plate was discarded and lentivirus at a MOI of 2 in polybrene containing media 
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was added to the HEK293T cells. The plate was centrifuged at 450 g for 20 minutes and 
incubated. After 24 hours, the media containing lentiviral particles was removed and was 
replaced with fresh media. 
2.7 Western blotting 
For ERK phosphorylation, HEK293 cells expressing CXCR3, A1-CXCR3 or A2A-CXCR3 
were serum starved for 2-3 hours (incubated with DMEM containing 0.5% Bovine Serum 
Albumin, BSA) and were treated with either 100 ng/mL CXCL11, 100 nM CGS-21680 
hydrochloride hydrate (CGS21680) or 100 nM 2-chloro-N6-cyclopentyladenosine (CCPA) 
respectively for different time points. HEK293 cells were stimulated with 25 ng/mL of phorbol 
myristate acetate (PMA, Calbiochem #407950) and 0.75 µg/mL of ionomycin (Calbiochem 
#524400) for 5 minutes and used as a control. For other experiments involving the detection of 
gene expression at protein level, HEk293T cells transfected with pSBtet-GP incorporating 
either miR96/83 or miR155 were treated with doxycycline for 48 hours. Following treatment,  
all cells, irrespective of the treatments, were briefly spun, supernatant was removed and the 
cells were lysed with 100 µL of RIPA lysis buffer (0.02% azide, 150 mM NaCl, 0.25% CHAPS, 
0.5% Triton-X100, 100 mM Tris, pH 8.0) and freshly added complete protease inhibitor (Roche 
#25178620), vanadate (100 mM) and okadaic acid (1mM). The cells were lysed in RIPA lysis 
buffer and the protein in cell lysate analysed by BCA. A total of 10 μg protein was separated 
by SDS-PAGE using Bolt 4-12 % Bis-Tris Plus gel (Invitrogen) along with a pre-stained 
protein ladder (SeeBlueTM plus2; ThermoFischer scientific; # LC5925 or Colour Prestained 
protein standard; New England Biolabs; # P7719S), transferred to nitrocellulose membrane 
(Bio-Strategy; # GE10600016) and blocked with 1% BSA/PBS for an hour. Following 
blocking, the membrane was incubated overnight with primary antibody in 1% BSA/PBS at 4 
°C. Next day, membrane was washed three times with PBS/0.1% Tween 20 (PBST) solution 
for 20 minutes and incubated with the secondary antibody in 1 % BSA/PBS for an hour. A list 
of primary and secondary antibodies used is shown in the Table 2.9 and Table 2.10 respectively. 
Following antibody treatment, the membrane was washed three times with PBST solution and 
scanned using Odyssey Fc Imaging system (Licor, USA). Analysis was performed using Image 
StudioTM Lite software (LI-COR Biosciences). To quantify the western blot images, integrated 
pixel densities were measured, and the background was subtracted from the values and finally 
normalized with the values of loading control (β-actin). 
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Table 2.9: List of primary antibodies used for western blotting 
Primary antibodies used Manufacturer Dilution Used 
p44/42 MAPK (Erk ½) CST #9107 Cell Signaling Technology 1:1000 
phospho-p44/42 MAPK (Erk ½) (Thr 
202/Tyr204) #4377 
Cell Signaling Technology 1:2000 
Mouse monoclonal β-actin (A1978-200UL) Sigma-Aldrich 0.5 mg/mL  
Rabbit monoclonal PKA RI-α (D54D9) 
(5675)  
Cell Signaling Technology 1:1000 
Mouse monoclonal anti- EGFP (ab184601) Abcam 1:1000 
Biotin anti-c-myc (# BIOT-150L)  Thermo Fisher Scientific 1:2500 
 
Table 2.10: List of secondary antibodies used for western blotting 
Secondary antibodies used Manufacturer Dilution Used 
Anti-mouse IgG, DyLight 680 #SA5-10170 Thermo Fisher 
Scientific 
1:10000 
Anti-rabbit IgG, DyLight 800 #SA5-10044 Thermo Fisher 
Scientific 
1:10000 




2.8 Luciferase assay 
HEK293 cells were transfected with the combination of pmirGLO with PRKAR1A 3' UTR and 
pSBtet-GP empty plasmid or the combination of pmirGLO with PRKAR1A 3' UTR and pSBtet-
GP with miRNAs (either miR96/183 or miR155) or the combination of pmirGLO with 
PRKAR1A with mutated 3' UTR and pSBtet-GP with miRNAs (either miR96/183 or miR155) 
at 1:1 ratio using lipofectamine 3000. The following day, doxycycline (5 μg/mL) was added to 
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the cells. After 48 hours of doxycycline treatment, luciferase assay was carried out using Dual-
Glo luciferase assay system (Promega, #E2920). Briefly, cells were plated in a 96-well flat-
bottom plate at a concentration of 2 × 106 cells/mL (50 µL/well) and 50 µL Dual-Glo reagent 
was added to each well. The plate was incubated at RT for 45 minutes and the firefly 
luminescence was measured in Varioscan Luv multimode microplate reader (Thermofischer, 
USA). To the same plate, 50 µL/well Dual-Glo Stop and Glo-Reagent mix was added and 
incubated at RT for additional 45 minutes. The plate was then used to measure Renilla 
luminescence in the same order as firefly luminescence. For analysis, ratio of the reading for 
firefly luminescence to Renilla luminescence for the same well was taken and were normalized 
with the ratio of the control well (HEK293 cells transfected with the combination of pmirGLO 
with PRKAR1A 3' UTR and pSBtet-GP empty plasmid). 
2.9 RNA extraction, cDNA synthesis and real-time RT-PCR 
HEK293 cells were transfected with either pSBtet-miR96/183 or pSBtet-miR155 and treated 
with doxycycline for 24 hours, 48 hours and 72 hours. The cells were then lysed, and total 
RNA was extracted using Nuceospin RNA plus kit (MACHEREY-NAGEL). The RNA was 
then converted to cDNA using PrimeScript RT reagent kit (Takara bio) following incubations 
at 25 °C, 37 °C, 42 °C for 15 minutes each and final inactivation at 85 °C for 5 minutes. For 
RT-PCRs to assess miRNA overexpression, RT-Forward primers were also added in the 
reaction mix (Table 2.11). SNORD47 was used as a housekeeping gene for miRNA 
overexpression. For real time RT-PCR, the master mix was prepared by mixing Luna® 
Universal qPCR Master Mix (NEB) and forward and reverse primers. A total of 1 µL of diluted 
cDNAs (1:2 dilution) were added to the mix. The reaction was carried out using the following 
cycling conditions: initial denaturation at 95 °C for 60 seconds and 40 cycles of denaturation 
at 95 °C for 15 seconds and extension at 60 °C for 30 seconds. The primers used are listed in 
Table 2.11. Gene expression was calculated by comparative Ct (2-ΔΔCt) method as follows:  2-
ΔΔct = 2-(ΔCt [sample] – ΔCt [control]) using β-actin as a house keeping gene; ΔCt for sample and control 
was calculated as ΔCt (sample or control) = Ct (sample or control) – Ct (β-actin). The real time 
PCR primers to assess expression of PRKAR1A, TET2, FOXO3, PTPN2 and IL-6R are shown 
in the Table 2.12. 
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Table 2.11: Primers used for real time RT-PCR 











miR96-qPCR Fwd  CGTTTGGCACTAGCACAT 
miR183-qPCR Fwd  TATGGCACTGGTAGAATTCACT 
miR155-qPCR Fwd GCGGTTAATGCTAATCGTGATA 
SNORD47-qPCR Fwd ATCACTGTAAAACCGTTCCA 
Uni-reverse-qPCR GAGCAGGGTCCGAGGT 
 
Table 2.12: Primers used for real time PCR 
Name Primer sequence 
-actin Fwd CTTCCTTCCTGGGCATG 
-actin Rev GTCTTTGCGGATGTCCAC 
PRKAR1A Fwd TTGACGTCAGTAGCCGAACG 
PRKAR1A Rev GGGCACAAAAGTCAACTGG 
TET2 Fwd CCCGCTGAGTGATGAGAACA 
TET2 Rev AATGTTTGCCAGCCTCGTTC 
FOXO3 Fwd CTACGAGTGGATGGTGCGTT 
FOXO3 Rev TGTGCCGGATGGAGTTCTTC 
PTPN2 Fwd GCATTGTGGAGAAAGAATCGGTTA 
PTPN2 Rev TCTGACAAGAGCTTCACACTGA 
IL-6R Fwd GGGACCATGGAGTGGTAGC 
IL-6R Rev ACTGGTCAGCACGCCTCT 
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2.10 ELISA 
Jurkat cells transfected with pSBtet-GP to overexpress miR96/183 and miR155 (1 × 106 
cells/mL) were treated with doxycycline (concentration) for a total of 48 hours and activated 
with 2.5 µg/mL of CD3 (BioLegend #317315) and 2.5 µg/mL of CD28 (BioLegend #302923) 
for final 24 hours. The supernatant was collected and centrifuged at 500 g for 5 minutes to 
remove any cells/debris before transferring to a 96 well plate precoated with 2 µg/mL (100 
µL/well) purified mouse anti-human IL-2 (BD; # 555051) and IFN-γ capture antibody (BD 
Pharmingen; # 551221). Prior to adding supernatant, the 96 well plate with the capture 
antibodies was washed with 0.05% Tween20/ PBS (PBST) three times and blocked with 1% 
BSA/PBS for 30 minutes. The IL-2 and IFN-γ (PeproTech #300-02-100ug) protein standards 
were also prepared (concentrations ranging from 20 ng/mL to 0.0195 ng/mL for IL-2 and 40 
ng/mL to 0.0390 ng/mL for IFN-γ) and placed alongside the samples in the 96-well plate. 
Following overnight incubation at 4 °C, the plate was washed and was incubated with 1 µg/mL 
biotinylated anti-human IL-2 (BD Pharmingen; #555040) or IFN-γ (BD Pharmingen; 
#5514550) gamma for 1 hour followed by incubation with 1/5000 strepavidin-POD conjugate 
(Sigma-Aldrich; # 11089153001) for 1 hour. The plate was washed three times with PBST in 
between these incubations. Finally, TMB (3, 3ꞌ, 5, 5ꞌ-tetramethylbenzidine, 100 µL/well; 
Thermo Fischer Scientific #00-202-3) solution was added to each well and incubated till the 
colour of the wells changed from colourless to blue. The reaction was stopped with 2N 
sulphuric acid (H2SO4, 50µL/well) and the absorbance was measured in a Varioscan Luv 
multimode microplate reader at 450 nm. The standard curve of IL-2 and IFN-γ was used to 
determine the concentration of IL-2 and IFN-γ respectively in the samples.  
For experiments assessing anti-FRP5 HER2 CAR activation, the miRNA±HER2 CAR 
transduced human primary T cells were assessed for GFP expression by flow cytometry to 
calculate percent transduction. The cells were maintained to have same percent transduction 
across all the samples by mixing untransduced cells. A total of 100,000 cells/well were cultured 
on the top of one-day cultured MCF7 cells (E: T 100,000:50,000) in a 96 well plate for 24 
hours. Next day, the supernatant was collected, and cytokines (IL-2 and IFN-γ) were quantified 
by ELISA. 
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2.11 Cytotoxicity assay 
The breast cancer cell line MCF-7 stably transfected with firefly luciferase and HER2 antigen 
was seeded in a 96-well plate at a density of 104 cells/well in DMEM 10% FBS media. Before 
the experiment, the T cell transduction percentage (% of GFP positive cells) was determined 
and the cells were maintained to have same percent transduction across all the samples by 
mixing untransduced cells. A total of 105 T cells/100 µL/well were co-cultured with the MCF-
7 cells (E: T 10:1). After 24 hours, the supernatant from 96-well plate was removed carefully 
so that only 50 µL media remained in the wells. The T cell cytotoxicity assay was measured 
by pierce firefly luc one-step glow assay kit (Thermo Fischer Scientific, #16197) as per the 
manufacturer’s protocol. A working solution of firefly luc one-step glow assay was prepared 
and added into the wells (50 µL/well). The plate was then incubated at RT for 45 minutes and 
the luminiscence was measured in a Varioscan plate reader. The luciferase readings were 
analysed as percent killing by using the formula below.  
 
2.12 Flow cytometry  
2.12.1 Surface staining 
Cells directly following culture or treatment were washed twice with PBS and stained for the 
surface proteins for 25-30 minutes in ice. Following surface staining, cells were fixed with 2% 
paraformaldehyde for 20 minutes in ice followed by two times PBS washes. Samples were 
acquired in LSR Fortessa (BD Biosciences) and were analysed by FlowJoTM V10 (TreeStar, 
Ashland, USA). The dead cells were excluded using Zombie NIR Live/dead stain in all 
experiments. The antibodies used for staining surface proteins in primary human T cells 
(untransduced and transduced) are shown in Table 2.13. 
For assessing the expression of CXCR3, cells were stained with 1 µg/mL anti-CXCR3-BV421 
(mouse) antibody (Biolegend). For c-myc staining, the cells were stained with 2 µg/mL of 
biotin conjugated anti-c-myc antibody (BioLegend, #BIO908805) followed by 1:200 
Streptavidin-APC (BioLegend) in 0.1% BSA/PBS/2 mM EDTA solution. 
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Table 2.13: Antibodies used for staining primary human T cells 
Antibodies   Source Catalog no. # 
anti-CD3-AF 700 BioLegend 300424 
anti-CD4-BV711 BD Horizon 563028 
anti-CD8-BV786 BD Horizon 563823 
anti-CD45RO-PE-CF594 BD Horizon 562299 
anti-CD45RA-PE BD Pharmingen 555489 
anti-CD69-APC BioLegend 310910 
anti-CD25-PE-Cy7 BD Pharmingen 557741 
anti-CD27-BB700 BD Horizon 566449 
anti-CD62L-BV605 BD Horizon 562719 
anti-CD57 BD Horizon 563896 
anti-CD197(CCR7)-APC BioLegend 353214 
anti-CXCR3 BD OptiBuild 746283 
anti-CD127-AF 647 BD Pharmingen 558598 
anti-CD95-BV650 BD OptiBuild 740589 
Live/DeadTM NIR ThermoFischer Scientific L10119 
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2.12.2 Calcium flux assay 
A total of 5 × 105 HEK293 cells expressing CXCR3 or the chimeric constructs were incubated 
with 1 μM Fluo-4 acetoxymethyl ester (Fluo-4 AM, Invitrogen #F14201) for 40 minutes and 
washed and resuspended in DMEM with 2% FBS. The cells were then acquired in flow 
cytometer (LSR Fortessa) for two minutes to measure baseline calcium level. The tubes were 
removed and stimulating ligand was added and immediately acquired for an additional two 
minutes to assess signal transduction. CXCL11 (100 ng/mL, NOVUS), CCPA (Sigma, 20 nM-
1000 nM) and CGS21680 (Abcam, 20 nM-1000 nM) was used as stimulating ligands for 
HEK293 cells expressing CXCR3, A1-CXCR3 and A2A-CXCR3 respectively. Cells were kept 
at 37 °C throughout the experiment. 
2.13 Migration assay 
EL4-T cells expressing CXCR3 or the chimeric construct TDAG8-CXCR3 (both expressing 
GFP) were washed with 0.5 % BSA/PBS and resuspended in serum-free media at 1:1 ratio to 
EL4 only control cells transfected with empty pSBbi-RP plasmid expressing RFP. A total of 
1.5 × 105 cells/100 µL were transferred in the upper compartment of 8 µm pore size (6.5 mm 
diameter) polycarbonate membrane transwell (Corning, New York, USA) and allowed to 
migrate in response to the chemotaxis media added in the lower compartment (600 µL); 
CXCR3 (100 ng/mL) in RPMI for EL4-CXCR3-GFP and control EL4-RFP or media adjusted 
to different pH (6, 6.5, 7 and 7.5) for TDAG8-CXCR3-GFP and control EL4-RFP. After four 
hours of incubation at 37 °C with 5% CO2, the migrated cells in the lower compartment were 
collected and centrifuged. Cells were resuspended in 30 µL PBS and counted using an epi-
fluorescent microscope (Olympus IX-7, USA). 
2.14 Protein production and purification 
The pQE80L expression plasmid with CXCL11 was transformed into E. coli BL21 (DE3). A 
colony of transformed E. coli was inoculated into LB (Luria-Bertani) broth to prepare the 
starter culture for protein production and was incubated at 37 °C in a shaking incubator 
maintained at 200 rpm until the optical density (OD600) reached approximately 0.7. The culture 
was treated with 1M isopropyl β-D-1-thiogalactopyranoside (IPTG) (final concentration 1 
mM) for at least 4 hours to induce protein production and spun at 8000 rpm for 15 minutes at 
4 °C (Beckman Avanti J2-21). The pellet was then resuspended in TE buffer (10 mM Tris, 1 
mM EDTA, pH 8) and was spun at 8000 rpm for 15 minutes at 4 °C followed by overnight 
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incubation at -20 °C. Next day, the pellet was sequentially washed with 20 mL 10 mM Tris 
buffer containing DNase (20 µg/mL) and lysozyme (2 mg/mL) followed by 20 mL urea-TE 
buffer (4 M Urea, 10 mM Tris, 1 mM EDTA, pH 8) and 20 mL of Triton X-TE buffer (1% 
Triton X-100, 10 mM Tris, 1 mM EDTA). During each step, the resuspended pellet was 
centrifuged at 12,500 rpm for 15 mins at 4 °C. The resulting pellet was resuspended in 15 mL 
Guanidine-HCL-TE buffer (6M guanidine hydrochloride, 10 mM Tris, 1mM EDTA, pH 8) and 
was left overnight on a rocker at RT. For purification, the protein after centrifugation was run 
through Ni-NTA column. Briefly, the column was first equilibrated with NPI-10 buffer (50 
mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8) and the protein was run through the 
column. The column was then washed with NPI-20 buffer (50 mM NaH2PO4, 300 mM NaCl, 
20 mM imidazole, pH 8) and the protein was eluted in NPI-250 buffer (50 mM NaH2PO4, 300 
mM NaCl, 250 mM imidazole, pH 8) and dialysed against 100 mM acetic acid. 
2.15 Coomassie blue spot test and BCA 
Protein samples (diluted with PBS) and BSA standards (prepared at concentrations ranging 
from 2 mg/mL to 0.062 mg/mL) were pipetted onto a filter paper (1 µL/sample) and were 
allowed to air dry. The filter paper was stained with Coomassie brilliant blue G-250 stain for 
5-10 minutes on a rocker. The filter paper was removed and washed with Coomassie-destain 
solution. The protein concentration was determined based on colour intensities of the protein 
spots on filter paper and quantified by Odyssey as required. 
To stain protein gels (Bolt 4-12% Bis-Tris Plus gel), the gels were flooded with Coomassie 
stain and were incubated for an hour. The gel was treated overnight with Coomassie-destain 
solution in a rocker before scanning it in the Odyssey. 
The BCA protein assay kit (Thermo Fischer Scientific, #23225) was also used to determine 
protein concentration as per the manufacturer’s protocol. The protein samples were diluted in 
PBS and loaded into a 96 well plate alongside standards. The absorbance was read at 562 nm 
in a Varioscan Luv multimode microplate reader following incubation at 37 °C. The standard 
curve was used to determine the concentration of unknown protein sample. 
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2.16. Statistics 
Statistical analysis was performed in Graph Pad Prism (GraphPad, San Diego, CA). Data are 
presented as mean ± standard error of mean (SEM). Paired t-test was used when two treatments 
were compared, while one-way analysis of variance (ANOVA) and two-way ANOVA with 
Sidak and Tukey posttest respectively were used for the multiple comparison. A p-value of 
0.05 or lower was considered significant. 
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3.1 Background 
The presence of various inhibitory metabolites, such as adenosine, lactate and the acidic pH in 
and around solid tumour environment restricts the migration and activation of tumour 
infiltrating T cells. Although these metabolites are immunosuppressive in nature, we wanted 
to overcome such immunosuppression and enhance function of T cell by exploiting these 
metabolites. A major signaling pathway for T cell activation in the TME is the conventional T 
cell receptor activation following recognition of tumour antigen [330, 331]. However, 
additional signaling through G protein coupled receptor (GPCR) is also equally important for 
T cell migration to the tumour site and optimal activation within the microenvironment [257, 
332]. Among the several GPCRs, CXCR3 is an important chemokine receptor which is found 
to be highly upregulated in activated T cells and plays an important role in trafficking cytotoxic 
T lymphocytes to the site of inflammation [260, 267]. However, most solid tumours have been 
shown to produce a limited set of chemokines, including the ligands for CXCR3, in a very low 
amount leading to poor infiltration of T cells [333]. Furthermore, the immunosuppressive 
signals attenuate the activation of the tumour invading T cells conferring tumour the upper 
hand in the battle. The main aim of this chapter is to overexpress CXCR3 and check for its 
suitability to use for designing chimeric receptors for exploitation of tumour microenvironment 
to benefit cancer immunotherapy. We therefore designed chimeric CXCR3 receptor utilising 
either A1 or A2A adenosine receptors to determine if adenosine in tumour microenvironment 
could be utilised to traffic the chimeric CXCR3 receptors; A1-CXCR3 and A2A-CXCR3 to 
the tumour microenvironment. Likewise, TDAG8 receptor was also utilised to design acidic 
pH responsive CXCR3 chimera, TDAG8-CXCR3 (T8-C3). Previously, chimeric receptors 
designed by splicing GPCRs from the same families has been shown to be functional [334-
336]. TDAG8 and CXCR3 both belong to the same family of receptors (class A Rhodopsin 
receptor), however, we also investigated if splicing GPCRs from different family such as 
adenosine receptor (purinergic receptor or P1 receptor) to CXCR3 receptor rewires the receptor 
causing transduction of extracellular signal and stimulation of downstream signaling. We 
optimized assays to detect calcium mobilisation, ERK phosphorylation and migration to assess 
downstream functionality of the overexpressed CXCR3 alone. The chimeric receptor (A1-
CXCR3, A2A-CXCR3 and T8-C3) were then tested with the optimised assays. Additionally, 
we also produced the CXCL11; CXCR3 ligand, in E coli and tested its functionality. 
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3.2 Results 
3.2.1 Transfection of CXCR3 in different cell lines using sleeping beauty system 
First, we utilised the sleeping beauty system pSBbi-GP to incorporate CXCR3 and stably 
transfected EL4 T cells and HEK293 cells with CXCR3 receptor cloned into vector; final 
construct used for transfection is shown in Figure 3.1 A. EL4 T cells are one of the commonly 
used T cell lines in in vitro experiments and are suitable T cell line to assess migratory ability. 
HEK293 are easy to transfect and thus is the most used cell line for GPCR research [337]. 
Following puromycin selection, transfected cells were all positive for RFP expression (reporter 
gene) (Figure 3.1 B). Both cell lines showed enhanced surface expression of CXCR3 compared 
to respective non-transfected control cells when stained with anti-CXCR3 antibody and 
determined by flow-cytometry (Figure 3.1 C). 
Figure 3.1 Stable transfection of CXCR3 in EL4 T and HEK293 cells with sleeping beauty system. 
(A) Constitutive sleeping beauty system (pSBbi-GP/RP) with EF1 promoter that drives the gene of 
interest (CXCR3) and RPBSA promoter that drives fluorescent protein (GFP or RFP) and puromycin. 
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(B) Histogram showing RFP expression on transfected and non-transfected EL4 T and HEK293 cells 
assessed by flow cytometry. (C) Histogram for CXCR3 surface expression assessed by flow cytometry 
following staining of transfected and non-transfected EL4 and HEK293 with Brilliant Violet 421 
conjugated to murine anti-CXCR3 antibody. Dotted line represents non-transfected and solid line 
represents transfected cells (B and C). 
3.2.2 Production of recombinant CXCL11 in E coli 
Next, we aimed to synthesise the ligand (CXCL11) for CXCR3 to examine whether the CXCR3 
overexpressed in EL4 T and HEK293 cells was functional. Previously we had successfully 
produced and purified IL2 recombinant protein in our laboratory from E. coli inclusion bodies. 
We used this optimised protocol to produce recombinant CXCL11 with N-terminal Histidine 
tag. E. coli BL21 (DE3) strain was transformed with pQE80L expression plasmid (Figure 3.2 
A) containing the CXCL11 construct (Figure 3.2 B) and sub-cultured on ampicillin containing 
LB agar plate. Following day, a colony was selected and inoculated in 250 mL LB culture at 
37 °C, protein production was induced by IPTG treatment and sequentially purified. During 
each step of protein production and purification, we saved the bacterial pellet and the 
supernatant for later to run in SDS-PAGE gel and stain with Coomassie blue to detect the 
protein bands (Figure 3.2 C). Since CXCL11 was aggregated into inclusion bodies, it was 
detected predominantly in the pellet fractions following IPTG induction and lysis (lane 6, 8 
and 10) than the respective supernatant fractions (7, 9 and 11) but was hardly detected when 
left uninduced or not subjected to lysis (lane 2 to 5) [338, 339]. Following lysis and washing 
with urea-TE buffer and Triton X-TE buffer, protein pellets were solubilised with guanidine 
HCL Tris-EDTA. We detected more CXCL11 in the supernatant fractions (final solubilisation) 
following guanidine treatment (lane 13) compared to urea (lane 9) and triton-x 100 (lane 11) 
treatments. Interestingly, almost no CXCL11 was detected in the pellet fraction after guanidine 
treatment indicating the solubilisation step was highly efficient. Finally, we achieved a protein 
yield of 770 µg in 1 mL when CXCL11 was purified from the protein fraction using Ni-NTA 
column chromatography followed by dialysis (lane 15). However, when we incubated EL4 T 
cells expressing CXCR3 with the purified CXCL11 and performed western blotting, no ERK 
phosphorylation was detected (data not shown). Commercial CXCL11 was used as a positive 
control. 
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Figure 3.2 Recombinant CXCL11 (His-CXCL11) synthesis and purification. (A) pQE80L vector 
used for CXCL11 expression in E.coli BL21 strain and (B) the strategy used to clone CXCL11 with 
His tag in N terminal in pQE80L utilising BamHI and HindIII restriction enzymes (C) SDS-PAGE 
analysis of the pellet and supernatant during each protein purification step; samples were prepared from 
each step, run in Bolt 4-12% Bis-Tris Plus gel, stained with Coomassie blue and image was taken by 
Odyssey imaging system. The order of the lanes is as follows: (1) protein marker, (2) bacterial pellet, 
(3) un-induced bacterial culture supernatant sample, (4) IPTG induced bacterial pellet, (5) IPTG 
induced bacterial culture supernatant, (6) lysed IPTG induced bacterial pellet, (7) supernatant following 
lysis of IPTG induced bacterial pellet, (8) Urea pellet, (9) supernatant following Urea treatment, (10) 
Triton X pellet, (11) supernatant following Triton X wash, (12) Gu-HCL-TE pellet, (13) supernatant 
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following Gu-HCL-TE solubilization, (14) undialysed and (15) dialysed fraction of Gu-HCL-TE 
supernatant from previous step, and (16) protein marker. The closest band size of protein marker (17 
kDa) to CXCL11 is also indicated on the figure. 
As an alternative approach, we modified the protein production process by designing CXCL11 
with a pectate lyase B (PelB) signal sequence and a C-terminal His tag (Figure 3.3 A) and 
cloned PelB-CXCL11 into the pQE80L expression plasmid. PelB signal consists of a 
hydrophobic core that consists of 20-30 amino acids followed by a proteolytic cleavage site 
and is commonly used to direct the recombinant proteins in E. coli to the periplasm and reduce 
the formation of protein inclusion bodies [340, 341]. The addition of PelB also made the protein 
purification process less tedious as there was no need of treatment with chaotropic agents such 
as urea and guanidine following bacterial lysis. Once the bacterial culture reached the OD of 
approximately 0.7, IPTG induction was carried out for 2, 4 and 8 hours in 50 mL LB culture at 
30°C to determine optimal time of protein induction. As expected, CXCL11 was barely 
detected when bacteria were not lysed and not detected when culture supernatant following 
bacterial culture centrifugation was used (lane 4 to 9) (Figure 3.3 B). More CXCL11 was 
detected in lysed bacterial pellet fractions compared to supernatant fractions following lysis 
which was in contrast to the suggestion by various literatures [342, 343] this was seen for all 
IPTG induction time points (2, 4 and 8 hours) as shown in lane 11 to 16. However, the 
supernatant after lysis of the bacteria following 8 hours of induction (Lane 16) showed higher 
CXCL11 intensity compared to supernatants after 2 hours of induction (lane 12) or 4 hours 
(lane 14). CXCL11 was purified from the protein collected after 8 hours of IPTG induction and 
lysis using Ni-NTA column followed by dialysis. The protein yield was determined by 
Coomassie blue staining to be 93 µg when eluted in 1 mL. Unfortunately, CXCL11 obtained 
using this (PelB-CXCL11-His) strategy was also not functional when used for EL4-CXCR3 T 
cell activation and assessed for ERK phosphorylation by western blotting. Furthermore, the 
protein also precipitated soon after dialysis.  
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Figure 3.3 Recombinant CXCL11 (PelB-CXCL11-His) synthesis and purification. (A) The strategy 
used to clone CXCL11 with PelB signal sequence on N terminal and His tag on C terminal in pQE80L 
utilising EcoRI and HindIII restriction enzymes. (B) SDS-PAGE analysis of the pellet and supernatant 
during each protein purification process (pelB-CXCL11-His). Samples were prepared from each step, 
run in Bolt 4-12 % Bis-Tris Plus gel, stained with Coomassie blue and image was taken by Odyssey 
imaging system. The order of the lanes is as follows: (1) MW marker, (2) IPTG non-induced bacterial 
pellet, (3) IPTG non-induced bacterial culture supernatant, (4) IPTG induced bacterial pellet (2 hours), 
(5) IPTG induced bacterial culture supernatant (2 hours), (6) IPTG induced bacterial pellet (4 hours), 
(7) IPTG induced bacterial culture supernatant (4 hours), (8) IPTG induced bacterial pellet (8 hours), 
(9) IPTG induced bacterial culture supernatant (8 hours), (10) MW marker, (11) lysed bacterial pellet 
(2 hours), (12) supernatant after lysis of bacteria (2 hours), (13) lysed bacterial pellet (4 hours), (14) 
supernatant after lysis of bacteria (4 hours), (15) lysed bacterial pellet (8 hours), (16) supernatant after 
lysis of bacteria (8 hours). The closest band size of MW marker (17 kDa) to CXCL11 is also indicated 
on the figure. 
3.2.3 Testing the functionality of overexpressed CXCR3 
Failing to synthesise functional CXCL11 in E. coli, we purchased commercially available 
CXCL11 and investigated if the CXCR3 expressed on the surface of both HEK293 and EL4 T 
cells was functional by incubating cells with the CXCL11 and assessed calcium mobilisation 
and ERK phosphorylation as a readout of signal transduction. 
- 63 - 
 
Calcium ions are regarded as secondary messenger that regulates a wide range of physiological 
processes. The transduction of extracellular signals into intracellular response as a result of 
GPCR coupling to G protein causes calcium mobilisation. A measurement of change in calcium 
concentration in the cell is a convenient method of detecting GPCR induced signaling and has 
been extensively used in experiments involving GPCR-targeted drug therapy [344, 345]. For 
our experiment, we stained EL4-CXCR3 T and HEK293-CXCR3 cells (both expressing RFP 
following transfection) with Fluo-4-AM (non-fluorescent acetoxymethyl ester) and measured 
the intracellular (basal) level of calcium after which 100 ng/mL of CXCL11 was added to the 
cells and the cells were acquired again to detect any increase in calcium level due to CXCL11 
induced signaling via CXCR3. As Fluo-4-AM enters into the cells, the hydrophobic component 
AM gets cleaved by an endogenous esterase enzyme leaving the dye inside the cell. Binding 
of calcium to the dye renders it fluorescent which is detected by flow cytometry using B530/30 
nm channel [346]. Addition of CXCL11 to both EL4-CXCR3 T and HEK293-CXCR3 cell 
lines resulted in an increase in the calcium flux as detected by the rise in intensity of Fluo-4-
AM fluorescence. Cells treated with PMA (25 ng/mL) and Ionomycin (0.75 μg/mL) as positive 
control also showed rapid calcium mobilisation (Figure 3.4 A). 
Next, we performed western blotting as an alternative approach to confirm cell activation by 
measuring phosphorylated ERK when HEK293 cells were treated with the CXCL11. 
Extracellular signal related kinase (ERK1/2 or p42/44), related to the mitogen activated protein 
kinase family (MAPK) [347], phosphorylation of several downstream effectors is a 
downstream event of GPCR activation, essential for various induced cellular functions [348]. 
Treatment of HEK293 cells expressing CXCR3 receptor with CXCL11 ligand showed 
substantial phosphorylation of ERK, as compared to no CXCL11 treatment (0 min control) 
(Figure 3.4 B). The appearance of crisp phosphorylated ERK bands within a minute of 
CXCL11 addition highlights the rapidity of GPCR transduction processes. The positive control 
(PMA/ionomycin treated) HEK293 cells also clearly showed phosphorylation of ERK. Overall, 
the results from both calcium mobilisation and ERK phosphorylation assays suggest the 
overexpressed CXCR3 is functioning as it should in response to its ligand CXCL11. 
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Figure 3.4 Measuring signal transduction via overexpressed CXCR3 in response to commercial 
CXCL11. (A) Calcium flux assay was performed upon stimulation of EL4 and HEK293 cells 
expressing CXCR3 with 100 ng/mL of CXCL11 ligand. Treatment of cells with PMA (25 ng/mL) and 
ionomycin (0.75 μg/mL) was used as positive control. (B) Estimation of ERK phosphorylation in 
HEK293 cells expressing CXCR3. HEK293 cells expressing CXCR3 were stimulated with 100 ng/mL 
of CXCL11 ligand for different time durations (60, 30, 15, 10, 5, 2 or 1 min) or left unstimulated (0 
min). PMA (25 ng/mL) and ionomycin (0.75 μg/mL) stimulated cells were used as positive control and 
β-actin was used as loading control. Respective band sizes for phosphorylated ERK, total ERK and β-
actin are shown in the blot. 
3.2.4 Migration assay 
Chemokine receptors allow guided migration towards the cognate chemokine concentration 
gradient [335]. To assess whether the CXCR3 overexpression leads to an enhanced migration 
of cells in response to CXCL11, EL4 T cells were transfected with either CXCR3 cloned in 
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pSBbi-GP and pSBbi-RP alone to get green (GFP) fluorescing CXCR3 overexpressed cells 
and red (RFP) fluorescing control cells respectively (Figure 3.5 A). The migratory ability of 
EL4-CXCR3 T cells were then compared with the control EL4 T cells following transwell 
migration assay and counting of cells in the lower chamber using fluorescence microscopy 
(Figure 3.5 B). EL4-CXCR3 T cells showed enhanced migration compared to control EL4 T 
cells in response to 100 ng/mL CXCL11 as chemoattractant in the lower compartment (Figure 
3.5 C). The media in lower compartment was also adjusted to different pH (6 to 7.5) which did 
not seem to affect the migratory ability of EL4-CXCR3 T cells in the presence of CXCL11 
(Figure 3.5 C). 
 
Figure 3.5 Migration assay. (A) Assessment for the expression of GFP (green fluorescence) and RFP 
(red fluorescence) on EL4-CXCR3 and control EL4 T cells post-transfection by flow cytometry. (B) 
Diagrammatic illustration of migration assay in a transwell system displaying the upper compartment 
to which cells are added and the lower compartment to which CXCL11 is added. (C) Number of total 
cells, EL4-CXCR3 T cells only and control EL4 T cells only in the lower compartment of transwell 
system following migration assay. Briefly, the cells (control EL4 T and EL4-CXCR3 T cells mixed at 
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1:1 ratio) were added to the upper chamber of the transwell (with pore sizes of 8 µm) and were allowed 
to migrate in response to RPMI with or without CXCL11 (100 ng/mL) ligand in the lower compartment 
maintained at different pH for 4 hours (n=2). 
3.2.5 Engineering of chimeric G-protein coupled receptor 
Chimeric GPCRs are mostly designed to study the roles of specific receptor domain in ligand 
binding or receptor activation and signal transduction [336, 349]. However, limited studies 
have explored chimeric receptors to exploit the receptor specific ligands. A recent study 
highlighted photoactivable chimeric receptor PA-CXCR4, designed by fusion of photo-
rhodopsin receptor and chemokine receptor CXCR4, was found to enhance migration as well 
as improve local effector functions and killing of tumour by T cells expressing the chimera 
[335]. Similarly, our study aimed to design chimeric receptor that contain an extracellular 
region that can be triggered by adenosine or protons (low pH) present abundantly around 
tumour microenvironment but contain intracellular region of CXCR3. This would enable the 
conversion of immunosuppressive signal perceived by the extracellular domain into an 
activating signal by the CXCR3 intracellular domain resulting in enhanced activation of T cells. 
We designed the chimeric constructs based on previously published structures [335, 350]. The 
extracellular and transmembrane domain of either adenosine sensing receptor (A1 or A2A) or 
proton sensing TDAG8 receptor were spliced to the intracellular domains of chemokine 
receptor CXCR3. The extracellular and the transmembrane region of the A1, A2A and TDAG8 
receptors (shown in Figure 3.6 A-C) are involved in ligand binding and hence were kept intact 
while designing [351-353]. However, the conserved residues in CXCR3 receptor such as DRY, 
CWXP and NPLLY motifs present in transmembrane region TM3, TM6 and TM7 respectively 
play a vital role in activation of the receptor, as well as maintaining structural integrity [354, 
355]. These were therefore added to the transmembrane region of the chimeric construct 
(amino acids highlighted with red colour in the cartoon of the transmembrane region of the 
chimeric construct) (Figure 3.6 D). 
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Figure 3.6 Design of chimeric CXCR3 receptors. Amino acid sequences and structures of the G-
protein coupled receptors used to make chimeric CXCR3; (A) A1 or (B) A2A adenosine receptor, (C) 
proton sensing TDAG8 and (D) CXCR3. The blue highlighted region in A1 (A), A2A (B) or TDAG8 
(C) represents amino acids of the extracellular and transmembrane domain whereas the yellow 
highlighted region in CXCR3 (D) represents the amino acids of intracellular signaling domain. 
Conserved motifs in CXCR3 are also highlighted with red (D). 
The designed chimeras were cloned into pSBbi-RP/GP and cells were transfected; A1-CXCR3 
and A2A-CXCR3 was transfected into HEK293 cells only (A1-CXCR3 and A2A-CXCR3 in 
pSBbi-RP system) whereas T8-C3 was transfected into both HEK293 (T8-C3 in pSBbi-RP 
system) and EL4 T cells (with pSBbi-GP system). RFP and GFP fluorescence post transfection 
were measured by flow cytometry (Figure 3.7 A, 3.8 A and 3.9 A). In the absence of specific 
antibodies against the A1 and A2A receptor, a c-myc tag was placed on the extracellular region 
of the chimeric receptor was used to detect the expression of the chimeric receptors. Detection 
of small shift in c-myc expression on the surface of HEK293 cells suggested the expression of 
chimeric receptors on the cells when measured by flow cytometry (3.7A and 3.8A). The T8-
C3 chimera lacked a c-myc tag, therefore chimeric receptor expression on the surface could 
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not be assessed post-transfection. However, flow cytometric analysis was done to assess 
genetically linked fluorescent protein (GFP or RFP) (3.9 A). 
Next, we used CCPA and CGS21680 as ligands for testing A1AR and A2AAR activation 
respectively [356, 357]. HEK293 cells transfected with either A1-CXCR3 or A2A-CXCR3, 
irrespective of the c-myc tag, did not show any change in Fluo-4-AM intensity when treated 
with different concentrations of respective ligands while cells treated with PMA/Ionomycin 
showed a shift in the Fluo-4-AM signal post activation (Figure 3.7 B and 3.8 B). Similarly, 
ERK phosphorylation assay failed to detect ligand-mediated signaling on A1-CXCR3 or A2A-
CXCR3 HEK293 cells even after 2 hours of ligand treatment; no visible difference was seen 
between ligand treated cells and negative controls (MeOH or DMSO treatment) (Figure 3.7 C 
and 3.8 C). However, we observed clear band of ERK phosphorylation on positive control 
(PMA/ionomycin treated cells). 
For T8-C3 chimera, the cells were incubated with media adjusted to low pH values to assess 
chimeric GPCR activation [358]. Expression of RFP and GFP on HEK293 and EL4 T cells 
suggested efficient transfection by the pSBbi-system (Figure 3.9 A), but similar to A1-CXCR3 
and A2A-CXCR3 transfected HEK293 cells, calcium mobilisation via the T8C3 transfected 
HEK293 cells was not observed when cells were treated with medium adjusted to lower pH 
values (Figure 3.9 B). Incubation of EL4 cells transfected with T8-C3 chimera in media 
adjusted to pH 6.5 for different time points similarly failed to induce ERK phosphorylation 
(Figure 3.9 C). Additionally, we performed transwell migration assay by adding T8-C3-
transfected green fluorescent EL4 T cells (Figure 3.9 A) and red fluorescent control EL4 T 
cells (previously used for Figure 3.5) mixed at a ratio of 1:1 in response to a range of pH (6 to 
7.5). However, T8-C3 chimera failed to induce superior migration of T8-C3 harbouring EL4 T 
cells in comparison to control EL4 T cells alone (Figure 3.9 D). 
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Figure 3.7. Chimeric A1-CXCR3 expression in HEK293 cells and its functionality testing. (A) 
Assessment of RFP expression to measure transfection efficiency and histogram for cell surface 
expression of A1-CXCR3 assessed by c-myc staining. The dotted line represents non-transfected and 
the solid line represents HEK293 cells transfected with A1-CXCR3. (B) calcium flux assay performed 
upon treatment of HEK293 cells expressing A1-CXCR3 with different concentrations of CCPA; 
PMA/ionomycin was used as positive control. Cells with or without c-myc tag were also compared. (C) 
Western blot for the estimation of phosphorylated and total ERK following treatment of HEK293 cells 
expressing A1-CXCR3 with 100 nM CCPA for different time points (120, 60, 30, 15, 10, 5, 2 or 1 min) 
or unstimulated (0 min).  PMA (25 ng/mL) and ionomycin (0.75 μg/mL) stimulated cells and MeOH 
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treated cells were used as positive control and negative control respectively and β-actin was used as 




Figure 3.8 Chimeric A2A-CXCR3 expression in HEK293 cells and its functionality testing. (A) 
Assessment of RFP expression to measure transfection efficiency and histogram for cell surface 
expression of A2A-CXCR3 assessed by c-myc staining; dotted line represents non-transfected and solid 
line represents HEK293 cells transfected with A2A-CXCR3. (B) Calcium flux assay performed upon 
treatment of HEK293 cells expressing A2A-CXCR3 with different concentrations of CGS21680; 
PMA/ionomycin was used as positive control. Cells with or without c-myc tag were also compared. (C) 
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Western blot for the estimation of phosphorylated and total ERK following treatment of HEK293 cells 
expressing A2A-CXCR3 with 100 nM CGS21680 for different time points (120, 60, 30, 15, 10, 5, 2 or 
1 min) or unstimulated (0 min).  PMA (25 ng/mL) and ionomycin (0.75 μg/mL) stimulated and DMSO 
treated cells were used as positive control and negative control respectively and β-actin was used as 
loading control. Respective band sizes for phosphorylated ERK, total ERK and β-actin are shown in the 
blot. 
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Figure 3.9 Chimeric TDAG8-CXCR3 (T8-C3) expression in HEK293 cells and its functionality 
testing. (A) Assessment of RFP and GFP expression on HEK293 and EL4 T cells respectively to 
measure transfection efficiency (B) Calcium flux assay performed upon treatment of HEK293 cells 
expressing T8-C3 with different pH media (6 to 7.5); PMA/ionomycin was used as positive control. (C) 
Western blot for the estimation of phosphorylated and total ERK following culture of EL4 T cells 
expressing T8-C3 at pH 6 for different time points (10, 5, 2 or 1 min) or unstimulated (0 min).  PMA 
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(25 ng/mL) and ionomycin (0.75 μg/mL) stimulated cells were used as positive control and β-actin was 
used as loading control. Respective band sizes for phosphorylated ERK, total ERK and β-actin are 
shown in the blot. (D) Number of total cells, EL4-T8-C3 T cells only and control EL4 T cells only in 
the lower compartment of transwell system following migration assay. Briefly, the cells (control EL4 
T and EL4-T8-C3 T cells mixed at 1:1 ratio) were added to the upper chamber of the transwell (with 
pore sizes of 8 µm) and were allowed to migrate in response to RPMI adjusted to different pH for 4 
hours (n=2). 
3.3 Concluding remarks 
▪ CXCR3 receptor was designed and successfully cloned into a sleeping beauty system 
(pSBbi-GP/RP). EL4 T cells and HEK293 cells transfected with pSBbi-CXCR3 
construct showed over-expression of CXCR3. 
▪ Efficient signal transduction on both EL4 T cells and HEK293 cells expressing CXCR3 
in response to its cognate ligand CXCL11 was confirmed by enhanced calcium 
mobilisation and ERK phosphorylation. 
▪ EL4-CXCR3 T cells showed enhanced migration in response to CXCL11 ligand when 
compared to EL4 T cells alone. 
▪ Chimeric receptors (A1-CXCR3, A2a-CXCR3 and T8-C3) were successfully designed 
and cloned into sleeping beauty system (pSBbi-GP). Cells transfected with the chimeric 
constructs failed to transduce signal in response to low pH or respective adenosine 
ligands as detected by calcium flux, ERK phosphorylation and migration assays. 
▪ The recombinant CXCL11 protein was successfully produced and purified. However, 
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4.1. Background 
In this chapter, we utilised a different strategy to fortify tumour infiltrating T cells. Our 
approach was to enhance T cell function in solid tumour microenvironment by RNA 
interference (RNAi) mediated knockdown of inhibitory target; PRKAR1A. RNAi is a process 
that involves the use of double stranded RNA molecule to regulate gene expression and has 
emerged as a promising tool to regulate gene expression for functional studies [359, 360]. 
Previously, a RI anchoring disruptor peptide (RIAD) was used to inhibit localisation of 
PRKAR1A to immune synapse to upregulate T cell function [361]. Later, another group used 
this peptide in combination with a CAR-targeted to human mesothelin (Meso CAR) and 
showed enhancement in migration, adhesion, and function of Meso CAR T cell [362]. 
However, modulation of PRKAR1A expression at transcript level using shRNA or miRNA and 
its effect on T cell function during activation has not been studied yet. We utilised both shRNAs 
and miRNAs approaches and compared their efficacy to downregulate PRKAR1A. Firstly, we 
investigated if downregulating PRKAR1A expression would assist T cell function by assessing 
production of IL-2 and the expression level of CD69 (an early T cell activation marker) as a 
proof of principle in Jurkat T cells. Secondly, to exploit the RNAi approach in combating solid 
tumours, we designed and tested second generation FRP5 anti-HER2 CAR activation in Jurkat 
cells against HER2 positive breast cancer cell line (MCF-7) by measuring IL-2 by ELISA. 
Lastly, we enquired if combination of RNAi with FRP5 anti-HER2 CAR construct could be a 
good approach to expand CAR T cell therapy in solid tumour microenvironment. Since various 
combination therapies have been utilised to enhance anti-tumour effect of CAR T cells (e.g. 
monoclonal antibodies) and has been very effective to improve CAR T cell function and 
persistence [363, 364], we revisited the design of the tetracycline inducible sleeping beauty 
system to adjust and co-express RNAi and FRP5 anti-HER2 CAR from the same vector in 
primary human cells to understand if we could accomplish such combination and investigate 
the total outcome. 
4.2. Results 
4.2.1 ShRNAs to knockdown PRKAR1A expression 
Tetracycline inducible sleeping beauty vector (pSBtet-GP, Figure 4.1 A) was used to clone 
RNAi downstream of tetracycline inducible TCE promoter. pSBtet-GP is a tet-on system 
consisting of a mutant rtTA-M2 component that binds to tetracycline response element (TRE) 
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in TCE promoter in the presence of tetracycline or its stable analogue doxycycline and allows 
controlled expression of gene of interest (RNAi in this case). We designed and used ten 
different shRNAs to knockdown PRKAR1A expression in HEK293 cells. First, three shRNAs; 
shRNA 1, shRNA 2 and shRNA 3 were designed using BLOCK-IT RNAi designer; each 21 
nucleotides in length with four-nucleotides loop structure (5ꞌ-CGAA-3ꞌ). HEK293 cells 
transfected with the shRNAs (cloned into pSBtet-GP) were analysed for PRKAR1A mRNA 
expression by real time RT-PCR. All three shRNAs showed some downregulation of 
PRKAR1A, but the effect was not consistent between independent experiments (Figure 4.1 B). 
Next, we designed shRNAs 4, 5 and 6 based on already published siRNA sequences, each 19-
25 nucleotides in length with nine-nucleotides loop structure (5ꞌ-TTCAAGAGA-3ꞌ) [365, 366]. 
When tested in HEK293 cells, we achieved some downregulation with shRNAs 5 and 6, 
whereas shRNA 4 failed to show any reduction in PRKAR1A expression (Figure 4.1 C). We 
designed the last four shRNAs; shRNA 7, shRNA 8, shRNA 9 and shRNA 10, each 19-22 
nucleotides in length with 13-19-nucleotides loop structure (shRNAs 7, 8 and 9 with 5ꞌ-
TAGTGAAGCCACAGATGTA-3ꞌ and shRNA 10 with 5ꞌ-TGGGACTGGGTCA -3ꞌ) 
consisting of a poly A tail (AAAA) followed by a termination sequence (AATAAA) at the 3ꞌ 
end using RNAi codex tool to examine if addition of poly A tail and termination sequence 
would enhance shRNA activity by overcoming the asymmetric or imperfect complementarity 
of the 5p- and 3p-shRNA sequence [367, 368]. Unfortunately, the shRNAs did not show 
promising results to use as an effective means to downregulate gene expression in this study 
(Figure 4.1 D).  
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Figure 4.1 shRNAs used against PRKAR1A in HEK293 cells. (A) Sleeping beauty system (pSBtet-
GP) with tetracycline (doxycycline) inducible TCE promoter driving the gene of interest (shRNA) and 
RPBSA promoter driving GFP, reverse trans-activator: rtTA-M2 and puromycin. (B-D) Ten different 
shRNAs were designed, cloned into pSBtet-GP and were transfected into HEk293 cells. The transfected 
cells were treated with doxycycline for 48 hrs after which the cells were lysed, RNA was isolated and 
PRKAR1A expression was measured at mRNA level by real time RT- PCR (n=2 for B, C and D). 
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4.2.2 MicroRNAs; miR96/183 and miR155 overexpression decreases PRKAR1A    
expression 
We used another approach of RNAi called microRNAs as an alternative to shRNAs for the 
downregulation of PRKAR1A expression. MicroRNA target prediction tools such as 
TargetScanHuman, Diana-microT-CDS and miRanda were utilised to find the specific 
miRNAs that target human PRKAR1A 3' UTR; TargetScanHuman result is shown (Figure 4.2). 
TargetScanHuman is one of the comprehensible tools that provides various miRNAs for a 
given target based on the predicted efficacy of targeting or the probability of conserved 
targeting [369, 370]. Based on this, miRNAs: miR96/183 cluster (miR96-5p, miR183-5p) and 
miR155 (miR155-5p) were selected to target PRKAR1A (shown inside a red box in Figure 
4.2).  These miRNAs were further verified with other tools such as miRanda and Diana-
microT-CDS which predicts specific miRNAs for the given target using different algorithms 
[369]. In addition, published and experimentally validated miRNAs can also be identified 
through these tools.  
 
Figure 4.2 Target Scan snapshot showing miRNAs targeting the PRKAR1A 3' UTR. Possible 
miRNAs targeting PRKAR1A 3' UTR were predicted by TargetScanHuman with additional information 
(box at the bottom) on effectiveness of the miRNA in repressing 3' UTR (e.g. 8mer, 7 mer-m8). 
MiRNAs 96/183 and 155 are highlighted with red box. 
We PCR amplified the 663 base pair (bp) DNA fragment containing miR96 and miR183 
precursor sequence and 667 bp DNA fragment containing miR155 precursor sequence from 
human genomic DNA and cloned these fragments into the tetracycline inducible sleeping 
beauty system (pSBtet-GP; known as pSBtet-miR96/183 and pSBtet-miR155 from now 
onwards). The primers were designed based on the miRNA sequence available in NCBI 
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(https://www.ncbi.nlm.nih.gov/). Following transfection of HEK293 cells with the pSBtet-
miR96/183 or pSBtet-miR155 and upon treatment of cells with doxycycline, we examined if 
the miRNAs were overexpressed. To measure miRNA expression, we would need to assess the 
mature miRNA in the cytoplasm following Dicer processing [371, 372]. Mature microRNAs 
(miRNA) are approximately 17 to 24 nucleotides in size which make them too short to be 
amplified by normal PCR primers as standard or quantitative PCR requires the size of the 
template to be a minimum ~40 nucleotides and forward/reverse primers, each ~20 nucleotides 
in length. To overcome this limitation, we designed a set of stem-loop primers for each miRNA 
with a highly stable stem-loop structure to add length to the target cDNA, based on the miRNA 
sequences present in miRBase database. Stem loop primers for the detection of miR96, miR183 
and miR155 are shown in Figure 4.3 B-D. A small nucleolar RNA (snRNA) called SNORD47 
was used as housekeeping gene control (Figure 4.3 E). After cDNA synthesis, we utilised a 
forward primer complementary to the miRNA (either miR96 or miR183 or miR155 or 
SNORD47) and a reverse primer complementary to the sequence within the stem-loop primer 
in the next RT-PCR step. When HEK293 cells transfected with the miRNAs were tested for 
overexpression following 24, 48 and 72 hrs of doxycycline treatment, we achieved more than 
100 fold overexpression of miR96 and miR183 at all-time points tested compared to HEK293 
cells transfected with empty plasmid (pSBtet-GP) (Figure 4.4 A). Interestingly, HEK293 cells 
transfected with pSBtet-miR155 resulted in approximately 5000-fold overexpression of 
miR155 compared to pSBtet-GP empty plasmid transfected cells (Figure 4.5 A). 
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Figure 4.3 Stem-loop PCR for detection of miRNAs. (A) Schematic diagram showing the stem-loop 
RT-PCR process. A miRNA specific stem-loop RT primer (either B, C or D) initiates reverse 
transcription by binding to the 3' portion of the miRNA. The resulting RT product is then amplified 
using forward primer specific to the miRNA (FP) and a universal reverse primer (URP) using SYBR 
green based real time RT-PCR to assess the overexpression of miRNA. 
Confirming overexpression of both miRNAs in HEK293 cells, we assessed the effect of 
miRNA overexpression on PRKAR1A expression at mRNA level by real time PCR and at 
protein level by western blotting.  Overexpression of miR96/183 showed a 30-87% reduction 
in PRKAR1A transcript expression following doxycycline treatment for 24 to 72 hours (Figure 
4.4 B). The reduction in PRKAR1A transcript expression by miR155 overexpression was 
approximately 40% at both 24 hours and 48 hours following doxycycline treatment (Figure 4.5 
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B). Interestingly, overexpression of miRNA96/183 conferred significant reduction of 
PRKAR1A at protein level (Figure 4.4 C and D) whereas miR155 overexpression resulted in 
small non-significant reduction of PRKAR1A in HEK293 cells (Figure 4.5 C and D).   
                                                                                                                                       
Figure 4.4 Overexpression of miR96/183 reduced PRKAR1A expression in HEK293 cells. (A) 
Stem-loop RT-PCR for the overexpression of miR96/183 in HEK293 cells transfected with pSBtet-
miR96/183 and treated with doxycycline for 24, 48 and 72 hours. (B-D) PRKAR1A expression in 
HEK293 cells following miRNA96/183 overexpression was assessed at transcript level by real time 
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RT-PCR at different time points of doxycycline treatments (B) and  at the protein level by western blot 
after 48hrs doxycycline treatment (C, representative blot and D, cumulative expression after the blots 
were analysed by Image Studio software) (n=3 for A-D). 
 
Figure 4.5 Overexpression of miR155 reduced PRKAR1A expression in HEK293 cells. (A) Stem-
loop RT-PCR for the overexpression of miR155 in HEK293 cells transfected with pSBtet-miR155 and 
treated with doxycycline for 24, 48 and 72 hours. (B-D) PRKAR1A expression in HEK293 cells 
following miRNA155 overexpression was assessed at transcript level by real time RT-PCR at different 
time points of doxycycline treatments (B) and at the protein level by western blot after 48hrs 
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doxycycline treatment (C; representative blot and D; cumulative expression after the blots were 
analysed by Image Studio software) (n=3 for A-D). 
4.2.4 Luciferase assay to validate PRKAR1A 3' UTR as a target of miR96/183 and 
miR155 
Mature double stranded miRNAs in the cytoplasm are loaded into the RISC protein complex 
after which the passive strand is degraded, while the guide RNA acts on the target 3ꞌ UTR 
leading to the cleavage or translational repression of the target mRNA. Although prediction 
algorithms make it easier to identify specific miRNA for a given target based on the 
complementarity, thermodynamic stability and site conservation [373], the algorithm may be 
error prone and exclude possible mRNA modification, such as RNA editing and RNA 
methylation that may alter miRNA binding to target sites [374-376]. The algorithms may also 
fail to identify species-specific and non-canonical miRNA target sites [377, 378]. To probe the 
specific interaction between the miR96/183 or miR155 and its target (PRKAR1A 3ꞌ UTR), we 
carried out luciferase assays using pmirGLO dual-luciferase expression vector carrying 
PRKAR1A 3' UTR (reporter vector, Figure 4.6 A) downstream of the firefly luciferase gene 
(luc2) to measure direct interaction between PRKAR1A 3' UTR and respective miRNAs. The 
reporter vector also consists of Renilla luciferase (hRluc-neo) as a control reporter for 
normalisation and selection of transfected cells. The PRKAR1A 3ꞌ UTR sequence was obtained 
from human genome browser (UCSC) and miRNA binding regions were predicted using 
Target Scan. HEK293 cells were co-transfected with the reporter vector and either pSBtet-
miR96/183 or pSBtet-miR155 at 1:1 ratio and miRNA specific targeting of PRKAR1A 3' UTR 
was determined based on the relative change in the luminescence. Co-transfection of the 
reporter vector and pSBtet-GP empty vector was used as a control. Reduced luciferase 
expression in HEK293 cells following transfection with the pmirGLO with normal PRKAR1A 
3' UTR and pSBtet-miRNA (either miR96 /183 or miR155) compared to pmirGLO with normal 
PRKAR1A 3' UTR and pSBtet-empty vector confirmed that both miRNAs specifically target 
PRKAR1A 3' UTR (Figure 4.6 C and D). 
Additionally, the miRNA binding sites in PRKAR1A 3' UTR were mutated to validate the 
specificity of the miRNA binding to the 3' UTR. The PRKAR1A 3' UTR harboured one 
predicted binding site for miR96 and miR155 whereas miR183 had two binding sites (one 
shared with miR96 and other only for miR183). We generated mutations at the miR155 binding 
region (163-171 bp), miR183 binding region (271-278 bp) and miR96/183 binding region (793-
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802 bp) (Figure 4.6 B) using overlap extension PCR. PRKAR1A 3' UTR with mutation in the 
miR155 and miR96/183 binding region were called ‘mutated 155’ and ‘mutated 96’ 
respectively whereas mutation in both miR96/183 binding region and miR183 only binding 
region was called mutated miR96/183 (Figure 4.6 C and D). Interestingly, a small but 
significant increase in luciferase expression was observed when PRKAR1A 3' UTR with no 
mutation (normal) was replaced with ‘mutated 96’ PRKAR1A 3' UTR (Figure 4.6 C).  
Moreover, luciferase expression was significantly higher in HEK293 cells transfected with 
‘mutated 96/183’ PRKAR1A 3' UTR compared to both ‘mutated 96’ and normal PRKAR1A 3' 
UTR. Luciferase signal was reversed back to the level of control (normal 3' UTR without any 
miRNA overexpression) when both miR183 binding sites (including the shared with miR96) 
on PRKAR1A 3' UTR were mutated. (Figure 4.6 C). Also, the luciferase expression was 
significantly increased to the level obtained with normal 3' UTR without any miRNA 
overexpression when the normal PRKAR1A 3' UTR was replaced with ‘mutated 155’ 
PRKAR1A 3' UTR (Figure 4.6 D). These results confirm that both miR96/183 and miR155 
specifically target the PRKAR1A 3' UTR. 
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Figure 4.6 Luciferase assay confirms PRKAR1A 3' UTR as a direct target for miR96/183 and 
miR155. (A) The pmiRGLO vector used to clone PRKAR1A 3' UTR with firefly luciferase as the 
primary reporter to monitor mRNA regulation and Renilla luciferase as a control reporter for 
transfection selection and normalisation (left) and illustration of luciferase assay (right). (B) Regions of 
PRKAR1A 3' UTR with predicted binding sites for miR96, miR155 and miR183. Controls were 
generated for luciferase assay by introducing mutation at 163-171 bp (a, miR155 binding region), 271-
278 bp (b, miR183 binding region) and 793-802 bp (c, miR96/183 binding region) by overlap extension 
PCR. (C and D) HEK293 cells transfected with normal or mutated PRKAR1A 3' UTR were used to 
perform luciferase assay with or without miRNA overexpression (either miR96/183 or miR155) to 
confirm PRKAR1A was specifically targeted by miR96/183 (C) and by miR155 (D). The cells 
transfected with normal PRKAR1A 3' UTR + pSBtet-GP empty vector was used as a control for the 
assay. Data are represented as mean ± S.E.M and are from three independent experiments. Paired two-
tailed t-tests were used for statistical analysis (n = 3 for C and D), *p<0.05, ** p<0.01.  
4.2.5 Overexpression of miR96/183 and miR155 enhanced Jurkat T cell 
activation 
Next, we investigated the effect of miR96/183 or miR155 overexpression on T cell activation 
by transfecting Jurkat T cells with pSBtet-miR96/183 or pSBtet-miR155 and assessing IL-2 
production in the supernatant or CD69 expression on the surface following activation by anti-
CD3 and anti-CD28 antibody. Interestingly, IL-2 production by Jurkat T cells was significantly 
enhanced following overexpression of miRNA96/183 or miR155 by doxycycline treatment for 
48 hours and activation with anti-CD3/CD28 for 24 hrs compared to doxycycline non-treated 
but anti-CD3/CD28 activated Jurkat cells while no such effect was observed for empty vector 
control (Figure 4.7 A and B). This suggested the doxycycline treatment mediated miRNA 
overexpression specifically enhanced IL-2 production on pSBtet-miR96/183 or pSBtet-
miR155 transfected Jurkat T cells. Low level of IL-2 production could still be detected on 
pSBtet-miR96/183 or pSBtet-miR155 transfected Jurkat T cells in the absence of doxycycline. 
This was still significantly higher compared to empty vector transfected Jurkat cells suggesting 
miRNA overexpression to some extent due to leakiness of doxycycline inducible promoter 
(TCE). Several studies utilising tet-on system, including from our laboratory, have already 
reported the leaky basal transgene expression even in the absence of doxycycline [379-381]. 
Overexpression of miR155 also resulted in enhanced CD69 surface expression on Jurkat cells 
upon miR155 overexpression whereas similar effect was not observed following 
overexpression of miR96/183 (Figure 4.8 B).  




Figure 4.7 Detection of IL-2 production by Jurkat cells overexpressing miR96/183 and miR155 
activated with anti-CD3/CD28 antibodies. Jurkat cells overexpressing miR96/183 (A) and miR155 
(B) were treated with or without doxycycline (5 µg/mL) for 48 hours and activated with anti-CD3 (2.5 
µg/mL) and anti-CD28 (2.5 µg/mL) antibody for the final 24 hours. The supernatant was harvested, and 
IL-2 was measured by ELISA. Supernatant of cells treated with PMA and ionomycin was used as a 
positive control and Supernatant of cells transfected with empty plasmid and treated with or without 
doxycycline (5 µg/mL) for a total of 48 hours were also included as controls. Data are represented as 
mean ± S.E.M and are from three (A) and four (B) independent experiments. Each symbol represents 
average data from each experiment (n = 4 for A and n=3 for B), *p<0.05, ** p<0.01.  
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Figure 4.8 CD69 surface expression on Jurkat cells overexpressing miR96/183 and miR155. (A) 
CD69 surface expression on non-activated and anti-CD3/CD28 activated Jurkat T cells by flow 
cytometry. (B) Jurkat T cells transfected with pSBtet-miR96/183 or pSBtet-miR155 were treated with 
doxycycline (5 µg/mL) for a total of 48 hours and activated with anti-CD3 (2.5 µg/mL) and anti-CD28 
(2.5 µg/mL) for the final 24 hours. The cells were stained for CD69 expression; cells treated with PMA 
and Ionomycin was used as positive control and cells transfected with empty plasmid was used as 
negative control. Data are represented as mean ± S.E.M and are from four independent experiments. 
Paired two-tailed t-tests were used for statistical analysis (n = 4), *p<0.05, ** p<0.01.  
4.2.6 Other receptors targeted by miR96/183 and miR155 
The miRNA target prediction tools such as Target scan, miRanda, and Diana predict more than 
one target for the given miRNA. Therefore, we examined if miR96/183 and miR155 target 
other proteins that negatively regulates T cell function such as methylcytosine ten-eleven 
translocation 2 (TET2), forkhead box protein O3 (FOXO3) and protein tyrosine phosphatase 
N2 (PTPN2) which were also predicted by the target prediction tools [382, 383]. 
Overexpression of both miRNAs (miR96/183 and miR155) downregulated TET2, FOXO3 and 
PTPN2 transcript expression in HEK293 cells (Figure 4.9 A and B). The expression of TET2, 
FOXO3 and PTPN2 by miR96/183 was approximately 20 to 30 % (Figure 4.9 A). Similarly, 
miR155 reduced the expression of TET2, FOXO3 and PTPN2 by 30-60 % (Figure 4.9 B). Since 
IL-6 receptor (IL-6R) was a predicted target for miR155, we also looked at the effect of miR155 
overexpression on IL-6R transcript expression. Interestingly, the expression of IL-6R was also 
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downregulated upon overexpression of miR155 (Figure 4.10). This may be an added benefit of 
miR155 overexpression as this could be an advantage to tackle cytokine release syndrome 
caused by the hyperactivation of CAR T cells [384].   
 
Figure 4.9 Overexpression of miR96/183 or miR155 reduced expression of TET, FOXO3 and 
PTPN2 in HEK293 cells. HEK293 cells transfected with pSBtet-miR96/183 or pSBtet-miR155 were 
treated with doxycycline for 48 hours. The cells were lysed for RNA extraction and real time RT-PCR 
was performed to assess the expression of TET2, FOXO3 and PTPN2 in cells overexpressing 
miR96/183 (A) or miR155 (B). Data are represented as mean ± S.E.M and are from three independent 
experiments (n = 3 for A and B). 
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Figure 4.10 Overexpression of miR155 reduced expression of IL-6R in HEK293 cells. HEK293 
cells transfected with pSBtet-miR155 were treated with doxycycline for 48 hours. The cells were lysed 
for RNA extraction and real time RT-PCR was performed to assess the expression of IL-6R in cells 
overexpressing miR155. Data are represented as mean ± S.E.M and are from three independent 
experiments (n = 3). 
4.2.7 Transfecting and testing functionality of HER2 CAR in Jurkat T cells 
Next, we transfected Jurkat T cells with pSBbiRP-HER2 CAR (Jurkat- FRP5 anti-HER2 CAR, 
referred to as Jurkat-HER2 CAR from now onwards) and determined the activation of Jurkat-
HER2 CAR by co-culturing with different cell lines such as SKBR3, MCF-7, MDA-MB 231, 
HEK293T and B16-F10 available in the lab. We carried out ELISA to assess IL-2 released in 
the supernatant because of HER2 CAR activation and compared the response (Figure 4.11 A). 
Jurkat-HER2 CAR showed enhanced IL-2 production when co-cultured with SKBR and MCF-
7 but not against other cell lines used (Figure 4.11 A). No IL-2 was detected in the co-culture 
of Jurkat cells without HER2 CAR and cell lines, irrespective of the HER2 expression. MCF-
7 sublines have been shown to demonstrate a wide divergence in their relative expression of 
HER2, oestrogen receptor (ER) and PR (progesterone receptor) [385]. The growth of different 
variants of MCF-7 cells are believed to be controlled by the growth factors in the media; ER 
positive phenotype are favoured by the presence of small amount of oestrogen whereas HER2 
depending growth is suggested following extended growth in the absence of oestrogen [385-
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387]. Jurkat HER2 CAR was minimally activated when co-cultured with MCF-7 as shown by 
IL-2 release suggesting activation by HER2 expressed on MCF-7 cells (Figure 4.11 A). To 
determine if the MCF-7 in our lab was expressing HER2, we stained the cells with anti-human 
FRP5 single chain fragment (FRP5-Fc) followed by AF-647 conjugated human IgG. MCF-7 
cells were found to be positive for HER2 expression (Figure 4.11 B). We also transfected MCF-
7 with HER2 antigen (cloned in puromycin resistant constitutive sleeping beauty system, 
pSBbiRP-HER2 antigen) to enhance HER2 expression, and luciferase (cloned into blasticidin 
resistant constitutive sleeping beauty system, pSBbla-Luc) to utilise it as target cells for future 
cytotoxicity assays based on luciferase expression. HER2 expression was further enhanced 
following transfection with pSB-biRFP-HER2 antigen (Figure 4.11 B). Overexpressing HER2 
antigen on MCF-7 cell line triggered significant enhancement in IL-2 production by Jurkat-
HER2 CAR in the co-culture system compared to that obtained against MCF-7 cell line with 
normal HER2 expression; (Figure 4.11 C). This confirmed HER2 specific activation of Jurkat 
HER CAR. 
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Figure 4.11 Detection of IL-2 production by Jurkat-HER2 CAR. (A) Jurkat-HER2 CAR cells were 
cultured with different cell lines; SkBR, MDA-MB 231, B16-F10, HEK293T, and MCF-7 for 24 hours 
and IL-2 in the supernatant was measured by ELISA. Supernatant of PMA/ionomycin treated Jurkat-
HER2 CAR cells were used as positive control. (B) Flow cytometric assessment of HER2 expression 
on MCF-7 cell line; MCF-7 cells (both untransfected and transfected with pSBbi-RP HER2) were 
incubated with FRP5-Fc protein followed by staining with AF-647 (APC) conjugated anti-human IgG. 
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(C) Jurkat-HER2 CAR cells were co-cultured with MCF-7 cell line with normal or overexpressed HER2 
antigen for 24 hours, The supernatants were harvested and IL-2 was measured by ELISA; supernatant 
of Jurkat-HER2 CAR cells treated with PMA and ionomycin was used as positive control and 
supernatants of cells only (either MCF-7 or Jurkat-HER2 CAR) were used as negative controls. Since 
the values for MCF only and Jurkat-HER2 CAR only controls were negative, these were presented as 
zero. Data are represented as mean ± S.E.M for two (A; n=2) and three independent experiments (B; 
n=3). Paired two-tailed t-tests were used for statistical analysis. *p<0.05, ** p<0.01.  
4.2.8 Modification of sleeping beauty vector 
We revisited the tetracycline inducible sleeping beauty vector (pSBtet-GP) to express a GOI 
(either miRNA or coding gene) downstream of tetracycline inducible promoter (TCE) and 
HER2 CAR downstream of a constitutive RPBSA promoter (Figure 4.12 A and B, also see 
Appendix I). To achieve this, we first inserted a multiple cloning site downstream of RPBSA 
promoter following the removal of GFP-P2A-rtTA-M2-P2A-Puromycin fragment. We then 
cloned the removed fragments (except the puromycin) and HER2 CAR sequentially into the 
vector (an example is shown in Figure 4.12 B). We designed different combinations and tested 
to determine if altering the position of genes change the inducibility of the promoter with no 
or very less leakiness. For example, HER2 CAR construct followed by a P2A cleavage site 
was cloned downstream of RPBSA promoter with rtTA-M2 fragment at the distal end of the 
promoter to create HER2 CAR-P2A-rtTA-M2 combination. Furthermore, HER2 CAR-P2A-
rtTA-M2 was modified by cloning GFP fragment upstream of HER2 CAR separated by P2A 
to create a new combination; GFP-P2A-HER2 CAR-P2A-rtTA-M2. All these combinations 
consisted of luciferase gene downstream of TCE promoter which allowed the assessment of 
luciferase at protein level and detection of inducibility and leakiness of the promoter in the 
presence or absence of doxycycline. The inducibility of the system was also assessed by 
detecting the mRNA expression of codon optimised mouse myeloid cell leukemia 1 (Mcl-1) 
gene which was cloned by replacing luciferase gene. The rationale behind using codon 
optimised mouse Mcl-1 gene was to reduce background signal during gene expression in 
human HEK293 cell line. However, basal Mcl-1 expression was evident even in the absence 
of doxycycline induction. A study by Roney et al. showed that substituting the amino acid 
glycine with valine (G72V) in rtTA-M2 reduced the leakiness of the promoter without 
compromising the maximal gene expression in S. cerevisiae clones [388]. Therefore, we 
investigated if introducing G72V mutation in rtTA-M2 would also confer similar effect in 
HEK293 cells in HER2 CAR-P2A-rtTA-M2 and GFP-P2A-HER2 CAR-P2A-rtTA-M2. 
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Consistently, the construct with GFP and rtTA-M2 (with G72V) corrected leakiness of the TCE 
promoter; results for the modification can be found in the Appendix I. We therefore used the 
construct to examine inducible expression of miRNAs together with constitutive expression of 




Figure 4.12 Sleeping beauty system. (A) The original sleeping beauty system that consists of 
doxycycline-inducible TCE promoter that drives the miRNA (GOI) and a constitutive RPBSA promoter 
that drives green fluorescent protein (GFP), reverse transactivator rtTA-M2 with puromycin as selection 
marker. (B) Modified sleeping beauty system to remove puromycin and include HER2 CAR construct 
to be driven by RPBSA promoter. The rtTA-M2 transactivator was moved further downstream of the 
RPBSA promoter and the glycine residue in rtTA was mutated to valine. 
4.2.9 Modified sleeping beauty system was used to transfect T cells 
The modified sleeping beauty system consisting of miR96/183 (modified pSBtet-miR96/183) 
and FRP5 anti-HER2 CAR along with the transposase encoding plasmid was used to optimise 
and transfect human peripheral blood mononuclear cells (PBMCs). The original sleeping 
beauty system (pSBtet-GP) was used as a control. PBMCs were activated with 0.5 µg/mL plate 
bound CD3, 1 µg/mL soluble CD28 and 50 U/mL of IL2 before Neon electroporation with a 
total of 6 µg DNA (5 µg of modified pSBtet-miR96/183 or pSBtet-GP and 1 µg of transposase). 
Transfection / transposition efficiency using cells activated for 24 hours, 48 hours and 72 hours 
was compared as the percentage GFP reporter expression by flow cytometry.  The transfection 
efficiency of cells electroporated following activation for 48 hours was higher compared to 
cells electroporated following 24 hours and 72 hours activation (Data not shown). In addition, 
the transfection efficiency was relatively higher in cells transfected with empty control (~9%) 
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compared to the cells transfected with the modified sleeping beauty system (~5%) (Figure 
4.13). 
We also utilised P3 primary cell 4D-NucleofectorTM Kit (#V4XP-3032) following specified 
protocol for primary T cell to assess the transfection efficiency using Amoxa Nucleofector 
(Lonza, Switzerland). The plasmids used to transfect the cells were purified using endofree 
plasmid maxi kit (Qiagen # 12362), as suggested by the protocol. Unfortunately, the 
transfection efficiency was poor (less than 1%) when percent GFP expression was determined 
by flow cytometer (data not shown). We then utilised third generation LV system to clone the 
constructs and optimise the transduction of human primary T cells which is described in detail 
in Chapter 5. 
 
Figure 4.13 Assessment of GFP expression in PBMCs following Neon electroporation. PBMCs 
were activated by anti-CD3/CD28 antibody and IL-2 for 48 hours. The cells were transfected with 
pSBtet-GP and modified pSBtet-miR96/183. Three days post transfection, bulk PBMCs were analysed 
in flow cytometer to assess percent GFP expression. Untransduced PBMCs were used for the gating of 
GFP positive cells following transfection. 
4.3 Concluding remarks 
▪ The miRNA approach for gene silencing is more reliable compared to shRNA approach 
as both miR96/183 and miR155 downregulated PRKAR1A at both mRNA and protein 
level. Also, the downregulation of PRKAR1A by miRNAs were reproducible during 
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each independent experiment unlike shRNAs which gave much variation between 
independent experiments.  
▪ MiRNAs; miR96/183 and miR155 directly target 3' UTR of PRKAR1A, as determined 
by luciferase assay.  
▪ Overexpressing miRNAs: miR96/183 and miR155 enhanced IL-2 production by Jurkat 
T cells when activated by anti-CD3 and anti-CD28 antibodies, however, only miR155 
overexpression resulted in enhanced CD69 expression on Jurkat T cells following 
CD3/CD28 stimulation. 
▪ Overexpression of miR96/183 and miR155 miRNAs reduced the expression of other T 
cell inhibitory targets such as TET2, PTPN2 and FOXO3 at transcript level. 
Overexpression of miR155 showed additional advantage for its use in CAR T cell 
therapy by reducing IL-6R expression. 
▪ Sleeping beauty system was successfully modified to express miRNA (either 
miR96/183 or miR155) along with HER2 CAR. However, poor performance of the 
transfection techniques used (~9% with Neon transfection protocol and <1% with 
Amaxa Nucleofector) limited the use of modified sleepy beauty system in primary cells. 
  









Chapter 5: Results (Lentiviral vectors 
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5.1 Background 
The validation of PRKAR1A as a target for miRNAs; miR96/183 and miR155 and the enhanced 
IL-2 production and CD69 expression on CD3/CD28 activated Jurkat T cells overexpressing 
either miR96/183 and miR155 in previous chapter, directed us to expand this approach in 
primary human T cells. Unlike Jurkat cells which are human CD4 T cell line that express a 
limited set of surface T cell markers [389], the use of primary human T cells would make it 
possible to investigate the influence of miRNA overexpression on T cell phenotype (both 
activation and memory markers) to generate more clinically-relevant conclusions. 
Additionally, the effect of miRNA overexpression on cytotoxic ability of human CAR T cells 
(FRP5 anti-HER2 CAR) to eliminate tumour cells (HER2 positive), and the cytokines released 
as a result of antigen (HER2) recognition can also be assessed in vitro using primary T cells.  
In previous chapter, we utilised a non-viral gene transfer system (sleeping beauty transposon 
system) which has been argued to be a safer and cost effective method, as compared to the use 
of lentiviral or retroviral systems for primary T cells transfection. However, in our setting it 
failed to achieve efficient transfection of human PBMCs in the short term necessary for 
meaningful phenotypic comparisons  [390, 391]. In this chapter, we utilised a third-generation 
lentivirus system that contains a mutant enhancer/promoter region in 3' LTR with self-
inactivating properties (SIN) and U3 promoter region in 5'-LTR with CMV promoter [392]. As 
co-expression of non-coding RNA (miRNA), together with multiple protein coding genes 
(HER2 CAR and GFP) through single lentiviral vector has not been reported before, we 
designed and explored both single (e.g. EF1 or hPGK) and dual promoter (e.g. EF1 and 
RPBSA) lentiviral systems, subsequently assessing expressions of miRNA (by stem-loop RT-
PCR), HER2 CAR and GFP (by flow cytometry and western blotting). Optimized lentiviral 
constructs were used to transduce primary human T cells and the effect of miR96/183 or 
miR155 overexpression and PRKAR1A downregulation in HER2 CAR T cell activation and 
function was studied by T cell activation (ELISA) and cytotoxicity assays. Moreover, the effect 
on phenotypic markers such as CD25, CD69, CD27, CD62L, CD57, CD45RO, CD45RA, 
CXCR3, CCR7 and CD95 on transduced T cells were also assessed by flow cytometry. 
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5.2 Results 
5.2.1 Inducible lentiviral system  
A Tet-On inducible lentiviral system was designed for the controlled expression of either of 
the miRNAs (miR96/183 or miR155) with constitutive expression of FRP5 anti-HER2 CAR. 
The system consisted of the promoters and gene of interests in the same orientation as in the 
modified inducible sleeping beauty system (Chapter 4, Figure 4.12). In place of an internal 
ribosomal entry site (IRES) which may compromise the expression of the downstream genes 
in polycistronic vectors [393], we used a smaller P2A site between the two coding sequences 
of  GFP and the HER2 CAR to allow cleavage and expression of the polypeptides at near 
equimolar levels [394, 395]. HEK293T cells were transduced with the miRNA-encoding 
lentiviral particles and real time stem-loop RT-PCR was performed for miRNA expression. 
Both miR96 and miR183 were detected to be overexpressed by 15-fold and 12-fold 
respectively, as compared to empty (pCCL-Sin transduced) controls when assessed by stem-
loop RT PCR after 48 hrs of doxycycline treatment (Figure 5.1). Interestingly, much higher 
expression (3000-fold) of miR155 was observed following transduction of HEK293 T cells, as 
compared to empty and miR96/183 transduction (Figure 5.1). Although the inducible system 
provides the benefit of controlled gene expression, the inherent leakiness of the system allows 
basal gene expression, even in the absence of doxycycline which was also recently reported by 
our laboratory and others [381, 388, 396, 397]. In addition, there is accumulating evidence 
suggesting a negative effect of doxycycline treatment on metabolism, proliferation, and 
viability of human cell lines [398].  We therefore investigated if the use of single or double 
promoter constitutive system would enhance the expression of miRNAs. Constitutive 
expression would also make both in vitro and in vivo studies much simpler given that no drug 
treatment is needed to induce the promoter.  
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Figure 5.1 Tet-On inducible lentiviral system.  The miRNAs (either miR96/183 or miR155) were 
cloned downstream of doxycycline inducible promoter (TCE) while HER2 CAR and GFP were cloned 
downstream of constitutive promoter (RPBSA). The lentivirus transduced HEK293 T cells were treated 
with doxycycline for 48 hrs and overexpression of miR96, miR183 and miR155 in HEK293T cells 
assessed by stem-loop RT-PCR (n=3). Data are presented as fold-change values to empty control. 
5.2.2 Constitutive lentiviral system  
5.2.2.1 Single promoter system  
Next, we enquired if single promoter system could be used to increase the expression of 
miRNA (especially miR96 and miR183), together with the HER2 CAR and GFP. The rationale 
behind the use of single promoter system is that possible transcriptional interference in 
polycistronic lentiviral vectors might lead to poor transcription, low lentiviral titre and 
infectivity [399, 400]. We cloned miRNA-HER2CAR-P2A-GFP downstream of the single 
promoter constitutive system that consisted of the hPGK promoter in the pCCL-Sin vector 
(Figure 5.1 A). When HEK293T cells were transduced with this construct, we could only 
achieve ~1-3 fold overexpression of miR96 and miR183 while ~1000-15000 fold 
overexpression was achieved for miR155 when assessed by stem-loop RT-PCR (Figure 5.2 B). 
We also performed flow cytometry to assess c-myc (placed in the CD8 hinge region of HER2 
CAR) and GFP expression in HEK293T cells transduced with hPGK lentivirus system to 
determine the expression level of the genes placed distal to the promoter (Figure 5.2 C). HER2 
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CAR expression as detected by c-myc expression was ~60% and ~75% in hPGK system with 
miR96/183 and miR155, respectively. The GFP expression was much lower in miR155 
construct (~4%) compared to miR96/183 constructs (~25%). 
Recent work from our laboratory compared the efficacy of different promoters (EF1, RPBSA, 
hPGK and CMV) in a lentiviral system for driving long mRNA expression. We showed that 
EF1 promoter was the strongest promoter for driving short and long transcripts in HEK293T 
and primary human T cells consistent with other studies [401, 402]. Therefore, a second 
constitutive single promoter was designed by replacing hPGK promoter with EF1 to determine 
if this would lead to enhanced miR96 and miR183 expression. Since EF1 promoter drives the 
longer transcript consisting of three GOIs [401], we placed miRNA downstream of GFP and 
HER2 CAR in contrast to the original hPGK system (Figure 5.2 D). When HEK293T cells 
were transduced with EF1 driven construct, both miR96 and miR183 could not be enhanced 
more than ~1-4 fold whereas expression of miR155 was much reduced (~200-1700 fold) 
compared to hPGK system (Figure 5.2 E). In EF1 system, both HER2 CAR and GFP 
expression was enhanced compared to hPGK system; HER2 CAR expression was ~70% and 
~85% while GFP expression was ~70% and ~85% in constructs containing miR96/183 and 
miR155 respectively which was consistent with our observations [401]. However, the 
expression of miR96/183 remained the same (low) in both systems (hPGK and EF1) and 
miR155 expression decreased in EF1 system (Figure 5.2 B and E). We speculated that miRNA 
expression could have been affected during the processing of long transcript consisting of 
miRNA-GFP-HER2 CAR (hPGK system) or GFP-HER2 CAR-miRNA (EF1 system) by 
spliceosome or simply removed as transcriptional noise regardless of the promoter used [403]. 
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Figure 5.2 Single promoter constitutive systems. (A) The hPGK promoter driving miRNA (either 
miR96/183 or miR155), HER2 CAR and GFP. (B and E) expression of miR96, miR183 and miR155 
assessed by stem-loop RT-PCR upon transduction of HEK293T cells with the construct containing 
either miR96/183 or miR155. (C and F) GFP and HER2 CAR (by c-myc staining) expression 
determined by flow cytometry following transduction of HEK293 T cells with miRNA constructs. (D) 
EF1 promoter driving GFP, HER2 CAR and miRNA (either miR96/183 or miR155) (n=3 for B and D, 
n=2 for C and F). 
5.2.2.2 Dual promoter system  
Failing to achieve satisfactory miR96 and miR183 expression through single promoter system, 
we further enquired if the use of two constitutive promoter would enhance the expression of 
miRNAs. As the inducible system seemed more promising in miR96/183 expression compared 
to single promoter system (Figure 5.1), we replaced the TCE promoter in inducible lentivirus 
system with hPGK promoter to generate dual promoter constitutive system consisting hPGK 
and RPBSA promoter (uni-directional system). Although, this system could face 
transcriptional interference, it allowed us to place coding (GFP and HER2 CAR) and non-
coding miRNA under two different promoters (Figure 5.3 A). When HEK293T cells were 
transduced with the viral particles, miR96 and miR183 expression was still found to be poor 
while miR155 expression was increased (~8000-17000 fold) (Figure 5.3 B). To further explore 
the dual promoter system, we flipped the direction of hPGK promoter placing miRNA 
downstream of the promoter and replaced RPBSA promoter by EF1 promoter driving GFP and 
HER2 CAR expression to create bi-directional system with hPGK and EF1 promoters running 
in opposite directions (Figure 5.3 D) [401, 404]. Surprisingly, expression of both miR96 and 
miR183 was enhanced and the fold change expression values were ~18-50 and ~14-29 
respectively when tested in HEK293T cells (Figure 5.3 E).  
Expression of both HER2 CAR and GFP, as measured by flow cytometry were similar 
following transduction of HEK293T cells with uni-directional and bi-directional lentivirus 
system. Furthermore, the expression of HER2 CAR and GFP were also comparable in cells 
transduced with constructs containing miR96/183 and miR155. However, GFP expression was 
lower in these systems, as compared to EF1 system mentioned previously.  
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Figure 5.3 Dual promoter constitutive systems. (A) Dual promoter system with hPGK driving 
miRNA (either miR96/183 or miR155) and RPBSA driving HER2 CAR and GFP. (B and E) Expression 
of miR96, miR183 and miR155 assessed by stem-loop RT-PCR upon transduction of HEK293T cells 
with the construct containing either miR96/183 or miR155. (C and F) GFP and HER2 CAR (by c-myc 
staining) expression determined by flow cytometry following transduction of HEK293T cells with 
miRNA constructs. (D) Dual promoter system with hPGK driving miRNAs (either miR96/183 or 
miR155) and EF1 driving HER2 CAR and GFP, hPGK and EF1 runs in different direction (n=3 for B 
and D, n=2 for C and F).  
Western blot analysis was used to further confirm the expression of GFP and HER2 CAR (c-
myc tag) in HEK293T cells transfected with the constitutive single promoter and dual promoter 
constructs (Figure 5.4). In line with lower GFP expression by flow cytometry, the GFP was not 
detectable by western blot in HEK293T cells transduced with hPGK single promoter 
constitutive system (Figure 5.4 A). Of note, western blot analysis failed to detect any HER2 
CAR expression. For all other constructs, both c-myc and GFP protein were strongly detected 
and were consistent to the results shown in Figure 5.2 and 5.3 by flow cytometry. 
Based on the strong expression of c-myc, GFP (by flow cytometry and western blotting) and 
miR96/183 or miR155 (by stem-loop RT-PCR), the bi-directional dual promoter constitutive 
systems were used for the further study in primary T cells and are referred to as miR96/183-
HER2 CAR and miR155-HER2 CAR constructs from now onwards. We also constructed 
HER2 CAR-P2A-GFP downstream of EF1 promoter without miRNA to use as control HER2 
CAR construct in experiments assessing the effect of PRKAR1A knockdown and miRNA 
overexpression in HER2 CAR expressing primary T cells. The expression of c-myc and GFP 
in HEK293T cells transduced with control HER2 CAR construct assessed by western blotting 
and by flow cytometry is shown in Figure 5.4 A and 5.4 B respectively confirming efficient 
transduction and HER2 CAR expression. 
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Figure 5.4 Assessing HER2 CAR and GFP expression at protein level in HEK293T cells 
transfected with different lentiviral constructs. (A) Detection of c-myc and GFP in HEK293 T cells 
transduced with different lentiviral constructs; pCCL-Sin empty vector, control HER2 CAR, bi-
directional system (hPGK+EF1), EF1 system, unidirectional system (hPGK+RPBSA) and hPGK 
system. Transduced cells were lysed to extract protein for the western blot analysis. β-actin was used 
as loading control. (B) GFP and HER2 CAR expression on HEK293T cells transduced with HER2 CAR 
construct was assessed by flow cytometry. Data are representative of two independent experiments 
(n=2). 
5.2.3 Measuring PRKAR1A expression following microRNAs (miR96/183 or 
miR155) overexpression through bi-directional lentivirus system  
Next, we transduced HEK293 T cells with miR96/183-HER2 CAR or miR155-HER2 CAR to 
determine if the overexpression of miR96/183 and miR155 in the lentivirus system would 
reduce PRKAR1A expression to the similar extent shown in chapter 4. Both miR96/183 and 
miR155 overexpression reduced PRKAR1A expression by ~30 to 80-fold at mRNA level 
respectively (Figure 5.5).  
- 107 - 
 
 
Figure 5.5 Reduced PRKAR1A transcript expression in HEK293T cells following overexpression 
of miRNA96/183 or miR155. HEK293 T cells transduced with either miR96/183-HER2 CAR or 
miR155-HER2 CAR and lysed to isolate the RNA to assess the expression of PRKAR1A by real time 
RT-PCR (n=3). 
5.2.4 Transduction of T cells  
To investigate the effect of designed lentiviral constructs (control HER2 CAR, miR96/183-
HER2 CAR and miR155-HER2 CAR) in human T cells, we sought to optimise the transduction 
protocol and the transduction efficiency. Control HER2 CAR construct was used for the 
optimisation. We concentrated the viral particles by ultra-centrifugation at 120,000 g for 2.5 
hrs prior to use for all transductions. Briefly, human T cells were activated with anti-
CD3/CD28 beads for 24 hours, after which the cells were incubated with different MOI of 
lentivirus (MOI 5, 10 and 20) in retronectin-coated plate for another 24 hours. Use of 
retronectin (recombinant fibronectin fragment) has been shown to improve infectivity of 
lentivirus [405]. Next day, the beads were removed, and the cells were incubated for three days 
in fresh media with IL2 before analysing the GFP expression (transduction percentage) by flow 
cytometry; flow cytometric gating is shown in Figure 5.6. We achieved a maximum of ~21% 
transduction with the control HER2 CAR construct at a MOI 20 (Figure 5.7 A). To enhance 
the transduction efficiency, we utilized spinoculation of the retronectin coated plate with the 
lentivirus at 2000 g for 2 hours. Following centrifugation, the lentivirus was removed to add 
CD3/CD28 activated T cells and again centrifuged at 800 g for 20 minutes. Interestingly, we 
achieved ~ 50% GFP positive cells with spinoculation when MOI 20 was used for transduction 
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and ~ 65% with MOI 45 (Figure 5.7 B). The cells were stained with live dead stain and dead 
cells were excluded when GFP expression percentage was measured. When repeated we could 
achieve more than 90% transduction with pCCL-Sin empty vector and more than 80% 
transduction with control HER2 CAR construct when MOI 45 was used (Figure 5.7 C). 
Next, we determined the transduction efficiency in human T cells for miR96/183-HER2 CAR 
and miR155-HER2 CAR lentiviral constructs at MOI 45. The transduction efficiencies for 
miR96/183-HER2 CAR and miR155-HER2 CAR were similar (~ 55%, Figure 5.8). T cells 
transduced with either construct expressed similar amount of HER2 CAR on the surface 
measured by c-myc staining. Although, slightly better transduction efficiency was observed for 
control HER2 CAR construct, the HER2 CAR expression was comparable on cells transduced 
with all three (control HER2 CAR, miR96/183-HER2 CAR and miR155-HER2 CAR) 
constructs (~ 80%, Figure 5.8). 
 
Figure 5.6 Representative flow cytometry gating strategy for assessing transduction efficiency. 
CD3/CD28 stimulated human T cells were transduced with lentiviral constructs and percentage 
transduction was measured by GFP expression on live cells. The number in each flow cytometry plot 
indicates the percentage parent population. The GFP positive cells were further analysed for the 
expression of certain cell surface proteins in later sections. 
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Figure 5.7 Transduction of human T cells. (A) Histograms showing GFP expression on human T 
cells 3 days post transduction with control HER2 CAR construct at MOI of 5, 10 and 20. T cells were 
activated with anti-CD3/CD28 antibodies coupled beads for 24 hrs prior to transduction. (B and C) 
Histogram showing GFP expression on human T cells pre-activated with CD3/CD28 for 48 hrs and 
transduced with lentivirus at (B) MOI of 15, 20, 30 and 45 and (C) MOI 30 by spinoculation; HER2 
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CAR (B and C-right) and pCCL-Sin (C-left) constructs were used for the transduction and transduction 
efficiency was measured as percent GFP positive cells on 3 days post transduction by flow cytometry. 
 
Figure 5.8 HER2 CAR and GFP expression in primary T cells transduced with lentiviral 
constructs. CD3/CD28 activated human T cells were transduced with the lentivirus constructs and total 
live T cells were gated to determine GFP expression (transduction efficiency) by flow cytometry. The 
GFP positive cells were further gated to determine the percentage of transduced T cells expressing 
HER2 CAR (c-myc). The miRNA constructs (miR96/183-HER2 CAR and miR155-HER2 CAR) were 
used at MOI of 45 while control HER2 CAR construct was used at MOI of 30 for transduction. 
5.2.5 Assessment of CAR T cell activity in vitro 
5.2.5.1 Activation and cytokine production 
We transduced T cells with HER2 CAR constructs (control HER2 CAR, miR96/183-HER2 
CAR and miR155-HER2 CAR) and the transduction efficiency was checked after transduction 
and before each experiment. The transduced T cells were co-cultured with HER2 
overexpressing breast cancer cell line MCF-7 at effector: target ratio of 2:1 for 24 hours and 
- 111 - 
 
the cell supernatant was used to detect IL-2 and IFN-γ by ELISA. Cells were also stained for 
the assessment of CD69 surface expression by flow cytometry. Upon incubation with HER2 
overexpressing MCF-7, T cells transduced with either of the control HER2 CAR or 
miRNA96/183-HER2 CAR or miR155-HER2 CAR produced more cytokines (both IL-2 and 
IFN-γ) compared to untransduced T cells, suggesting efficient recognition of HER2 antigen on 
MCF-7 cells by HER2 CAR ± miRNA transduced T cells (Figure 5.9 A and B). While IL-2 
production was comparatively higher in miR96/183 or miR155-HER2 CAR transduced T cells 
compared to control HER2 CAR transduction, this was not significant (Figure 5.9 A). Control 
HER2 CAR and miRNA-HER2 CAR transduced T cells produced similar levels of IFN-γ 
(Figure 5.9 B). CD69 expression was significantly increased following antigen recognition by 
HER2 CAR±miRNA transduced T cells, as compared to untransduced T cells (Figure 5.10 A). 
Interestingly, higher levels of CD69 were detected on the surface of miR155-HER2 CAR 
transduced T cells, as compared to control HER2 CAR and miR96/183-HER2 CAR transduced 
cells but this was not significant (Figure 5.10 A). Similar results were obtained when CD4 and 
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Figure 5.9 Measuring IL-2 and IFN-γ produced by transduced T cells. Control HER2 CAR, 
miR96/183-HER2 CAR, miR155-HER2 CAR or untransduced T cells were co-cultured with HER2 
overexpressing MCF-7 cells at 2:1 ratio for 24 hours and cytokine production ((A) IL-2 and (B) IFN-γ) 
was detected in the supernatant by sandwich ELISA. Data are represented as mean ± S.E.M and are 
from three independent experiments where each experiment indicates different donor (n=3). 
 
Figure 5.10 Measuring CD69 surface expression on transduced T cells. Control HER2 CAR, 
miR96/183-HER2 CAR, miR155-HER2 CAR or empty control (pCCL-Sin empty vector) transduced 
T cells were co-cultured with HER2 overexpressing MCF-7 cells at 2:1 ratio for 24 hours and the cells 
were stained for the surface expression of CD69 by flow cytometry; (A) CD3 T cells, (B) CD4 T cells 
and (C) CD8 T cells. Data are represented as mean ± S.E.M and are from four independent experiments 
where each experiment indicates different donor (n=4).  
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5.2.5.2 Cytotoxicity  
We next determined the killing ability (cytotoxicity) of transduced T cells utilising a luciferase 
assay. For this, control HER2 CAR, miR96/183-HER2 CAR or miR155-HER2 CAR 
transduced T cells (effector cells) were co-cultured with HER2 overexpressing MCF-7 cells 
stably expressing luciferase (transfected with pSBbi-Luc) (target cells) at 10:1 ratio (effector : 
target). The cytotoxicity of T cells was determined at both 24 and 48 hours. The killing ability 
of miR96/183-HER2 CAR and miR155-HER2 CAR was found to be similar to control HER2 
CAR transduced T cells (Figure 5.11 A). However, the killing was largely triggered upon 
HER2 antigen recognition as little to no killing was observed when MCF-7 cells were 
incubated with untransduced T cells. Since strong cytotoxic response (close to 100%) was 
observed for control HER2 CAR transduced T cells at both 24 and 48 hours (Figure 5.11 A), 
we were unable to gauge the effect of miRNA overexpression on cytotoxic ability of HER2 
CAR T cells. Further work will be required to determine if lower effector to target ratios will 
uncover differences in cytolytic potential between control CAR T cells and CAR T cells co-
expressing miRNA. 
Mesothelin targeted CAR designed to resist negative effect of PRKAR1A when co-cultured 
with respective tumour cell line in the presence of adenosine or prostaglandin demonstrated 
resistance to immunosuppression by these metabolites and enhanced killing [362]. We 
enquired whether the immunosuppressive metabolites, adenosine or prostaglandin affect the 
killing ability of T cells transduced with the miRNA constructs, we co-cultured HER2 CAR ± 
miRNA transduced T cells with HER2 overexpressing MCF-7 cells in the presence of varying 
concentrations of adenosine or prostaglandins to mimic solid tumour microenvironment and 
determined the killing ability following 24 and 48 hrs of incubation. However, the killing 
ability of T cells transduced with either of the HER2 constructs at both time points was not 
affected by different doses of adenosine and prostaglandin used (Figure 5.11 B and C).  
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Figure 5.11 Luciferase assay to detect cytotoxicity of transduced T cells. (A) Cytotoxicity measured 
by luciferase activity following co-culture of T cells transduced with lentiviral construct (control HER2 
CAR, miR96/183-HER2 CAR and miR155-HER2 CAR) and MCF-7 overexpressing HER2 at 10:1 
ratio for 24 hours and 48 hours. Untransduced T cells were used as controls. (B and C) Effect of different 
concentrations of adenosine (1 µM, 5 µM and 10 µM) and prostaglandin (1 µg/mL, 2.5 µg/mL and 5 
µg/mL) during the co-culture were also studied at 24 hours (B) and 48 hours (C). Data are represented 
as mean ± S.E.M and are from three independent experiments where each experiment indicates different 
donor (n=3). 
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5.2.6 Phenotypic analysis 
The effect of miRNA overexpression on activation (CD69 expression, and IL-2 and IFN-γ 
production) and cytotoxicity of HER2 CAR expressing T cells was not clearly observed in 
previous experiments which could be due to strong activation via HER2 CAR that may have 
masked the effect of miRNA. To further investigate the effect of miRNA overexpression, we 
analysed differences in CD4:CD8 ratio and expression of phenotypic markers on transduced T 
cells by flow cytometry. Briefly, T cells were activated with CD3/CD28 coupled beads for 48 
hours in the presence of IL-2 before transduction with lentiviral constructs (HER2 
CAR±miRNA) and were maintained in media containing IL-2 post transduction. After 10 days, 
the transduced T cells were stained to determine the proportion of CD4 and CD8 T cells by 
flow cytometry. Overexpression of miRNA resulted in small but significant enhancement in 
the percentage of CD4+ T cells compared to control HER2 CAR transduced T cells (Figure 
5.12 A and B). Similarly, there was small but non-significant reduction in CD8+ T cell 
percentage following miRNA overexpression (Figure 5.12 A and B). 
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Figure 5.12. Assessing percentage of CD4+ and CD8+ T cells following transduction with different 
constructs. Flow cytometric analysis for the percentage of CD4+ and CD8+ gated under live GFP+CD3+ 
T cells 10 days post transduction with control HER2 CAR, miR96/183-HER2 CAR, miR155-HER2 
CAR and pCCL-Sin empty vector (Empty control); (A) Representative flow cytometry plots and (B) 
cumulative data. Data are represented as mean ± S.E.M and are from three independent experiments (n 
= 3). Two-way ANOVA with Tukey test (B) was used for the statistical analysis. *p<0.05, ** p<0.01. 
We next stained for the expression of IL-2 receptor (CD25) and IL-7 receptor (CD127) on 
transduced T cells on day 10 post transduction (Figure 5.13a and 5.13b). T cells transduced 
with HER2 CAR±miRNA constructs showed enhanced CD25 expression compared to empty 
vector transduced T cells (Figure 5.13a). However, it was only significantly increased 
following miR155-HER2 CAR transduction (Figure 5.13b A-C). Interestingly, the 
enhancement of CD25 expression was clearly seen as a result of appearance of a distinct 
population of CD25+CD127- in T cells transduced with either control HER2 CAR or miR155-
HER2 CAR and similar enhancement in the percentage of CD25+CD127+ population with 
HER2 CAR±miRNA transduction (Figure 5.13a). The appearance of CD25+CD127- in HER2 
CAR±miRNA155 transduced T cells was matched by a proportional loss of the CD25-CD127+ 
subset (Figure 5.13a). Similar trend was observed when separately analysed for CD4+ or CD8+ 
T cells (Figure 5.13a and 5.13b). The striking difference was that the CD25+ CD8+ T cells were 
significantly higher following miR155-HER2 CAR transduction compared to miR96/183-
HER2 CAR transduction which was not observed for CD4+ compartment (Figure 5.13b B and 
C). Unlike the significant enhancement of CD25+CD127+ cells seen with HER2 CAR±miRNA 
in the CD4+ compartment, only miRNA96/183 overexpression resulted in significant 
enhancement of CD25+CD127+ cells within the CD8+ compartment (Figure 5.13b B and C). 
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Figure 5.13a Assessing CD25 and CD127 expression following transduction of T with different 
constructs. Flow cytometric analysis for the expression of CD25 and CD127 on T cells transduced with 
control HER2 CAR, miR96/183-HER2 CAR, miR155-HER2 CAR or pCCL-Sin empty vector (empty 
control) on day 10 post transduction; CD25 and CD127 expression on total CD3+, CD4+ T cells and 
CD8+ T cells are also separately analysed. Representative flow cytometry plots are shown from three 
independent experiments where each experiment indicates different donors (n=3). 
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Figure 5.13b Assessing CD25 and CD127 following transduction with different constructs. 
Cumulative analysis for the percentage of CD25 and/or CD127 expressing T cells transduced with 
control HER2 CAR, miR96/183-HER2 CAR, miR155-HER2 CAR or pCCL-Sin empty vector on day 
10 post transduction; gating shown in Figure 5.12a was used. The four populations CD25+, CD127+, 
CD25+CD127+ and CD25-CD127- under (A) total GFP+ CD3+T cells, (B) CD3+ CD4+ T cells and (C) 
CD3+ CD8+ T cells were compared. Data are represented as mean ± S.E.M and are from three 
independent experiments where each experiment indicates different donors (n = 3). Two-way ANOVA 
with Tukey test was used for statistical analysis. *p<0.05, ** p<0.01.  
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The discrepancy between miRNA96/183 and miRNA155 overexpression in HER2 CAR 
expressing T cells observed for CD25 vs CD127 expression inspired us to do further 
phenotypic analysis. Since the primary human T cell population is a heterogenous mixture of 
naive and memory T cells, we compared the proportion of naive, effector memory (EM), 
central memory (CM) and terminally differentiated effector memory (TEMRA) T cells on day 
21 post transfection. Although the clear separation of these subsets by flow cytometry could be 
difficult sometimes, we used two different ways of analysis using the combination of CD45RA 
with either CD27 or CD62L which have been shown to be a success in dissecting T cells into 
the four memory subsets [406, 407]. 
Assessing CD45RA and CD27 expression worked effiently showing clear separation of the 
memory populations (Figure 5.14a). Compared to the empty vector control, reduction in naive 
T cells and to some extent on CM T cells but rapid expansion of TEMRA T cells was seen 
following HER2 CAR±miRNA155 transduction. In contrary, some enhancement in the 
percentage of CM T cell population with no concomitant change in the percentage naive T cells 
was observed in T cells tranduced with miRNA96/183-HER2 CAR. When separetly analysed 
similar trend was observed for CD4+ and CD8+ T cells except that more CD4+ T cells were 
observed in the naive compartment following miRNA155-HER2 CAR compared to other 
transductions (Figure 5.14a). 
Assessing the expression of CD62L and CD45RA on T cells also provided useful information 
and we were able to dissect CD3+ T cells into different compartments (Figure 5.14b). Similar 
to observations made in Figure 5.14a, HER2 CAR and miR96/183-HER2 CAR expression 
resulted in the expansion of the TEMRA T cells and the CM T cells respectively (Figure 5.14b). 
However, the effect of miR155-HER2 CAR was similar to empty control except that CD4+ T 
cells were more in the naive compartment following miR155-HER2 CAR tranduction 
compared to other tranductions as observed in Figure 5.14a. 
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Figure 5.14a Assessing memory phenotype using CD45RA and CD27. Flow cytometric analysis for 
the expression of CD45RA and CD27 on T cells transduced with control HER2 CAR, miR96/183-
HER2 CAR, miR155-HER2 CAR or pCCL-Sin empty vector (empty control) on day 21 post 
transduction; CD45RA and CD27 expression on total CD3+, CD4+ T cells and CD8+ T cells are also 
separately analysed. Representative flow cytometric plots are shown from three independent 
experiments where each experiment indicates different donors (n=3). Numbers in flow cytometry plots 
indicate percentage of parent population. 
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Figure 5.14b Assessing memory phenotype using CD45RA and CD62L. Flow cytometric analysis 
for the expression of CD45RA and CD62L on T cells transduced with HER2 CAR, miR96/183-HER2 
CAR, miR155-HER2 CAR or pCCL-Sin empty vector (empty control) on day 21 post transduction; 
CD45RA and CD62L expression on total CD3+, CD4+ T cells and CD8+ T cells are also separately 
analysed. Representative flow cytometric plots are shown from three independent experiments where 
each experiment utilises different donors (n=3). Numbers in flow cytometry plots indicate percentage 
of parent population. 
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Next, we analysed the expression of various other cell surface proteins along with those used 
to dissect memory phenotypes (Figure 5.15a and 5.15b). Compared to empty control, HER2 
CAR±miRNA transduced T cells showed reduced CD27 expression, a significant reduction 
was observed following HER2 CAR±miRNA155 transduction compared to miR96/183-HER2 
CAR (Figure 5.15a A). While there was no significant change in CD57 expression between 
control HER2 CAR and miR155-HER2 CAR transduced T cells, CD57 expression was 
significantly reduced on miR96/183-HER2 CAR transduced T cells (Figure 5.15a B). Similar 
trend was observed for CD62L expression (Figure 5.15a C). While CCR7 expression was 
reduced following HER2 CAR±miRNA transduction compared to empty control, the reduction 
was significantly more with control HER2 CAR (Figure 5.15a D). Interestingly, CD95 
expression was significantly higher following HER2 CAR±miRNA155 transduction (Figure 
5.15b A). The expression of these proteins was similarly modulated in CD4+ and CD8+ T cells 
(Figure 5.15 a A-D and 5.15b A).  Expression of CXCR3 and CD45RO was comparable on T 
cells transduced with HER2 CAR±miRNA whereas CD45RA expression was significantly 
lower on T cells following miR96/183-HER2 CAR transduction (Figure 5.15b B-D). 
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Figure 5.15a Assessing surface expression of CD27, CD57, CD62L and CCR7 in T cells following 
transduction with different constructs. Expression of (A) CD27, (B) CD57, (C) CD62L and (D) 
CCR7 on T cells was compared on day 21 post transduction with control HER2 CAR, miR96/183-
HER2 CAR, miR155-HER2 CAR or pCCL-Sin empty vector. Expression on total CD3+ T cells, CD4+ 
T cells and CD8+ T cells are shown. Data are represented as mean ± S.E.M and are from three 
independent experiments where each experiment indicates different donors (n=3). One-way ANOVA 
with Sidak test was used for statistical analysis. *p<0.05, ** p<0.01, ns = non-significant.  
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Figure 5.15b Assessing surface expression of CD95, CXCR3, CD45RA and CD45RO on T cells 
following transduction with different constructs. Expression of (A) CD95, (B) CXCR3, (C) 
CD45RA and (D) CD45RO on T cells was compared on day 21 post transduction with HER2 CAR, 
miR96/183-HER2 CAR, miR155-HER2 CAR or pCCL-Sin empty vector. Expression in total CD3+ T 
cells, CD3+ CD4+ T cells and CD3+ CD8+ T cells are shown. Data are represented as mean ± S.E.M and 
are from three independent experiments where each experiment indicates different donors (n=3). One-
way ANOVA with Sidak test was used for statistical analysis. *p<0.05, ** p<0.01, ns = non-significant. 
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There are distinct distributions (especially naive vs memory) among the T cells as demonstrated 
in Figure 5.15a and 5.15b, we analysed the expression of CD57, CD95 and CXCR3 on different 
memory populations. Since the frequency of naive and memory populations were comparable 
when either CD62L or CD27 was used with CD45RA, comparisons were only made on the 
populations distinguished by CD45RA and CD62L (Figure 5.16). Compared to empty control, 
CD57 expression was increased in HER2 CAR±miRNA155 transduced naive as well as 
memory (TCM, TEM and TEMRA) populations whereas much lesser enhancement on CD57 
expression was observed following miR96/183 transduction (Figure 5.17 A). CD95 expression 
was increased on HER2 CAR±miRNA transduced TCM populations; not much change was 
observed within TEM and TEMRA populations (Figure 5.17 B). Interestingly, HER2 
CAR±miRNA155 selectively resulted in enhanced CD95 expression on naive T cells. Similar 
to the observations made with CD3, CD4 and CD8 T cells, CXCR3 expression was reduced in 
all naïve and memory populations following HER2 CAR±miRNA transduction compared to 
empty control (Figure 5.17 C). 
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Figure 5.16 Comparison of naïve and memory populations by two gating strategies, CD45RA and 
CD62L versus CD46RA and CD27. Flow cytometric analysis for the expression of CD45RA, CD27 
and CD62L on T cells transduced with HER2 CAR, miR96/183-HER2 CAR, miR155-HER2 CAR or 
pCCL-Sin empty vector (empty control) on day 21 post transduction. Representative flow cytometric 
plots are shown where each experiment utilises different donors (n=3). Numbers in flow cytometry 
plots indicate percentage of parent population. 
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Figure 5.17 Assessing surface expression of CD57, CD95 and CXCR3 on different memory 
subsets following transduction with different constructs. Expression of (A) CD57, (B) CD95 and 
(C) CXCR3 on naive, TCM, TEM and TEMRA T cells distinguished by CD45RA and CD62L staining 
was compared on day 21 post transduction with HER2 CAR, miR96/183-HER2 CAR, miR155-HER2 
CAR or pCCL-Sin empty vector; cells were gated under CD3+GFP+ T cells. Data are represented as 
mean ± S.E.M and are from three independent experiments where each experiment indicates different 
donors (n=3). One-way ANOVA with Sidak test was used for statistical analysis. *p<0.05, ** p<0.01, 
ns = non-significant. 
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5.2.7 Concluding remarks 
▪ Different lentiviral system was designed and tested to co-express miRNA, GFP and 
HER2 CAR. The bi-directional system consisting hPGK promoter (driving miRNA) 
and EF1 promoter (driving GFP and HER2 CAR) placed in a divergent direction, 
resulted in enhanced expression of miRNAs (by stem-loop RT-PCR), GFP and HER2 
CAR (by flow cytometry and western blotting) compared to single promoter (hPGK or 
EF1) and uni-directional dual promoter system (hPGK and RPBSA). 
▪ Transduction of T cells by lentiviral constructs (control HER2 CAR, miR96/183-HER2 
CAR and miR155-HER2 CAR) was optimised. Transduction by spinoculation method 
substantially enhanced the transduction efficiency compared to the other method used.  
▪ The miRNA-HER2 CAR transduced T cells showed similar cytokine response (IL-2 
and IFN-γ) and cytotoxicity compared to control HER2 CAR transduced T cells. A 
similar result was observed for CD69 surface expression. 
▪ The ratio of CD4:CD8 T cell subset was higher in T cells transduced with miRNA 
constructs compared to HER2 CAR construct.  
▪ T cells transduced with miR155-HER2 CAR and control HER2 CAR resulted in 
increased CD25+ T cells and reduced CD127+ T cells. All three HER2 CAR±miRNA 
constructs enhanced percentage of CD25+CD127+ T cells. 
▪ HER2 CAR±miRNA155 transduced T cells showed rapid expansion of TEMRA T cells 
on 21 days post transduction while miRNA96/183-HER2 CAR transduced T cells 
showed increased CM T cell population when T cells were assessed for the expression 
of CD45RA and CD27. Similar observations were made when the memory phenotypes 
were assessed using the expression of CD62L and CD45RA.  
▪ Expression of various other surface proteins (CD27, CD57, CD62L, CCR7, CD95, 
CXCR3, CD45RA and CD45RO) suggested that the overexpression of miR155 did not 
substantially change the phenotype of anti-CD3/CD28 activated HER2 CAR T cells, 
whereas significant differences in the expression of CD27, CD57 and CD95 were 
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Utilisation of the immune system to boost the body’s natural defense has emerged as an 
important tool in cancer therapy. Genetically modified T cells that express a CAR have 
demonstrated outstanding results clinically for a subset of hematological malignancies and 
research projects are being carried out to reduce potential side effects to benefit wider cohorts 
of cancer patients [408-410]. Unlike hematological malignancies, which may be targeted by 
the expression of single antigen targeting CAR, solid tumours express heterogeneous cancer-
associated antigens. In addition, solid cancers have a tendency to develop resistance and 
respond differently to therapeutic interventions [411, 412]. The therapeutic potential of  CAR 
T cells designed to target solid tumours is influenced by the complex and  immunosuppressive 
tumour microenvironment [413]. For this reason, the efficiency of CAR T cell therapy in 
treating solid tumour is still unsatisfactory, despite its success in treating hematological 
malignancies [414]. This thesis explored strategies to target and/or overcome the 
immunosuppressive tumour microenvironment to expand CAR T cell therapy approach in solid 
tumour malignancies. 
6.1 Chimeric CXCR3 receptor to exploit immunosuppressive metabolites 
To overcome inhibition by the TME, we designed chimeric CXCR3 receptors to harness 
inhibitory tumour metabolites as a positive signal for T cell function and assessed their 
functionality based on assays optimized using the unmodified CXCR3 receptor (Chapter 3). 
First, we showed that HEK293 cells expressing CXCR3 stimulated with CXCL11 exhibited an 
elevation of intracellular calcium and ERK phosphorylation within minutes, indicating the 
rapidity and specificity of the signal transduction process via CXCR3 [415, 416]. Consistent 
with the previous findings, EL4 T cells overexpressing CXCR3 demonstrated enhanced 
migration in vitro in response to CXCL11 in a transwell system [417]. Therefore, the 
overexpression of CXCR3 on anti-cancer T cells can be beneficial for tumour regression [279, 
418]. For example, a GD2 targeting CAR T cells co-expressing C-C chemokine receptor type 
2 (CCR2b) demonstrated enhanced migration and anti-tumour response both in vitro and in 
vivo suggesting modulation of chemokine receptor could be one of many approaches to target 
cancerous cells [419].  
This thesis introduces the strategy for the development of chimeric GPCRs to exploit tumour 
metabolites and enhance the function of anti-cancer T cells including CAR T cells. Low 
chemokine production by many tumors and subsequently lower expression of chemokine 
receptor on effector T cells result in limited trafficking of lymphocytes for successful therapy 
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[420, 421]. The potentiality of a chimeric receptors was demonstrated by Xu Y et al by utilising 
CXCR4 to design a chimeric receptor, rhodopsin-CXCR4 (PA-CXCR4) that couples an 
extracellular optical signal perceived by the rhodopsin receptor to intracellular CXCR4 
receptor and leads to stimulation of downstream signaling events [335]. The PA-CXCR4 
chimera displayed T cell polarization and migration both in vitro and in vivo as well as 
improved antigen specific tumour regression. Thus, the CXCR3-based tumour metabolite 
sensing chimeric receptors used in this thesis might also be useful to enhance the migration of 
T cells towards tumour. 
T cells that reach the tumour are suppressed by the immunosuppressive metabolites in TME 
[422]. To overcome such inhibitory metabolites, we designed some CXCR3-based chimeras, 
namely A1-CXCR3, A2A-CXCR3 and T8-C3, by coupling extracellular and transmembrane 
regions of either adenosine receptor (A1 or A2A receptor) or TDAG8 receptor (which are 
mainly involved in ligand binding) to the intracellular signaling domain of CXCR3 [423, 424]. 
We focused on the increase in calcium flux and ERK phosphorylation to assess chimeric 
receptor activation as these second messenger pathways are rapidly activated upon specific 
signaling via Gαi protein linked CXCR3 receptor within few minutes. Unfortunately, no signal 
transduction was observed through the chimeric A1-CXCR3 and A2A-CXCR3 receptors 
(with/without tag) in response to different concentrations of specific ligand (CCPA and 
CGS21680 respectively). Similarly, T8-C3 tested in acidic media failed to show signal 
transduction. However, we cannot rule out the possibility of signal transduction that might 
occur by coupling of the receptors to other G proteins such as Gαs, Gα12/13 and Gαq which may 
induce different signaling pathway [425]. For example, both wild type A2A AR and TDAG8 
can couple to Gs protein leading to the rise in cAMP level [284, 426]. 
The non-functionality of the chimeric receptors in this study could also be due to the design of 
the chimeric receptor consisting of ligand binding extracellular domain and signaling 
intracellular domains of two different GPCRs. The chimeras included critical motifs for ligand 
binding and receptor signaling based on tools such as UniProt, GPCRdb and previous studies 
[427-429]. Critical motifs were included such as DRY located in TM3 plays an important role 
in chemotaxis and calcium mobilisation, CWXP and NPLLY located in TM6 and TM7 
respectively plays a vital role in receptor activation and maintaining structural integrity [355, 
430, 431]. However, studies suggest that a chimeric receptor designed by exchanging 
intracellular receptors between different GPCRs may change their coupling specificity to a 
particular G protein, and thus the resulting chimeric receptor may couple to either donor or 
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acceptor or an incompatible G protein [336, 432]. GPCRs may also form oligomers with other 
GPCRs which may confer different signaling properties and this may differ across different 
cell lines [337, 433, 434]. Hence, further work such as structural homology modelling should 
focus on understanding the structural properties of the resulting chimeric receptor. Ligand 
binding assays could also be utilised to determine the binding affinities of these chimeric 
receptor to specific ligand as well as to detect the expression level of these chimeric receptors.  
Previously, similar CXCR3 based TDAG8 chimera was designed in our lab which unlike the 
chimera (TDAG8-CXCR3) discussed in this thesis also included amino acids from the 
transmembrane domain of CXCR3 receptor. However, the previous receptor failed to transduce 
signal when assessed by ERK phosphorylation assay and migration assay. Inclusion of 
PMA/Ionomycin as a positive control in these assays suggested that the failure in detecting 
signal transduction in transfected cells was not due to the poor assay design and/or choice of 
assay used but might be due to the technical problem associated with the chimera-design. 
Although the CXCR3 receptor was used as a positive control in this study to compare the signal 
transducing ability of the CXCR3-based chimeras, one of the major limitations was the lack of 
cells expressing wild type A1, A2A and TDAG8 receptors which otherwise could have served 
as a control in the assays mentioned above and/or to optimise various parameters such as 
optimal ligand concentration or pH to induce signal transduction via A1/A2A and TDAG8 
receptors respectively. Therefore, it is difficult to pinpoint the precise reason for not detecting 
signal transduction via the chimeras which could lie in the chimera designing part or the 
technical part to assess the signal transduction and could only be answered in future with the 
inclusion of cells expressing relevant receptors (A1, A2A or TDAG8) and careful modification 
of receptor designing for better functionality and/or efficient receptor surface expression. 
6.2 Production of CXCL11 in bacterial system 
We utilised E. coli BL21 (DE3) as an economic and convenient method to synthesize 
recombinant CXCL11 protein in our laboratory. E. coli BL21 (DE3) is a derivative of BL21 
strain which harbours a prophage DE3 derived from bacteriophage λ that carries T7 RNA 
polymerase for robust transcription and production of recombinant protein in inclusion bodies 
[435, 436]. Production of functional protein from inclusion body was a challenging task which 
required isolation and washing of inclusion bodies, solubilisation of aggregated proteins 
(guanidine-HCL and urea) and refolding of solubilised protein (Ni-NTA column and dialysis). 
Although the final yield of CXCL11 was satisfactory when E. coli transformed with MRGS-
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His (6x)-CXCL11 was used for protein expression, no ERK phosphorylation was observed 
following stimulation of HEK293-CXCR3 cells with the purified CXCL11.One of the reasons 
could be due to improper folding of the protein during renaturation step because renaturation 
of protein is the most delicate step which depends heavily on the type of protein and the 
heterogeneity of the co-aggregated molecules during protein production [437]. Also, MRGS-
His (6x)-tagged CXCL11 (MRGS-His (6x)-CXCL11) obtained by this method might have 
altered the N-terminal phenylalanine in CXCL11 which is critical for interaction with CXCR3 
and subsequent signal transduction [438, 439]. As an alternative approach to produce 
functional CXCL11, pelB signal sequence was fused to the N-terminus of CXCL11 with His-
tag in the C-terminal, which still failed to enhance solubility of the protein and the resulting 
protein remained non-functional. This is in contrary to the published literature suggesting 
successful use of N-terminal signal sequence with several recombinant proteins to achieve 
higher protein stability, correct folding, and improved downstream processing of protein [440, 
441]. The solubility of the protein might also have been affected because of the excessive gene 
expression in the recombinant bacterial system which saturates the sec-translocon capacity, a 
protein-conducting channel present in the cytoplasm that helps to escort the protein to the 
periplasm, resulting in misfolding and / or accumulation of the protein in the cytoplasm [442, 
443]. Additionally, improper cleavage of signal peptide could also interfere with functionality 
of the protein [444-446]. Besides pelB, fusion partners such as maltose binding protein (MBP), 
E.coli N-utilising substance A (NusA) are frequently used for enhancing solubility and 
production of protein most likely to form inclusion body which could be explored in future 
[424]. 
6.3 Downregulation of PRKAR1A by RNAi approach 
 A different approach to downregulate PRKAR1A expression via RNAi approach to overcome 
immunosuppression was studied in this thesis (Chapter 4). We first utilised RNAi based 
shRNA approach which has been widely employed as an efficient tool to knockdown various 
target genes [447]. However, the shRNAs used in this study showed little to no reduction in 
PRKAR1A gene expression. The efficacy of shRNA mediated knockdown is affected by 
various factors associated with the shRNA design such as the loop structure, stability, and the 
secondary structures within the sequence which may lead to insufficient target knockdown and 
off-target effect [448]. For example, shRNAs with longer hairpin loop are susceptible to 
inaccurate processing [449]. Although three sets of shRNAs with different loop structures were 
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designed and tested, this study did not explore other avenues of shRNA processing. Moreover, 
loop counting methods could also be implemented in future to ensure precise cleavage of the 
parental shRNA by Dicer to get the desired siRNA sequence [450]. To date, both polymerase 
(pol) II (such as TCE promoter) and pol III (U6 and H1 promoter) based promoters have been 
employed to express potent shRNA for specific knockdown of the target gene [451, 452]. 
However, most studies use Pol III promoters for driving shRNA expression because of the 
precise transcription (initiation and termination) carried out by the pol III promoters to facilitate 
accurate shRNA design compared to pol II promoters (used in this study) which involves post 
transcriptional processing [453]. Alternatively, we could take advantage of the artificial pri-
miRNA mimics which have opened the door to design potent shRNAs for silencing various 
targets, most of which are based on a naturally occurring miR-30 backbone with various 
flanking region, stem and loop [454, 455]. The advantage of using miRNA intermediate 
harbouring the shRNA sequence is that it can be expressed from both pol II and pol III promoter 
as the sequence undergo the same processing and export pathway as the endogenous miRNA 
[456, 457]. Park SK et al designed shRNA embedded in human miR-30a miRNA precursor by 
addition of CNNC motif (CCTC and CTTC) in the 3' flanking region of the shRNA precursor 
which resulted in efficient knockdown of the murine p53 gene [458]. Use of such advance 
designing strategies might help the efficacy of shRNA mediated PRKA1RA knockdown.  
As an alternative to shRNA, we overexpressed miR96/183 and miR155 to downregulate 
PRKAR1A expression. Although the upregulation of miR155 expression was more than 10-
fold compared to upregulation of miR96/183 expression which could be due to the differences 
in the intrinsic elements within the miRNA sequence and their state of stability [459], both 
miRNAs downregulated PRKAR1A expression at both mRNA and protein level. Furthermore, 
luciferase reporter assay validated PRKAR1A 3' UTR as a direct target of miR96/183 and 
miR155 suggesting the presence of both miR96/183 and miR155 binding region or MRE in 
PRKAR1A 3' UTR. Luciferase assay have been widely used to validate target genes linked to 
the 3' UTR and thus it is a specific method of miRNA target validation. However, in studies 
that require the validation of hundreds of target genes, the conventional reporter assays using 
whole 3' UTR used in this study could be inefficient and expensive. A more efficient and cost-
effective linker reporter assay has been developed which uses linker sequence (18-22 bp or 60 
bp) corresponding to the predicted MRE instead of whole 3' UTR as in conventional reporter 
assay and thus can be utilised for high-throughput screening for the targets [460]. Utilization 
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of such assay will make it possible to find potential other targets of the miRNAs used in this 
thesis which might further to aid in uncovering any possible off target effect of the miRNAs.  
6.4 Effect of miRNA overexpression on Jurkat T cells during activation 
We further investigated the effect of miRNA overexpression and PRKAR1A downregulation 
on Jurkat T cells. Jurkat T cells, which are human CD4 cell lines, have been shown to be 
defective in two lipid phosphatases namely phosphatase and tensin homologue (PTEN) and 
SH2-domain containing inositol polyphosphate 5’ phosphatases (SHIP) which are otherwise 
expressed in human CD4+ T cells [389]. Although, the precise role of SHIP on TCR signaling 
is still poorly understood, loss of PTEN results into constitutive activation of 
phosphatidylinositol 3-kinase (PI3K)-signaling leading to hyperresponsiveness to CD3 
stimulation [461]. One of such enhanced response is robust IL-2 production making Jurkat T 
cells a good in vitro model to study T cell biology.  
PRKAR1A inhibits TCR mediated T cell activation and many strategies have been used in past 
to combat inhibitory role of PRKAR1A. For example, displacement of PRKAR1A from the lipid 
raft by disruption of PKA-A kinase anchoring protein (AKAP) association in the immune 
synapse by RIAD peptide have shown to diminish phosphorylation of Y505 in Lck, thus 
enhancing T cell signaling [361, 462]. Lck is a SRC family protein tyrosine kinase that 
determines the fate of TCR signaling and is highly regulated by phosphorylation and 
dephosphorylation of key regulatory tyrosines, Y394 and Y505 [463]. Similarly, RI specifier 
region (RISR) that enhances RIAD binding to PKA (RSIR-RIAD) was designed and expressed 
on T cells under the control of distal Lck promoter which demonstrated enhanced TCR 
signaling and IL-2 production by murine T cells [464]. Consistently, enhanced activation and 
functions were achieved when RISR-RIAD approach was extended in CAR T cells by cloning 
RISR-RIAD in T cells expressing CAR against human mesothelin (mesoCAR) [362].  
In this study, targeting PRKAR1A via overexpression of miR96/183 or miR155 amplified IL-2 
secretion in Jurkat T cells during TCR stimulation by anti-CD3/CD28 beads which is in line 
with previous observations. Mice deficient in miR155 has been shown to exhibit reduction in 
both T cell expansion and IL-2 production by T cells [465, 466]. IL-2 is an important cytokine 
required for generation, differentiation, and maintenance of effector T cells as well as 
regulatory T cells (Tregs) [467, 468]. However, it is not clear if enhanced IL-2 production as a 
result of miRNA overexpression induced downregulation of PRKAR1A observed in this study 
involves the same mechanism as observed in previous studies (mentioned in previous 
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paragraph) which were carried out by dislocation or displacement of the PRKAR1A subunit 
from the lipid raft. Upon T cell activation, PRKAR1A localises to the immune synapse with 
the TCR-CD3 complex, where it phosphorylates the PTK, Csk on serine 364 which in turn 
negatively regulates Lck by phosphorylating carboxy-terminal inhibitory tyrosine residue, 
Y505 and stabilising Lck in inactive state [469-471]. Thus, future investigation could be 
performed to detect phosphorylation status of these proteins upon downregulation of 
PRKAR1A following miR96/183 or miR155 overexpression. Additionally, MAP kinase 
pathway, which is one of the major pathways induced upon TCR stimulation and plays a crucial 
role in regulating T cell response, could also be explored in future by assessing the 
phosphorylation status of ERK proteins upon miRNAs overexpression [472].  
Overexpression of miR155 enhanced the expression of CD69, an early activation marker, upon 
stimulation of Jurkat T cells with anti-CD3/CD28 beads which is in line with previous finding 
that showed increase in CD69 expression and STAT5 activation following miR155 
overexpression [473]. However, overexpression of miR96/183 did not have any effect on CD69 
expression despite having greater enhancing effect on IL-2 production than miR155 
overexpression. Assuming similar downregulation in PRKAR1A expression in Jurkat cells 
following miRNA overexpression as in HEK293T cells, and the Jurkat experiment being a 
proof-of-concept experiment before the validation in primary human T cells, PRKAR1A 
expression was not assessed in Jurkat cells. Although, this thesis demonstrated both miRNAs 
target PRKAR1A 3' UTR, miRNA can also target the CDS. However, binding of miRNA to 
CDS causes efficient inhibition of translation in contrast to binding of miRNA to 3' UTR which 
causes mRNA degradation [474]. Therefore, it would be interesting to assess PRKAR1A 
expression in Jurkat cells in future to see if there is any relationship between the discrepancy 
in CD69 expression/IL-2 production and PRKAR1A expression at both mRNA and protein 
level following miR96/183 or miR155 overexpression. 
6.5 Added benefits of miR96/183 and miR155 
A miRNA can target multiple mRNAs [191, 475]. Therefore, in addition to PRKAR1A, 
miR96/183 and miR155 used in this study may regulate T cell function by targeting various 
genes. Interestingly, overexpression of both miR96/183 and miR155 in HEK293 cells reduced 
the expression of several genes which were predicted targets, such as TET2, FOXO3 and 
PTPN2. TET2 mediates DNA methylation and is involved in regulating immune homeostasis. 
Loss of TET2 in CD8 T cells or CD19 CAR T cells has previously been demonstrated to result 
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in enhanced effector functions and increase in memory phenotype [476, 477]. FOXO3 is a 
transcription factor that plays vital role in regulating T cell homeostasis and deletion of FOXO3 
was shown to increase cytotoxicity of T cells [478, 479]. Likewise, PTPN2 dephosphorylates 
Lck and negatively regulates TCR signaling [480]. PTPN2 deficient CAR T cells exhibited 
enhanced activation [481]. Therefore, downregulating these inhibitory proteins by miR96/183 
and miR155 overexpression in T cells may have some hidden benefits. However, further 
validation at protein level using western blotting and specific targeting by luciferase assay are 
required to confirm direct targeting of the above-mentioned genes by miR96/183 and miR155.  
Overexpression of miR155 resulted in reduced IL-6R expression at mRNA level highlighting 
potential usage of miR155 in combating life threating cytokine storm [482]. Anti-IL-6R 
antibodies such as tocilizumab has been used to reverse life-threatening CRS in patients with 
viral infection or cancer patients treated with CAR T cells [483, 484]. Therefore, fine tuning 
IL-6R by miR155 overexpression could be a good approach to minimise such effect in 
immunotherapeutic approaches including CAR T cell therapy and viral infections [485]. 
The miRNA target gene sets that are associated with a common cellular function (e.g. T cell 
activation, metabolism or suppression).  The effect of miRNA on individual gene expression 
may be subtle, but the combinatorial effects on the expression patterns of multiple genes 
involved in a common pathway may be profound. In this regard so called "off-target effects" 
may be useful for gene therapy applications. While the scope of the study was to assess miRNA 
overexpression and its effect on PRKAR1A expression, the expression of some other genes 
such as suppressive genes TET2, FOXO3 and PTPN2 were also found to be downregulated 
[477]. It is difficult to answer how miRNAs are modulating their expression which could be 
due to a direct effect (can easily be assessed as demonstrated in this thesis for PRKAR1A) or 
could be an indirect effect which could be an outcome of a shared modulatory pathway affected 
by miRNA overexpression. Global gene expression analysis following miRNA overexpression 
would give some idea on potential multiple targets and any off-target effects compared to 
control cells with normal miRNA expression. 
6.6 Non-viral SB approach to express miRNAs and HER2 CAR in primary T cells 
The immunosuppressive solid tumour microenvironment is the major barrier to CAR T cell 
therapy. Overcoming such immunosuppression may involve systemic administration of 
antibodies against immune checkpoints to improve the outcome of the therapy [486]. For 
example, John et al. reported increased PD1 expression on antigen stimulated HER2 CAR T 
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cells was associated with significant reduction in their activation and proliferation, which was 
reversed when anti-PD1 antibody was used in combination with the HER2 CAR T cells [487]. 
Similar combinatorial therapy with A2A receptor antagonist have also shown to enhance anti-
tumour efficacy of HER2 CAR T cells [488]. However, an alternative approach explored here 
is genetic modifications to improve the cell intrinsic response of CAR T cells within the TME. 
We modified the sleeping beauty vector (pSBtet-GP) to incorporate HER2 CAR downstream 
of constitutive-RPBSA promoter and GOI (e.g. miRNAs) downstream of inducible-TCE 
promoter [381]. This modified vector can be used for inducible expression of genes (e.g. 
survival genes) in combination with a CAR. Additionally, this vector can be utilised for the 
expression of death switch to promptly ablate CAR T cells following the onset of cytokine 
release syndrome. While the SB transposon system has been established as a viable non-viral 
approach to effectively mediate gene transfer in primary human T cells, efficient transfection 
of primary human T cells is difficult to achieve without extensive in vitro expansion using 
artificial antigen presenting cells, or primary feeder cells [489, 490]. Previous studies have 
employed artificial APCs to activate and successfully expand antigen specific cytotoxic T 
lymphocytes which could be utilised in future to expand the transfected cells in this study [491-
495]. 
6.7 Lentiviral vector mediated overexpression of non-coding and coding genes 
in primary T cells 
CAR T cell therapy requires the efficient transduction of primary human T cells. In Chapter 
5, we utilised a lentiviral system to characterize the functional impact of miR96/183 or miR155 
overexpression in primary T cells expressing a HER2 CAR. Although lentiviral vectors have 
been used to successfully transduce multiple cell types, there are limited number of studies 
reporting multiple transgene expression from a single lentiviral vector. Additionally, co-
expression of a non-coding (miRNA) and two coding genes (HER2 CAR and GFP) from a 
single LV used in this study has not been reported before. Here, we designed and compared 
different promoter system to co-express three transgenes (miRNA, GFP and HER2 CAR) to 
avoid the need of additional plasmid that may affect the transduction efficiency [496]. Using 
lentiviral vector (pCCL-Sin) with promoters and GOIs cloned in the same order as the tet-on 
system showed lower inducibility of miRNAs in our study. However, replacing miRNA with 
protein coding GOI (such as Mcl1 and cFLIP) in the same cassette in another study by our 
laboratory (unpublished data), showed enhanced expression in the presence of doxycycline 
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suggesting its implication in expressing protein coding genes. As doxycycline has been shown 
to adversely affect the cell morphology and growth rate, further improvement of the tet-on 
system is desirable to avoid cellular side effects [497]. 
This study also describes a new method to co-express miRNAs, HER2 CAR and GFP utilizing 
constitutive promoters either single constitutive promoter (EF1 or hPGK) or dual constitutive 
promoters (hPGK and RPBSA or hPGK and RPBSA) in a lentiviral vector. Here, both hPGK 
and EF1 promoter (single promoter system) failed to induce miR96/183 expression cloned 
immediately downstream (hPGK-miRNA-HER2 CAR-P2A-GFP) and distal (EF1-GFP-P2A-
HER2 CAR-miRNA) to the promoter, respectively. By contrast, HER2 CAR cloned upstream 
and downstream of miRNA in EF1 and hPGK system respectively showed enhanced and 
comparable expression irrespective of the type of the promoter used. The exact reason for poor 
miR96/183 expression remains elusive, but it appears to be associated with miR96/183 
sequence, since miR155 was consistently overexpressed by both promoter systems. 
Additionally, GFP placed at the distal end of the hPGK promoter resulted in very low 
expression (for both miRNAs) which is in line with our previous finding which compared four 
different promoters (hPGK, RPBSA, EF1 and CMV) and showed hPGK being consistently 
weak promoter to drive longer and shorter transcripts in HEK293T and primary T cells [401]. 
Similar observations have been made by other studies that have compared different constitutive 
promoters showing hPGK as the weaker and EF1 as the stronger promoter [402, 498]. In 
contrast, we achieved approximately 5-10-fold higher expression of miR155 with hPGK 
promoter, as compared to the EF1 promoter. 
To co-express miRNA and GFP-HER2 CAR from separate promoters in a LV vector, we 
further explored the dual promoter system consisting of either hPGK with RPBSA or hPGK 
with EF1. The dual promoter system consisting of miRNA downstream of the hPGK promoter 
and GFP-HER2 CAR downstream of the RPBSA promoter resulted in comparable expression 
of GFP and HER2 CAR with the other promoter system where RPBSA was replaced by the 
EF1 promoter. However, expression of miR96/183 but not miR155 remained low throughout 
which could not be explained. Of note, the dual promoter system led to enhanced miR155 
expression, as compared to the one promoter system.  However, the dual promoter system with 
two promoters; hPGK driving miRNA and EF1 driving GFP and HER2 CAR, placed in 
opposite direction (bi-directional system) enhanced the expression of both miR96 and miR183. 
Although, the expression of GFP-HER2 CAR was similar, miR155 expression was slightly 
reduced in the bi-directional system compared to the uni-directional dual promoter system 
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(hPGK-RPBSA). The bi-directional system with promoters placed in opposite direction could 
exclude the chances of mutual interference between the two adjacent transcriptional units 
which may otherwise lead to overlapping of the downstream gene sequence as they share the 
same polyadenylation signal at 3' LTR [499]. The dual lentiviral system with EF1 and hPGK 
or CMV and EF1 placed in the same direction have previously been used to efficiently express 
two transgenes in LV system [499, 500]. This setting could also be explored in future to express 
miRNA, GFP and HER2 CAR and, compared with the hPGK-EF1 bi-directional system 
designed in this study. The assessment of the co-expression of all three transgenes (miRNA, 
HER2 CAR and GFP) performed in this study by flow cytometry could also be compared at 
the mRNA level to understand the expression pattern of GFP and HER2 CAR together with 
miRNAs. Since all the experiments were carried out in HEK293T cells, these constructs could 
also be explored in other cell types as the promoter activity greatly varies depending upon 
specific cell type [402]. Consistent to the one promoter system, miR155 expression was highly 
upregulated compared to miR96/183 in all dual promoter lentiviral systems used in this study, 
which could again be sequence dependent and requires further investigation to enhance 
miR96/183 expression. 
6.8 Comparing cytokine production, CD69 expression and cytotoxicity of T cells 
transduced by HER2 CAR±miRNA 
In this study, HER2 specific CAR T cells (HER2 CAR±miRNA) were strongly activated when 
stimulated with HER2-expressing MCF-7 cells, as assessed by cytokine production (IL-2 and 
IFN-γ) and CD69 expression. Additionally, T cells expressing HER2 specific CAR±miRNA 
exhibited strong killing of HER2 expressing MCF-7 cells in vitro. However, the effect of 
miRNA overexpression could not be assessed because of the similar response shown by all 
constructs (HER2 CAR±miRNA). This could have been due to robust CAR expression on T 
cells resulting strong CAR signaling and killing of almost all HER2 expressing MCF-7 cells. 
While the killing of HER2 overexpressing MCF-7 by untransduced T cells was increased 
following longer incubation (48 hours vs 24 hours), it might suggest some non-specific effects 
which might be due to anti-CD3/CD28 activation done before the transduction and IL-2 
supplementation until the cytotoxicity experiments were performed, or residual LAK or NK 
cell activity in the CAR T cell preparations. The killing was similar between all HER2 CAR ± 
miRNA although there was a small change in the proportions of activated T cells however this 
could also be of less significance if the killing was achieved by small number of activated T 
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cells. In future, functional assays such as cytokine release and killing could be performed 
following incubation of HER2 expressing MCF-7 cells and T cells expressing HER2 
CAR±miRNA for shorter durations to minimize overactivation of T cells and probe the role of 
miRNA overexpression. Additionally, different target: effector ratios used in this study (1:2 for 
ELISA and 1:10 for cytotoxicity) could be further optimised by reducing target or effector cell 
number to finetune T cell activation via HER2 CAR. Alternatively, the stronger EF1 promoter 
driving the HER2 CAR transgene could be replaced by a weaker promoter such as hPGK or 
RPBSA which may reduce CAR expression and minimise activation of HER2-CAR T cells. 
Adenosine and prostaglandin are major inhibitors of T cell function present in the TME at 
varying concentrations [501, 502]. Several studies have demonstrated the inhibitory effect of 
these immunosuppressive molecules in CAR T cell function [362]. However, the in vitro 
cytotoxicity of HER2-CAR T cells was not altered with the addition of increasing 
concentrations of adenosine or prostaglandin in this study, suggesting either the need of further 
optimisation of the concentrations, or further investigation to understand the effect of adenosine 
and prostaglandin in cytokine producing ability of HER2 CAR±miRNA expressing T cells by 
ELISA or flow cytometry.  
6.9 Comparing phenotypic markers in T cells transduced by HER2 CAR±miRNA 
The phenotype of adoptively transferred T cells has been shown to be critical predictive 
indicator of the success of a CAR T cell therapy [503]. We observed an elevated CD4:CD8 
ratio in all transduced anti-CD3/CD28 activated T cells, which could be due to an enhanced 
proliferative capacity of CD4+ CAR T cells in the IL-2 supplemented media during the in vitro 
expansion phase (as determined at 10 days). However, we also observed significantly higher 
CD4:CD8 ratio following both miR96/183-HER2 CAR and miR155-HER2 CAR transduction 
compared to HER2 CAR only transduction which suggested more proliferative capacity of 
CD4+ T cells following miRNA transduction. The ratio of CD4 and CD8 was not assessed at 
day 0 (before experiment), and thus a longitudinal effect of microRNA overexpression could 
not be performed which would be worth considering for future experiments. Although, 
cytotoxic CD8+ T cells have been considered as the primary population of interest for CAR T 
cell therapy given their rapid TEM-like function (cytotoxic potential), studies have also 
highlighted the importance of CD4+ T cells with their IL-2 and IFN-γ secretion potential 
(leading to TCM-like skewing) in efficient tumour eradication and memory CD8+ T cell 
formation [504-506]. Since CD8+ T cells were fewer than CD4+ T cells following culture in 
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this study, the specific effect of miRNA overexpression on CD8+ T cells could have been 
masked by more numerous CD4+ T cells because the assay used was focused on overall 
cytokine (IL-2 and IFN-γ) production in the supernatant by ELISA. Therefore, flow cytometric 
assessment of cytokines on CD8+ and CD4+ is advised to get a population specific response. 
Furthermore, cytokine assessment by ELISA and cytotoxicity assay using luciferase assay can 
also be performed with isolated CD8+ or CD4+ to specifically assess effect of miRNA 
overexpression on either cell population. 
In addition to the tumour killing by conventional T cell based CAR T cell therapy, newer 
approach using regulatory T cells (CAR Tregs) has proven to be successful to supress unwanted 
stimulation of conventional T cells or other immune cells to combat graft versus host disease, 
allograft rejection and autoimmunity [507].  Stimulation in vivo via CD28 domain was reported 
to maintain the suppressive function of these CAR Tregs [508]. Therefore, we assessed bulk T 
cells or CD4/CD8 populations for the expression of CD25 and CD127, which are the subunits 
of IL-2R and IL-7R respectively and are often used together as surrogate markers for Tregs 
[509]. While both HER2 and HER2-miR155 constructs resulted in high CD25 and low CD127 
expression (a characteristic of Treg cells) as compared to empty vector transduced T cells, this 
was only significant for miR155-HER2 CAR transduced T cells (CD3+ CD4+ and CD8+) [510]. 
This finding is in line with the previous study suggesting the role of miR155 in promoting 
JAK/STAT signaling by SOCS1 downregulation and generating Tregs [511, 512]. However, 
these findings do not conclude that the populations observed in this study were Tregs and 
therefore additional Treg markers such as CTLA4, HLA-DR and transcriptional factors such 
as FoxP3, BLIMP-1, EOMES should be used to fully characterise and confirm the populations 
to be Tregs. Furthermore, HER2 CAR±miRNA transduction significantly increased 
CD25+CD127+ expression, which is also a characteristics of effector T cells, therefore future 
investigation simultaneously looking at memory markers in cells expressing CD25/CD127 
could be performed to characterise these population to fully understand the phenotypic effect 
of miRNA overexpression on HER2 CAR T cells [513-515]. Additionally, the tendency of 
CD25 upregulation and CD127 downregulation on T cells following activation makes the 
detection of Tregs in vitro by these two markers dubious. Interestingly, expression of certain 
cytokine receptors such as CD25 (IL-2R) can be increased on the surface in the presence of its 
cognate ligand (IL-2) which results in enhanced proliferation [516]. Consistently, Hoffman JM 
et al reported increased number of immunosuppressive CD4-CD8- and CD4+ Treg CAR T cells 
when IL-2 was used for culturing CAR T cells, as compared to IL-7/IL-15 as stimulant [517]. 
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Furthermore, IL-2 can negatively regulate IL-7 receptor alpha chain (CD127) on activated T 
cells [518]. If the cells transfected with different constructs were producing different amounts 
of IL-2, although not assessed for this experiment, there could still be slight possibility of 
differential modulation of CD25 and CD127 expression on these cells. Therefore, the 
assessment of Tregs with CD25 and CD127 expression pattern, which is more relevant in ex 
vivo settings, become more difficult in these in vitro experimental set up. Additionally, IL-7 
and IL-15 could also be used to replace IL-2 for T cell culture in future during the expansion 
of HER2 CAR T cells to reduce the unwanted effect of IL-2 and compare/confirm the 
expression pattern of CD25 and CD127 in T cells following HER2±miRNA expression. 
Adoptive transfer of T cells in an effector phenotype has been shown to result in poor survival 
of transferred T cells [394]. Similarly, CAR T cell product containing central memory cells has 
demonstrated better expansion and persistence in vivo [519]. Therefore, we performed the 
phenotypic analysis of expanded CAR T cells in this study at day 21. Majority of the T cells 
transduced with empty vector and HER2 CAR±miRNA were naïve-like cells expressing 
CD45RA and CD27. Moreover, most CD8+ cells were CD45RA+ as compared to CD4+ cells. 
It has been shown that when CAR T cells are infused in cancer patients, already differentiated 
T cells mediate lysis of malignant cells after which naïve or TCM T cells differentiate into 
effector T cells to mediate subsequent lysis [520]. Thus, the high proportion of naïve T cells 
observed in this study may be advantageous for CAR T cell protocols.  
All transduced T cells showed an increase in TEMRA-like cells when dissected using CD45RA 
and CD27 following HER2 CAR±miRNA overexpression. Additionally, expression of CD57 
which separates cells into highly proliferative (CD57-) and terminally differentiated cells 
(CD57+) [23, 521] was lower in both CD4+ and CD8+ T cells following miR96/183-HER2 
CAR transduction. This suggests a role for miR96/183 in enhancing the proliferation of HER2 
CAR T cells. Higher CD57 expression in HER2 CAR±miR155 transduced T cells also suggests 
the expansion of terminally differentiated cells, in contrast to a study reporting enhanced T cell 
function and accumulation of TEM-like cells following overexpression of miR155 [230]. 
While the expression of other memory markers (CD45RO, CCR7 and CXCR3), and stem-cell 
like markers (CD45RA, CCR7, CD127, CD62L, CD27, and CD28) were comparable in HER2 
CAR±miRNA transduced T cells, the expression of CD95 was downregulated on T cells 
following HER2 CAR-miR96/183 transduction. Although distinct T cell phenotype and 
memory population separation was achieved, no clear separation of distinct populations 
expressing CD57, CD95 and CXCR3 were observed. Therefore, we were unable to compare 
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the frequency of cells expressing these proteins and as an alternative we assessed the MFI 
which gives the average expression of the protein on the cell and detects small changes in 
expression. The limitation of assessing expression of these proteins on total transduced T cells 
or individual CD4 and CD8 subsets is the potential masking of miRNA effect in the 
heterogenous population of naïve and memory populations. Predefining the populations into 
naïve, TCM, TEM and TEMRA allowed the observation of CD95 enhancement due to HER2 
CAR±miR155 was specific to naïve T cells. The differential expression of CD57 on HER2 
CAR±miR155 transduced T cells and miR96/183-HER2 CAR transduced T cells was also 
observed in the memory subsets except for the TCM population. These in vitro findings are 
less informative, however, in vivo study may reflect a different outcome and give a clear picture 
following phenotypic characterization of adoptively transferred HER2-CAR±miRNA T cells 
[19, 522, 523]. Furthermore, the populations expressing the proteins studied here could be more 
distinct with further optimizations which was not possible due to COVID-19 pandemic 
mediated lockdown and restrictions. 
6.10 Impacts due to COVID19 or other uncontrollable factors.  
I consider myself fortunate to complete this PhD project despite many obstacles. Most of the 
work involved in this PhD project were relatively new to the lab such as chimeric receptor 
designing and assays to assess signal transduction, miRNA mediated knockdown of target 
genes and assays to validate it, primary human T cell culture and lentivirus mediated gene 
delivery and panel design as well as optimization for multicolour flow cytometry to assess the 
effect of miRNA overexpression in primary human T cells. Nevertheless, we were able to 
optimise the techniques and assays to run efficiently in our experimental setup. The training 
for lentivirus handling and ethical approval for mice work as well as initial training on mice 
handling were few uncontrollable factors which caused some delay in initiating the work with 
primary human cells and animal work respectively. The major hurdle was the COVID-19 
pandemic that started at the end of 2019. As a response to this pandemic the whole nation was 
moved alert level 3 and to alert level 4 in a span of 48 hours which lasted for more than 3 
months in total. Unfortunately, the labs were completely shut down under level 4 lockdown 
and only semi-functional at level 3 restrictions with limited access to students and staffs. While 
the lentiviral transduction of primary T cells was fully optimised and tested with limited sample 
size, in vivo studies with NSG mice could not be performed further and the mice which were 
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supposed to be used for the study were culled. Hence, I had to wrap up my thesis with the 
results from the in vitro experiments with primary human cells.  
The overexpression of miRNAs and expression level of PRKAR1A upon overexpression of 
miRNA in primary T cells could not be assessed due to time limitation as the percent 
transduction of T cells with miRNA±HER2 CAR was about 50-60% which required sorting of 
cells through flow cytometer and extensive culture of the sorted cells to get healthy cells. The 
effect of miRNA overexpression on PRKAR1A expression on primary cells should be assessed 
both at mRNA and protein level. More pronounced effect at protein level over mRNA level 
would indicate an off-target effect although the study with HEK cells in this study suggested 
comparable effect on both PRKAR1A mRNA and protein following miRNA overexpression. 
However, high-throughput study such as global gene expression could be helpful to identify 
possible targets and possible explanation for any possible off target effect. 
The expression of HER2 on MCF-7 is consistent with the work of Siddiqa et al demonstrating 
that individual sublines possess a plasticity of HER2 and other receptor expression [386]. 
MCF-7 cells used in this study was confirmed to express HER2 as measured by flow cytometry. 
The MCF7 cells used in this thesis were certified by short tandem repeat (STR) genotyping by 
CellBank Australia in January 2013 to be 100% MCF7 at 14/14 loci and therefore the 
possibility of contamination with HER2 expressing cells is less likely. However, future 
experiments could benefit from the use of another HER2 positive cell line, SKBR3, which 
could not be tested for HER2 CAR functionality due to time limitation. Although technically 
demanding experiments in primary T cells such as activation assays, cytokine response and 
cytotoxicity and, flow cytometry, was done successfully, due to lockdown the experiments had 
to be done at the same time without the time to go back and analyse the data and change the 
experimental plan. In vivo studies to study the effect of miRNA±HER2 CAR in tumour 
regression could not be studied as the tumour bearing mice had to be abandon due to the 
lockdown period. However, I have tried my best to justify the objective with in vitro results 
and sufficient discussion. 
6.11 Thesis conclusions and future perspectives  
This thesis focused on the intrinsic modulation of T cells, including CAR T cells, with a view 
to enhance their activation in the solid tumour microenvironment. Since immunotherapy for 
solid tumours is subjected to inhibition by immunosuppressive molecules such as low pH, 
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adenosine, prostaglandin in the tumour microenvironment [306, 524], we designed a novel 
approach to explore such immunosuppressive molecules by designing a chimeric chemokine 
receptor wherein extracellular and transmembrane region of tumour metabolite sensing 
receptors was fused to intracellular region of CXCR3. Based on the rapid calcium flux and 
ERK phosphorylation in response to CXCL11 and efficient migration of CXCR3 expressing 
cells in response to CXCL11, we demonstrated the ease of probing signal transduction via 
CXCR3 based chimeric receptors. The chimeric receptors: A1-CXCR3, A2A-CXCR3 and T8-
C3, designed in this study have laid a foundation which could benefit future studies involving 
chimeric receptor designing.  
Expression of inhibitory molecule, PRKAR1A was downregulated at both transcript and 
protein level by miR96/183 or miR155 overexpression and we further demonstrated specific 
regulation by targeting PRKAR1A 3' UTR by both miRNAs (miR96/183 and miR155). This 
study validates PRKAR1A as a direct target for miR96/183 and miR155 for the first time and 
provides an efficient approach of PRKAR1A downregulation to understand the underlying 
regulation of T cell effector functions. Besides PRKAR1A, overexpression of both miRNAs 
downregulated other T cell inhibitory targets such as PTPN2, FOXO3 and TET2 at transcript 
level which highlights additional advantages of overexpressing miR96/183 and miR155 in 
CAR T cell to overcome multiple inhibitory targets. Furthermore, the use of single miRNA 
targeting multiple genes as demonstrated in this thesis provides an advantage in therapeutic 
approaches which are constrained with limited size of the cargo. 
The combinational approaches for CAR T cell therapy have been used to express CAR in 
conjugation with other molecules such as checkpoint blocker to enhance the efficacy of the 
therapy. In this study, we explored the tetracycline inducible sleeping beauty system to co-
express multiple gene of interest while maintaining the inducibility and background expression 
to the level of original pSBtet-GP plasmid which can have great implication in the field of CAR 
T cell therapy. As opposed to lentiviral vectors, sleeping beauty plasmid which is a non-viral 
transposon mediated gene transfer system has become increasingly popular in therapeutic 
approaches and has demonstrated promising results clinically [314]. Lentiviral vectors with 
inducible and constitutive promoters (single promoter and dual promoter) were also designed 
and the expression of miRNA (either miR96/183 or miR155) and GFP-HER2 CAR was 
compared. Although only the bi-directional LV system enhanced the expression of miR96 and 
miR183 compared to other systems, both inducible and constitutive system demonstrated 
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enhanced expression of a coding gene (Mcl1) suggesting the applicability of the system for the 
co-expression of multiple protein-coding genes. However, the effect of miRNA overexpression 
in HER2 CAR expressing primary T cells could not be determined due to the already optimal 
activation of all transduced T cells following HER2 recognition. This might reflect the potency 
of CD28 and CD3ζ signaling masking subtle miRNA effects in these types of assays. 
Nevertheless, some phenotypic discrepancy could be seen among the HER2 CAR±miRNA 
constructs. It would be interesting to see if such phenotypic differences persist in vivo. Future 
work can be performed in immunodeficient NOD scid gamma (NSG) mice by adoptive transfer 
of HER2 CAR±miRNA transduced T cells following establishment of breast cancer cell line 
(subcutaneously injected with HER2+ MCF-7) to compare the efficacy of HER2 CAR±miRNA 
in eliminating the tumour. Phenotypic studies can also be performed on tumour infiltrating 
lymphocytes (TILs). 
In recent years, CAR T cell therapy has emerged as a potent treatment to benefit patients with 
blood cancer. The impressive outcome of CAR T cell therapies used to treat haematological 
cancers has attracted many researchers to extensively explore this approach in solid tumours. 
However, there are still many challenges associated with CAR T cell therapy such as CAR 
related toxicities (e.g. CRS), low patient response or tumour recurrence following adoptive 
transfer of CAR T cells. Insights provided in this thesis could help in designing strategies to 
counter some of the challenges faced with effective tumour treatment using CAR T cell 
therapy. Moreover, this thesis also provides the evidence of efficient use of both non-viral 
(sleeping beauty plasmid) and viral vector to express multiple gene of interest (both coding and 
non-coding genes). These optimized vectors could be used in CAR T cell therapy to combine 
two different approaches with the aim of enhancing efficacy or to incorporate control 
mechanisms such as (suicide gene) to control CAR T cell activity. Overall, this thesis presents 
a prospect to various strategies in CAR T cell therapy which could also be adopted in other 
therapeutic approaches such as stem cell therapy and gene therapy where similar modulation 
of cells is required. 
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optimisation of tet‑on inducible 
systems for Sleeping Beauty‑based 
chimeric antigen receptor (cAR) 
applications
S. M. Ali Hosseini Rad1,2, Aarati Poudel1,2, Grace Min Yi Tan1,2 & Alexander D. McLellan1*
Regulated expression of genetic elements that either encode polypeptides or various types of 
functional RnA is a fundamental goal for gene therapy. inducible expression may be preferred over 
constitutive promoters to allow clinician‑based control of gene expression. existing tet‑on systems 
represent one of the tightest rheostats for control of gene expression in mammals. However, basal 
expression in absence of tetracycline compromises the widespread application of tet‑controlled 
systems in gene therapy. We demonstrate that the order of P2A-linked genes of interest was critical 
for maximal response and tightness of a chimeric antigen receptor (cAR)‑based construct. the 
introduction of G72V mutation in the activation region of the TetR component of the rtTA further 
improved the fold response. Although the G72V mutation resulted in a removal of a cryptic splice 
site within rtTA, additional removal of this splice site led to only a modest improvement in the fold-
response. Selective removal of key promoter elements (namely the BRE, TATA box, DPE and the four 
predicted Inr) confirmed the suitability of the minimal CMV promoter and its downstream sequences 
for supporting inducible expression. The results demonstrate marked improvement of the rtTA based 
tet‑on system in Sleeping Beauty for applications such as cAR t cell therapy.
Inducible-gene expression is one of the most sought-after elements of synthetic gene regulation systems. Engi-
neering mammalian cells to express proteins or RNA in an inducible fashion offers opportunities for the devel-
opment of safe cellular-based therapies to treat a wide spectrum of inborn and acquired diseases. Compared 
to prokaryote genetic systems, the development of tight, inducible gene expression in eukaryote cells has been 
 challenging1–3. Unlike prokaryotes, mammalian genetic control is not usually mediated by single or oligo-compo-
nent regulators, but rather by multiple transcription factors that bind to both promoters, as well as often distant 
enhancer regions located on different chromosomes. Moreover, both promoters and enhancers may be regulated 
by epigenetic control mechanisms, and the site of transgene insertion in the genome influences the response 
profile of  transgenes4. Tet-On systems utilise a mutant TetR component that binds to tetracycline response ele-
ments (TRE) in the presence of tetracycline, or its stable analogue  doxycycline5. To activate transcription, fusion 
of the herpes-simplex VP16 transcriptional activator to the C-terminus of the mutant TetR, recruits generalised 
transcription factors, as well as RNAP II to initiate gene transcription. Modified tetracycline-inducible systems 
represent the most widely used inducible system in eukaryotic systems, from yeast to human  cells5. The potential 
exists for drug inducible systems to be used in cell-based immunotherapy to control the expression of genes 
or other sequences of interest (GOI). Although  103 to  106-fold induction of gene expression with tetracycline-
based control systems has been reported, basal expression in the absence of inducer can result in undesirable 
GOI  expression5. In vivo use would be compromised by such leakiness, particularly if the GOI was involved in 
T cell survival, or resistance to apoptosis. Unfortunately, compared to Tet-Off systems, Tet-On systems are less 
sensitive to tetracycline and generally exhibit a higher level of basal expression in the absence of  induction6. On 
the other hand, Tet-Off systems are slow to respond to withdrawal of tetracycline and this may be compounded 
by sequestration of tetracycline in vivo, especially within  bones2,7.
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The Sleeping Beauty (SB) transposon system was developed from extinct Salmonid transposons awoken 
after 10 million years of inactivity through consensus-based correction of accumulated  mutations8. Compared 
to retroviral-based insertions into transcriptional units and their regulatory regions, SB vectors insert almost 
randomly into TA-sites throughout the genome. This property minimises deleterious integrations and helps 
maintain constitutive or inducible gene  expression9,10. SB-based vectors carry a GOI along with optional mark-
ers or selection elements flanked by inverted terminal repeats (ITRs)9–12. Although the transposase has been 
re-engineered to enhance  activity12,13, a lower-activity SB-transposase is preferred for human clinical trials to 
minimise the incidence of multiple genome integrations. Along with piggy bac transposase systems, SB trans-
posase systems have been used in CAR T cell therapy trials for B cell  malignancies14,15. To expand the utility of 
SB-based vectors to express a CAR together with additional GOI under drug-control, we revisited the SB-based 
Tet-On system, through: (1) alterations in the placement of genes within the P2A-linked CAR cassette, (2) the 
introduction of a G72V mutation in rtTA-M2 – previously only described for yeast Tet-On  control16 (3) the 
placement of rtTA under auto-regulatory control, (4) the removal of cryptic splicing sites, and (5) modifications 
of the proximal promoter. To test the induction of the Tet-On system, we expressed myeloid leukaemia cell dif-
ferentiation (Mcl-1) as a GOI involved in T cell survival and resistance to apoptosis.
Results
The rtTA location within a multi-gene cassette influences responsiveness of the Tet-On sys‑
tem. We reasoned that placing a codon-optimised rtTA-M2 gene proximal to the RPBSA promoter (pSBtet-1) 
should result in robust rtTA-M2 expression and therefore tight control of inducible gene expression (Fig. 1).
Surprisingly, this setting led to a decrease in both the fold-expression of luciferase and Mcl-1 mRNA 
(Fig. 2A,B). It has previously been reported that expression of rtTA-M2 by strong promoters compromises 
inducible  expression16,17. We therefore relocated the original rtTA-M2 sequence distal to the RPBSA and down-
stream from either one (pSBtet-2) or two (pSBtet-3) additional GOI. However, inducibility of the GOI was still 
poor (Figs. 1, 2C,D).
Introduction of a G72V mutation in rtTA-M2 enhances the tightness of the Tet-On sys‑
tem. Roney et al.16 reported that a GGG to GTG (G72V) missense mutation in rtTA mitigated basal gene 
expression in the absence of an inducer in S. cerevisiae clones. Because of the similarity of transcriptional 
machinery amongst eukaryote cells, we reasoned that this approach may give similar results in human cells. The 
G72V mutation was next introduced into pSBtet-2 and pSBtet-3 to create the pSBtet-4 and pSBtet-5 constructs 
(Fig. 1). The G72V mutation in rtTA-M2 decreased the background expression of TCE promoter in the absence 
of doxycycline at both the mRNA and protein level (P < 0.001, Fig. 3A,B). The G72V mutation also restored the 
maximal expression of pSBtet-2 and pSBtet-3 constructs following induction with doxycycline (Fig. 3C). As pre-
viously reported, G72V-rtTA-M2 appeared less sensitive to doxycycline compared to original rtTA-M2, though 
this was not statistically significant (Fig. 3C, P > 0.9)16. A similar pattern of results was obtained after two weeks 
passage of cells to ensure stable integration of the pSBtet-5 (Fig. 3D,E). Note, the GFP expression of the trans-
fected cell lines dropped from ~ 90 to ~ 70% after two weeks of culture, most likely due to a shift from transient 
gene expression to that from integrated cassettes.
Figure 1.  Schematic illustration of SB-based Tet-On systems used in this study. Constructs derived from 
original pSBtet-GP developed by Kowarz et al. TCE: tet-responsive promoter/ GOI: gene of interest (Mcl-1 
or firefly luciferase); PA: polyadenylation site; P2A: 2A self-cleaving; rtTA-M2: reverse tetracycline-controlled 
transactivator; RPBSA: constitutive promoter comprised of the Rpl13a core promoter and exon 1, plus 
additional exon and intron elements from Rpl41.
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Investigation of autoregulatory strategy with G72V variant. We next investigated possible 
improvements in inducibility of multiple GOIs using positive feedback control in an autoregulatory cassette. 
Autoregulation can improve tetracycline-regulation in a retroviral  vector18 and in a bi-directional19 or uni-direc-
tional lentiviral  vector7. The bi-directional approach appears tight in transient transfection, however, high back-
ground was detected when cells were stably  transduced19. Therefore, we utilised a uni-directional strategy with 
a P2A sequence in place of an Internal Ribosome Entry Site (IRES) sequence, to allow expression of GOI-P2A-
G72VrtTA under TCE promoter (pSBtet-6,Fig. 1). We speculated that the leaky expression of the TCE would 
still allow sufficient levels of G72V-rtTA inducer to respond to doxycycline stimulation. Although the positive 
feedback system resulted in tight expression at the protein level (Fig. 4A), as previously  reported7,18,19, the system 
was leaky at the mRNA level for Mcl-1 (Fig. 4B). Basal expression of luciferase in pSBtet-6 was lower than for 
pSBtet (P < 0.05) and showed a higher response upon induction (P < 0.05, Fig. 4C). Compared to the constitu-
tive expression of G72V-rtTA, the autoregulatory system showed greater sensitivity to doxycycline induction 
(P < 0.05; Fig. 4C), although the basal expression was higher (P = 0.0066).
Removing cryptic alternative splice sites within rtTA reduces the background expres‑
sion. Since the first description of the eukaryotic Tet-On inducible system, most optimisation studies have 
focused on rtTA mutations: for example, the removal of cryptic splice sites (flanking amino acids 8–144) in the 
TetR  sequence20,21. Using recently-developed  software22, we identified eight additional potential cryptic splice 
sites within the coding region of rtTA-M2 (Fig. 5A and Table S1). Because the G72V mutation resulted in the 
loss of a cryptic splice site at position 215 (Fig. 5A and Table S2, we determined if the success of the G72V muta-
tion was due to the removal of the potential cryptic splice site at 215. These cryptic splice sites are located in two 
regions of rtTA; one in a surface residue (215 nt and seven in the dimerisation domains (320 nt, 326 nt, 367 nt, 
392 nt, 408 nt, 456 nt and 541 nt; Fig. 5A, Figure S1). We therefore removed all eight cryptic splices sites by silent 
or conserved missense-mutations in the pSBtet construct (Table 1).
The removal of six cryptic splice sites modestly enhanced the tightness of Tet-On system 7.7–19.6 fold com-
pared with original rtTA (P < 0.001, Fig. 5B). The remaining two mutations at position 320 (~ twofold, P = 0.8) 
and 367 (~ fivefold, P = 0.08) did not significantly affect Tet-On performance. The mutation at position 320 
produced E106Q, while 367 (Q122) was a silent mutation (Table 1). It is possible these two splice sites are weak 
5′ acceptor splice sites which are only used if other competing splice sites are  removed23. Indeed, positions 
320 and 367 have low score and confidence which represent strength and the probable occurrence of a splice 
site, respectively (Table S1). Combining all mutations together, improved the leaky background of the Tet-On 
system ~ 40 fold compared to original rtTA (P < 0.0001, Fig. 5B). However, superior results were still seen with 
G72V mutation (Fig. 5C).
Surprisingly, combining the G72V mutation and removing all cryptic splice sites abolished responsiveness 
and inducibility of Tet-On system (Fig. 5C,D). There are four altered amino acid positions within rtTA-M2 that 
result in a reverse activator phenotype, as compared to the original TetR: E71K, D95N, L101S and  G102D2. In 
TetR, E71 is a surface residue amino acid, D95 connects the DNA reading head to the core domain, while L101 
and G102 are crucial for dimerisation and the tetracycline response,  respectively2. In TetR the E71 and G72 amino 
acids create the turn between α-helix-4 and 5 (Fig. 6). This region bridges the DNA binding domain to the tetra-
cycline binding domain and the combination of both the E71K and G72V mutations might destroy the structure 
of this critical turn, causing a loss of rtTA-M2 activity. This may also explain the drop in tetracycline-induction 
observed with the position 320 mutant (E107 to Q107, Fig. 5D), since this residue is close to a ’high sensitivity 
Figure 2.  Locating a commercially-codon optimised rtTA-M2 (cop-rtTA; pSBtet-1) proximal to RPBSA 
increases the leakiness of TCE promoter as measured by (A) luciferase fold induction and (B) qPCR for Mcl-1 
mRNA. Relocating the unmodified rtTA-M2 distal to the RPBSA in (pSBtet-2 &-3) did not improve the basal 
expression measured by (C) luciferase fold induction and (D) qPCR for Mcl-1 mRNA. Experiments were 
carried out 96 h post-transfection. Statistical analysis: (A, B) two-tailed t-test, (C, D) one-way ANOVA test with 
Bonferroni post-test correction (*P < 0.05, **P < 0.01, ***P < 0.001).
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region’ (Figure S2)21,24–26. It is possible that the G72V mutation affected the secondary structure of  rtTA16, rather 
than simply removing a cryptic splice site. It is interesting to note that further commercial algorithm-mediated 
codon optimisation of rt-TA-M2 attempted in pSBtet-1 (see Fig. 2) re-introduced 13 cryptic alternative splice 
sites with high score and confidence (Fig. 5A, Table S3) within the rtTA coding region. This may have contributed 
to the poor performance of the first pSBtet-1 construct analysed, since cryptic splice sites might be associated 
with poor performance of Tet-On  systems20,21 (Fig. 2A,B).
Dissection of the tce proximal promoter. Modification of the minimal CMV promoter can affect TCE 
promoter  performance27. Removing elements downstream of the TATA box can reduce the maximal expres-
sion, whereas deleting the upstream elements can decrease the  leakiness27. We therefore revisited the design of 
pTIGHT to ensure optimal performance in our setting. Core promoter elements were identified using the YAAP 
program (Fig. 7A). It is possible that the presence of alternative initiator element (Inr) might lead to a loss of 
control of the TCE-promoter. We therefore removed these elements in single or combinatorial mutation fashion 
from pSBtet and monitored the tightness and maximal expression of TCE promoter.
Removal of each, or all, downstream elements of the TATA box (Inr-1, -2, -3 and -4 sites, and the DPE ele-
ment) markedly decreased the tightness of the TCE promoter (Fig. 7B), and also reduced the maximal expression, 
as previously  reported27 (Fig. 7C). Specifically, removing Inr-3 increased the background expression remarkably 
Figure 3.  Introducing the G72V mutation into pSBtet-2 & -3 and generation of pSBtet-4 & -5. The efficacy of 
G72V-rtTA SB based Tet-On system was measured at 96 h by (A) luciferase fold induction and (B) qPCR for 
Mcl-1 mRNA. (C) The G72V mutation restores the inducibility of pSBtet-2 and pSBtet-3 upon doxycycline 
induction. (D, E) Confirmation of the improvement of SB-based Tet-On system after two weeks passaging, 
as quantified by luciferase fold induction and qPCR for Mcl-1 mRNA. Statistical analysis: (A–C) one-way 
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(P < 0.01). Inr-3 contains two CTF/NF1 binding sites that bind to DNA as  dimers28 (Fig. 7A). CTF/NF1 is an 
enhancer-blocker element which specifically blocks the interaction of other enhancers with the  promoter29. A 
general explanation would be that deletion of the CTF/NF1 binding site could increase the interaction of neigh-
bouring enhancers to the TCE promoter, resulting in high background.
The only core promoter element found upstream of the TATA box is B recognition element (BREu). As 
shown in Fig. 7D,E, removing BREu did not improve the tightness and the basal expression of the TCE promoter 
(P > 0.19) and optimal transcription through the TCE promoter was dependent on the TATA box. However, 
deleting the BREu site increased the response of the TCE promoter to doxycycline (Fig. 7E, P < 0.01).
Discussion
Several strategies have been proposed to reduce the leakiness and enhance the inducibility of Tet-On systems, 
with only some tested in human cells. Such approaches include: (1) increased expression of rtTA using a strong 
promoter and codon  optimisation21,30,31, (2) mutation of rtTA to increase binding to doxycycline or  DNA16,20,21,26, 
(3) autoregulatory  systems7,18,19,32, (4) removing a cryptic splice sites in the rtTA coding  region20, and (5) altera-
tion of the core promoter elements within the proximal region of the TCE promoter 27. We revisited these strate-
gies for use in the SB-based Tet-On system in a human cell line for future investigation in CAR T cell therapy.
The introduction of a single mutation G72V, gave the optimal induction results at both mRNA and protein 
level, as reported in S. cerevisiae16. Future studies may explore the use of a G72P instead of G72V in our system 
as a candidate amino acid at position G72, though G72P appeared to result in a small loss in sensitivity, as 
compared to  G72V16. It is interesting that independent efforts into the rtTA structure have resulted in distinct 
amino acid changes in different studies, but with similar outcomes. For example, mutations introduced into the 
rtTA-M2 gene used here are present in distinct positions, as compared to the original four mutations in  rtTA6,20. 
Moreover, introducing sensitivity enhancing (SE)  mutations24–26 (V9I, F67S, G72P, F86Y, and R171K) could 
further increase the sensitivity to doxycycline, without increasing the background, as demonstrated in  yeast16.
Autoregulatory systems have recently generated interest, with both the rtTA and GOI transcribed by a single 
TCE promoter, using either a bi-directional  promoter19 or an IRES  sequence7,18,32. However, our constitutive 
expression of G72V-rtTA gave tighter expression, but was less sensitive to doxycycline compared to the autoregu-
latory system. The autoregulatory system may be preferred for controllable expression of a toxic rtTA or toxic 
GOI in mammalian protein  production32–35.
Next, our analysis found evidence of cryptic splice sites within an rtTA, a sequence that was previously opti-
mised for mammalian expression by Urlinger et al.30 Removing these splice sites reduced the basal expression 
and further increased the maximal expression. Unfortunately, using the combination of the G72V mutation with 
all splice sites removed (using predominantly silent, but with two necessarily non-silent, mutations) created a 
non-responsive system. It appears likely that the combination of the E71Q and G72V mutations disrupted the 
turn between two critical α-helixes 4 and 5.
It is also noteworthy that different programs identified other possible splice sites that needed to be inves-
tigated (Table S4). At least three independent approaches for codon optimisation of rtTA have been reported 
to enhance Tet-On  function21,30,31. For example, Urlinger et al. modified the S. cerevisiae-developed rtTA-M2 
sequence to remove potential hairpin, splice, and endonuclease sites, as well as codon optimising the sequence 
for use within mammalian  systems21.
Figure 4.  pSBtet-6 autoregulatory system showed superior regulation to pSBtet with (A) luciferase fold 
induction, but (B) higher background expression at the mRNA level for Mcl-1. (C) Comparison of maximal 
expression of luciferase in pSBtet-6 versus constitutive expression of G72V (psBtet-5) after induction 
with doxycycline. pSBtet-6 showed higher sensitivity, but higher background expression in the absence of 
doxycycline compared to pSBtet-5. Experiments were carried out 96 h post-transfection. Statistical analysis: 
one-way ANOVA test with Bonferroni post-test correction (*P < 0.05, **P < 0.01, ***P < 0.001).
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Figure 5.  Investigation of potential cryptic splice sites within rtTA. (A) Predicted cryptic alternative splice sites within (top): original 
rtTA-M2, (middle): G72V-rtTA-M2 and (below): commercially codon optimised (cop)-rtTA-M2 using ASSP program. The default 
cut-off values of the ASSP program was used. The cut-off 2.2 for acceptor sites and 4.5 for donor sites have shown to correctly predict 
75 to 80% of cryptic splice sites (Wang M and et al. 2006). (B) Removing the eight potential cryptic splice sites alone, or combination 
of all eight, improved the tightness of Tet-On system. (C) Comparison of the fold induction of pSBtet-5 with removing all cryptic 
splice sites in pSBtet-5. Combining G72V mutation with the eight cryptic splice sites removed, resulted in a non-responsiveness 
Tet-On system (D) Induction of luciferase expression in mutated rtTA-M2 proteins upon doxycycline induction. The missense E107Q 
mutation at position 320 bp showed lower induction. Experiments were carried out 96 h post-transfection. Statistical analysis: one-way 
ANOVA test with Bonferroni post-test correction (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).
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In the proximal region of the TCE promoter, we confirmed that the TATA box was essential for the function 
of the TCE  promoter27. Removal of the BREu element increased maximal expression, but did not markedly 
affect the tightness of the TCE. The deletion of the BRE site might enhance the elongation and / or reduce the 
TFIIB-rtTA sequestration. BRE plays a role in the preinitiation complex (PIC), leading to the dissociation of 
TFIIB from the promoter which is necessary for RNA polymerase II to initiate the elongation  step36–38. Hence, 
interrupting the BRE-TFIIB interaction may enhance transcription via the enhancement of  elongation39. Alter-
natively, direct sequestration VP16 on TFIIB has been  reported40,41 that may act to reduce VP16-mediated 
transcriptional activation.
Collectively, our results demonstrate marked improvements to the rtTA-M2 based Tet-On system in a Sleep-
ing Beauty system through the yeast-optimised G72V mutation. The results especially highlight the necessity 
to investigate the placement of individual GOI and rtTA within an expression cassette. The use of the clinically 
relevant CAR cassette within this setting offer the possibility to enhance adoptive cell therapy though drug-
inducible expression of cell-survival and memory enhancing genes, or death switches to conditionally ablate 
CAR T cells following the onset of cytokine release syndrome.
Material and methods
plasmid construction and cloning. The Tet-On SB (pSBtet-GP) contains the tetracycline-inducible 
pTIGHT promoter upstream of two asymmetric SfiI sites for cloning genes of interest (GOI), with a down-
stream RPBSA promoter driving GFP-P2A-rtTA-P2A-puromycin. pSBtet-GP and the SB-transposase vector 
(pCMV(CAT)T7-SB100) were purchased from Addgene. The pTIGHT promoter is a derivative of (Ptet-14) 
with shorter spacer (16–17 bp)  sequences27 between the TRE and the minimal CMV promoter (see Fig. 7)9,27,42. 
To generate the modified SB plasmids, a multiple cloning site (MCS) with Bsu36I and BstBI sites was cloned into 
pSBtet to remove GFP-P2A-rtTA-P2A-puromycin to create pSBtet-MCS. The codon optimised rtTA-M2 gene 
and FRP5 scFv Her2-CAR 43 were synthesised as gene blocks (IDT Singapore) and cloned into pSBtet MCS to 
create pSBtet-1. Other plasmids were generated by splicing by overlap extension (SOE) PCR to fuse the original 
rtTA2S-M2 (rtTA)9,21, GFP and Her2CAR in different combinations as illustrated in Fig. 1. Mutations into rtTA 
was introduced using inverse or SOEing PCR. Codon optimised-mouse Mcl-1 (Cop-Mcl-1) was synthetised 
as a gene block (IDT) with SfiI overhangs to replace the Firefly luciferase gene in the pSB-tet constructs. Both 
the Mcl-1 and firefly luciferase genes were used as GOI in this study. To modify the core promoters elements 
(Fig. 5A), the proximal promoter of TCE was PCR amplified from pSBtet and then subcloned into a pUC19 vec-
tor (Addgene) using conventional restriction fragment ligation method with EcoRI and NcoI enzymes. Inverse 
PCR with primers carrying point mutations were used to change the core promoter elements. Finally, each of the 
modified fragments were PCR amplified from pUC19 and cloned back to pSBtet using PshAI and NcoI restric-
tion sites. To alter the cryptic splice sites within rtTA (Table 1), rtTA was sub-cloned into PUC19 and mutations 
introduced using inverse PCR.
Bioinformatics analysis. Analysis of the TCE proximal promoter for core promoter elements, including 
the initiation repeats (Inr1, 2, 3 and 4), TATA box, B recognition element (BRE) site and downstream pro-
moter element (DPE), was carried out using YAPP Eukaryotic Core promoter predictor. TF binding sites were 
predicted using AliBaba 2.144 and  PROMO45,46 programs. The transcriptional start site (TSS) was predicted as 
reported previously for the minimal CMV  promoter47. Screening of rtTA for cryptic splice sites was carried out 
using Alternative Splice Site Predictor (ASSP) software and Human Splicing Finder (HSF)22,48. The protein struc-
ture of TetR and the prediction of secondary structure were obtained from Protein Data Bank (PBD).
Table 1.  Putative cryptic acceptor and donor splice sites within rtTA. Dinucleotide splice sites (AG or GT) are 
highlighted in bold and mutated sequences are underlined.
Name Type Original sequence Mutated sequence Mutation type
215 Acceptor CCC CTG GAA GGC GAG TCA Pro Leu Glu Gly Glu Ser
CCC CTG GAT GGC GAG TCA 
Pro Leu Asp Gly Glu Ser
Missense
(conservative)
320 Acceptor CCA ACA GAG AAA CAG TAC Pro Thr Glu Lys Gln Tyr
CCA ACA CAA AAA CAG TAC 
Pro Thr Gln Lys Gln Tyr
Missense
(conservative)
326 Donor CCA ACA GAG AAA CAG TACPro Thr Glu Lys Gln Tyr
CCA ACA GAG AAA CAA TAC
Pro Thr Glu Lys Gln Tyr Silent
367 Acceptor TGT CAG CAA GGC TTC TCC Cys Gln Gln Gly Phe Ser
TGT CAA CAA GGC TTC TCC 
Cys Gln Gln Gly Phe Ser Silent
392 Donor AAC GCA CTG TAC GCT CTG Asn Ala Leu Tyr Ala Leu
AAC GCA TTA TAC GCT CTG 
Asn Ala Leu Tyr Ala Leu Silent
408 Donor TCC GCC GTG GGC CAC TTT Ser Ala Val Gly His Phe
TCC GCC ATC GGC CAC TTT 
Ser Ala Ile Gly His Phe
Missense
(conservative)
456 Donor GAG CAT CAA GTA GCA AAA Glu His Gln Val Ala Lys
GAG CAT CAA GTG GCA AAA 
Glu His Gln Val Ala Lys Silent
541 Acceptor GAC CGG CAG GGA GCC GAA Asp Arg Gln Gly Ala Glu
GAC CGG CAA GGA GCC GAA 
Asp Arg Gln Gly Ala Glu Silent
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cell culture and transfection. The human embryonic kidney 293 (HEK293; ATCC CRL-1573) cell line 
was cultured in high glucose Dulbecco’s Modified Essential medium (DMEM) supplemented with tetracycline-
free 10% foetal bovine serum (FBS; Pan Biotech), Pen-Strep (100 U/mL penicillin and 100 µg/mL streptomycin) 
(Gibco) at 37 °C with 5%  CO2. One day prior to transfection, HEK293 cells were cultured in a 24 well plate at 
2 × 105 cells/ mL. A ratio of 5:1 (transfer plasmid: transposase) was used to stably transfect HEK293 cell line 
using Lipofectamine 3,000 (Thermo Fisher) and the medium was replaced at 24 h post transfection. For induc-
tion of the TCE promoter, at 72 h post transfection, cells from each well were detached and divided into four 
wells in a 96-well plate. Two wells were cultured with DMEM containing 5 µg / mL of doxycycline (Sigma), 
while control wells were maintained with only DMEM, for additional 24 h. Doxycycline-induced and control 
values for each construct are derived from each independent transfection to eliminate the possibility of different 
Figure 6.  (A) Secondary structure of TetR obtained from protein data bank (PBD) with focus on the E71 and 
G72 (highlighted by red box) that form a turn between α-helix-4 and 5. Mutating both amino acids may cause a 
conformational change in rtTA. (B) Annotation of TetR protein sequence and position of the ten α-helices.
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transfection efficiencies between Dox + and Dox- wells. Then, cells were proceed either with qPCR or luciferase 
assays. For Fig. 3D,E cells were maintained for to two weeks to confirm the consistency of gene-regulation over 
longer time periods.
Figure 7.  Investigation of core promoter elements in the proximal region of TCE promoter. (A) Annotated 
TCE promoter sequence for core promoter elements and TF binding sites. (B, C) Deleting elements downstream 
of TATA box including Inr-1, -2, -3, -4 and DPE in single or combination form increases leaky expression of 
TCE as well as reduction in TCE promoter induction (D, E) The effect of removing TATA box and BREu on 
luciferase induction with or without induction by doxycycline. Removing BREu does not affect the tightness of 
TCE promoter, whereas TCE showed to be sensitive over loss of TATA box. Only removing BREu improved the 
inducibility of TCE promoter, without increasing the basal expression. Experiments were carried out 96 h post-
transfection. Statistical analysis: one-way ANOVA test with Bonferroni post-test correction (*P < 0.05, **P < 0.01, 
***P < 0.001, ****P < 0.0001). Inr: initiation repeats; BRE: B recognition element (BRE); DPE: downstream 
promoter element; TSS: transcriptional start site.
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RNA extraction, cDNA synthesis and quantitative PCR (qPCR). Total RNA was extracted using 
NucleoSpin RNA Plus kit (Macherey–Nagel, Germany) and cDNA prepared using PrimeScript RT Reagent Kit 
(Takara Bio, USA). QPCR was carried out using Luna Universal qPCR Master Mix (NEB) in a ViiA 6 Real-Time 
PCR (Applied Biosystems, Foster City, CA). The comparative CT  (2−ΔΔct) method was used to analyse the relative 
expression level of cop-Mcl1, by normalising to β-actin. Primers used for the qPCR reactions were: Mcl1-Fwd: 
GCA GAA TTG TGA CAC TGA TAA G, Mcl1-Rev: TTT TGT TCT AAC CAA TAC ATC G, β-actin-Fwd: CTT 
CCT TCC TGG GCA TG, β-actin-Rev: GTC TTT GCG GAT GTC CAC.
Reporter assay. Luciferase assays were carried out using Pierce Firefly Luc one-step glow assay kit (Ther-
moFisher #16197) with cells at  105 cells per 100 µL in a 96 well plate. Firefly Luc One-Step Glow assay working 
solution (100 µL) was added to each well. Cells were incubated at room temperature for one hour before reading 
with a Varioskan LUX multimode microplate reader (Thermo Fisher, USA). Luciferase data was presented either 
as relative luminescence units (RLU) or fold change. Fold change was calculated with the following formula:
Statistical analysis. All data are presented as mean ± standard deviation (SD) and pooled from three 
independent experiments. Statistical analysis was performed by two-tailed t-test or one-way ANOVA test with 
Bonferroni post-test correction in GraphPad prism (version 8). The P values of ≤ 0.05 were considered statisti-
cally significant (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001). (* P < 0.05, ** P < 0.01, *** P < 0.001, **** 
P < 0.0001).
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Abstract
Chimeric antigen receptor (CAR) T cell therapy is an effective treatment for B cell malignan-
cies, with emerging potential for the treatment of other hematologic cancers and solid
tumors. The strength of the promoter within the CAR cassette will alter CAR-polypeptide lev-
els on the cell surface of the T cell–impacting on the kinetics of activation, survival and mem-
ory cell formation in T cells. In addition to the CAR, promoters can be used to drive other
genes of interest to enhance CAR T cell function. Expressing multiple genes from a single
RNA transcript can be effectively achieved by linking the genes via a ribosomal skip site.
However, promoters may differ in their ability to transcribe longer RNAs, or could interfere
with lentiviral production, or transduction frequencies. In this study we compared the ability
of the strong well-characterized promoters CMV, EF-1, hPGK and RPBSA to drive func-
tional expression of a single RNA encoding three products: GFP, CAR, plus an additional
cell-survival gene, Mcl-1. Although the four promoters produced similarly high lentiviral
titres, EF-1 gave the best transduction efficacy of primary T cells. Major differences were
found in the ability of the promoters to drive expression of long RNA encoding GFP, CAR
and Mcl-1, highlighting promoter choice as an important consideration for gene therapy
applications requiring the expression of long and complex mRNA.
Introduction
Promoters are of critical importance for expressing optimal levels of the transgene in CAR T
cells for the production of functional proteins or non-coding RNA [1–5]. It is also clear that
high expression of the CAR can result in antigen-independent CAR signaling, resulting in T
cell exhaustion and sub-optimal anti-tumor responses, or lead to the inappropriate recognition
of tumor antigen on self-tissue [1, 2]. In addition, controlling CAR T cell signaling is critical
for proper memory cell formation [6]. Because surface expression of the CAR may be limited
by mRNA levels, the choice of promoter is critical [1, 2].
There have been limited studies that directly compare the efficiency of different promoters
for driving long mRNA comprising multiple genes within CAR T cells [1, 2, 7]. Recent studies
investigating promoter performance in mouse or human T cells were usually limited to either
the CAR, a single gene of interest alone, or single fluorescent reporter genes of limited size [1,
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2, 7–9]. For the generation of lentiviral particles for transduction, using multiple internal pro-
moters or internal ribosome entry sites (IRES) for multiple genes may interfere with transcrip-
tion or reverse transcription of viral genomic RNA (vgRNA), impacting upon lentiviral
particle titre, and/or on the efficiency of integration into the target cell [8, 10]. Therefore, strat-
egies that employ single promoters to drive multiple genes may be preferred for CAR T cell
engineering [9].
Although all current, clinically-approved second and third generation CAR T cells rely on
the expression of a single gene encoding a single polypeptide, it may be advantageous to
express longer RNA containing the CAR, together with one or more genes of interest. For
example, endogenous growth factors or membrane bound or secreted cytokines could improve
T cell expansion and survival [6, 11]. Alternatively, markers of transduction efficiency or death
switches could be incorporated into the CAR element [4, 12–14]. Promoter choice for such
applications is crucial to obtain optimised gene expression of multiple, linked genes.
Because requirements for driving short versus long RNA might be distinct in CAR T cell
genetic elements, we investigated the ability of several promoters to drive an extended down-
stream genetic sequence comprised of GFP, anti-Her2-CAR and an additional cell survival
gene Myeloid leukemia cell differentiation protein (Mcl-1), an anti-apoptotic Bcl2 family
member. Mcl-1 aids in T cell development, mitochondrial function and lifespan and appears
to a suitable candidate for enhancing CAR T cell performance [15, 16]. Mcl-1 inhibits the
action of pro-apoptotic BIM / BAK / BAX at the mitochondrial membrane and is expressed
throughout T cell differentiation and is essential for memory T cell formation [16–20].
The individual elements were tested at protein level and for functional activity. The results
demonstrated clear differences in the ability of these internal promoters to drive expression of
multiple CAR-cassette associated transgenes.
Material and methods
Plasmid construction
The third-generation lentiviral vector pCCLsin.cPPT.hPGK.GFP.WPRE (pCCLsin) and
VSV-G-based packaging plasmids were a kind gift from Prof. Dr. Naldini and have been
described elsewhere [21]. The anti-Her-2 CAR FRP5, anti-CD19 CAR FMC63 (with–EQKLI-
SEEDL–c-myc tag between scFv and CD8 hinge) and codon-optimized human Mcl-1 (cop-
Mcl-1) were synthesized as gene blocks (IDT Technologies). Both CAR constructs are second
generation CAR with CD28 costimulatory domains (Fig 1A). Sap I Type IIs restriction enzyme
cloning was utilized for scarless assembly of the eGFP-P2A-CAR-P2A-Mcl-1. This cassette was
then cloned into the BamHI and SalI sites of the pCCLsin (Fig 1A). Promoters were amplified
with 5’ EcoRV and 3’ BamHI sites from respective plasmids: CMV from pcDNA3.1(-), EF-1
from Sleeping Beauty (pSBbiRP) and RPBSA from Sleeping Beauty (pSBtet-GP) and ligated
upstream of the GFP-CAR-mcl1 cassette. Codon optimized Leucine Zipper CD95
(LZ-CD95L) gene was synthesized by IDT with EcoRI and BamHI sites and cloned into
pcDNA3.1(-) (Addgene #104349).
Cell culture
Cell lines were cultured in a humidified atmosphere at 37˚C, 5% CO2 (or with 8% CO2 for
LV-Max and Expi293F). Human embryonic kidney 293T (ATCC CRL-1573) and MCF-7
(ATCC HTB-22) cell lines were cultured in high glucose Dulbecco’s Modified Essential
medium (DMEM) supplemented with 10% fetal bovine serum (FBS; Pan-Biotech GmbH),
penicillin (100 U/mL) and streptomycin (100 μg/mL) (Gibco). MCF-7 and HEK293T cells
were transfected using Lipofectamine 3000 according to manufacturer’s protocol. Human
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peripheral blood mononuclear cells (PBMC) were isolated from healthy donors. The Univer-
sity of Otago Human Ethics Committee (Health; Ethics Approval# H18/089) approved this
study and written consent was obtained from blood donors. Frozen PBMCs were thawed and
then rested overnight in T cell expansion media (Thermofisher #A1048501) supplemented
with 50 U/mL of hIL-2 (Peprotech, #200–02), L-glutamine and 10 U/mL penicillin and strep-
tomycin (Gibco), prior to CD4 and CD8 T cells isolation using EasySep Human T cell isolation
kit (STEMCELL Technology, #17951). Isolated T cells were activated with Dynabeads Human
T-Activator CD3/CD28 (Thermo Fisher, #111.32D).
Lentiviral production, titration and T cell transduction
Lentiviral production and titration were carried out using LV-Max Viral production system
(ThermoFisher #A35684) according to manufacturer’s protocol. HEK293T cells were trans-
duced at MOI 2:1 with 8 μg/mL of polybrene (Sigma-Aldrich). One day before T cell transduc-
tion, plates were coated with 40 μg/mL retronectin (TAKARA, #T100A/B) overnight at 4˚C,
blocked with 2% FBS/PBS for 15 min, before adding LV at 40:1 MOI to the plate; followed by
centrifugation at 800 ×g for 2.5 h at room temperature. After 48 h of activation with a 1:1 ratio
of CD3/CD28 Dynabeads, T cells were added to virus-coated wells and spinoculation carried
out at 500 ×g for 5 min. The next day, T cells were debeaded and cultured in media plus 50 U/
mL of hIL-2. Media was changed with fresh medium supplemented with 50 U/mL hIL-2 every
three days.
RNA extraction, long cDNA synthesis and RT-PCR
Total cellular RNA (containing viral genomic RNA) was extracted 48 h after transfection using
NucleoSpin RNA Plus kit (Macherey-Nagel, Germany) according to the manufacturer’s proto-
col. Then RNA was reverse transcribed using PrimeScript™ RT Reagent Kit (Takara Bio, USA)
according to manufacturer’s protocol RT-PCR was performed using internal primers PPT-
Fwd: GGGTACAGTGCAGGGGAAAG and Woodchuck-Rev: AAGCAGCGTATCCACATAGCG for
comparison with β-actin Fwd: CTTCCTTCCTGGGCATG and β-actin-Rev: GTCTTTGCGGA
TGTCCAC.
Quantification of gDNA/ integrated viral DNA ratio
At 48 h post transduction, integrated lentiviral DNA was quantified by extracting genomic
DNA using Qiamp DNA Mini kit (Qiagen, Germany) and the ratio of viral genome: human
gDNA were estimated using qPCR via Luna Universal qPCR Master Mix (New England Bio-
labs) using designed primers Gag-Fwd: GGA GCT AGA ACG ATT CGC AGT TA, Gag-Rev:
Fig 1. The effect of internal promoters in producing functional lentiviral particles. (a) Schematic illustration of the pCCLsin backbone bearing four different internal
promoters (CMV, EF-1, hPGK and RPBSA) for driving a long RNA consist of GFP-P2A-Her2CAR-P2A-Mcl-1, (b) HEK293T cells were transfected with lentiviral
constructs containing different promoters along with packaging plasmids. At 24 h post transfection, total RNA was extracted and 1 μg of RNA was converted to cDNA.
PCR was carried out using specific primers binding to PPT and woodchuck region. Agarose gel electrophoresis displays the PCR product band of each construct. Lower
band displays the PCR product of β-actin serving as a loading control. The ratio between viral genomic RNA (vgRNA) to β-actin was quantified and presented in the bar
graph (right) using Image Studio Lite. There was no statistically significant difference between promoters (P>0.05). (c) Shows the ratio between integrated viral cassettes
to gDNA 48 h post-transduction. Genomic DNA was extracted from cell lysates and qPCR was performed using Gag for integrated lentivirus and β2 microglobulin and β-
actin as a housekeeping genes for host gDNA quantification. There was no statistically significant difference between promoters (P>0.05). (d) Comparison of the viral
particle titration of four different constructs through analysis of the percent GFP expression in HEK293T cells using flow cytometry. Bar graph values represent the titre
unit/mL (TU/mL) from three independent repeats. There was no statistically significant difference between promoters (P>0.05). (e) Transduction efficiency of primary T
cells for the four lentivectors. CD3 / CD28 stimulated human primary T cells were transduced at MOI 40 and cells were analyzed for GFP expression at 72 h post-
transduction by flow cytometry. A representative experiment, and all GFP MFI values relating to graph, are presented in Fig 3A. Dead cells were excluded with Zombie
NIR viability dye gating at analysis. Bar graph values represent the mean values ± SD from three independent repeats. scFv; single-chain variable fragment, VH; variable
heavy chain, VL; variable light chain, TM; transmembrane domain.
https://doi.org/10.1371/journal.pone.0232915.g001
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GGT TGT AGC TGT CCC AGT ATT TG TC, PBS-Fwd: TCT CGA CGC AGG ACT CG;
PBS-Rev: TAC TGA CGC TCT CGC ACC, and β-actin forward and reverse primers
described above. All reactions were run in triplicate and were presented as mean ± SD.
Western blot
Cell lysates were prepared using RIPA lysis buffer and blotting carried out using mouse mono-
clonal anti-EGFP antibody (Abcam, #ab184601), rabbit anti-human Mcl-1 (Abcam,
#ab28147), biotin anti-c-myc (Biolegend #908805). Mouse monoclonal β-actin primary anti-
body (Sigma-Aldrich #A2228) was used as loading control. goat anti-mouse IgG DyLight 680
(Thermo Fisher #A3274), goat anti-rabbit IgG 800, streptavidin-800 in 1:10000 dilution as sec-
ondary antibody (#A32730 and # A32735). The membrane was scanned using an Odyssey Fc
imaging system (Licor, Germany) and analyzed using Image Studio Lite software.
Mitochondrial membrane potential assay (TMRE)
Transduced T cells were incubated overnight with 1 μg/mL LZ-CD95L, then 4 μM TMRE
(Invitrogen) was added at 37˚C for 30 min. DAPI (50 ng /mL) was added immediately prior to
flow cytometric analysis and GFP positive cells electronically gated for quantification of
TMRE and DAPI signals using the YG586/16 and BV421 channels.
Cytotoxicity and cytokine release assay
Luciferase-based cytotoxicity assay was carried out for Her2 and CD19 CAR T cells as previ-
ously described [22] at a 10:1 ratio of effector to target cells of using Firefly Luc One-Step Glow
assay (Thermo Fisher #16197). For analysis of cytokine release, CAR T cells were added to tar-
get cells in a 2:1 ratio. IL-2 and IFN-γ concentration secreted in cell supernatant were mea-
sured using sandwich ELISA according to manufacturer’s protocol (BD Biosciences, USA).
Plates were read on a Varioskan Lux multimode microplate reader (Thermo Fisher, USA).
Flow cytometry
CAR T cells were stained with biotin anti-c-myc antibody (Biolegend #908805) detected with
Streptavidin-Brilliant Violet 421 (Biolegend #405225). Antigen stimulated CAR T cells were
stained for CD69 expression using APC-conjugated anti-human CD69 antibody (Biolegend
#310910). Flow cytometric data was acquired using a BD LSRFortessa with BD FACSDiva soft-
ware. Data was analysed with FlowJo v10.6.2 software. Cells were subject to FSc and SSc dou-
blet discrimination and dead cells were excluded from analysis using Zombie NIR viability dye
(Biolegend #423106).
Statistical analysis
All experiments were carried out at least three times, presented as mean ± standard deviation (SD)
and analyzed by one-way ANOVA test with Bonferroni post-test correction. The P values of� 0.05
were considered statistically significant. (� P<0.05, �� P<0.01, ��� P<0.001, ���� P<0.0001)
Results
Compatibility of the promoter systems with a third-generation lentiviral
system
The four promoters were chosen based on their widespread use in the literature and docu-
mented ability to drive high level expression of transgenes in either lentiviral vectors, or in
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Sleeping Beauty transposon vectors [1, 8, 9, 21, 23]. Each of the four promoters were cloned
upstream of the series of P2A-linked genes comprised of GFP, the FRP5 anti-Her2 CAR fol-
lowed by human Mcl-1 (Fig 1A), a Bcl2 family member–the latter gene as a strategy to protect
CAR T cells against activation-induced cell death (AICD). A first consideration for the choice
of internal promoter driving transgenes within lentiviral systems is the effect on viral titration
and transduction efficiency. Generally, there is a difference in the degree of transcriptional
interference between the internal promoters and the promoter driving expression of genomic
RNA, resulting in a lower number of full-length viral genomic RNAs (vgRNA) particularly
when the CMV or EF-1 promoter is being used [10, 24]. In order to test the promoter interfer-
ence, HEK293 cells were transfected with four constructs along with helper plasmids and the
levels of vgRNA for four promoters were measured (P>0.05, Fig 1B). Similar levels of full-
length transcripts were obtained using all constructs, as assessed by RT-PCR carried out with
primers binding to cPPT and woodchuck regions (Fig 1B). Next, the effect of internal pro-
moter interference with provirus production was estimated. QPCR was performed on gDNA
extracted from HEK293 cells transduced with all constructs. The ratio between integrated cas-
sette to gDNA did not show significant differences among constructs (P>0.05, Fig 1C), sug-
gesting that the selected promoters do not adversely affect reverse transcription or integration
steps.
Next, we determined if the choice of internal promoter affects titre and transduction of pri-
mary T cells. As shown in Fig 1D, constructs containing any of the four promoters were able
to produce similar viral titres, as determined by transduction of the GFP marker into
HEK293T cells. To determine if the sequences of internal promoters altered primary T cells
transduction, we transduced primary T cells obtained from different donors and analyzed for
GFP expression by flow cytometry three days later. EF-1 gave superior transduction efficacy
compared to the other three promoters (P� 0.0001, Fig 1E).
Promoter comparison for long and complex gene expression
To determine if the promoters differed in their ability to transcribe individual gene products
within a long gene, the expression of individual genes were assessed in HEK293T and primary
T cells. From the data obtained with HEK293T, CMV and EF-1 were superior to hPGK and
RPBSA in producing all three products (Fig 2). We next examined the strength of the four pro-
moters in primary T cells by analyzing GFP and CAR expression. Live primary T cells were
gated for GFP, for determining the intensity of CAR and GFP expression. As shown in Fig 3,
EF-1 gave stronger expression of GFP and Her2 CAR compared to the other promoters. CMV
was weaker in primary T cells, as compared to its activity in HEK293T cells. This could be due
to the differences in the transcriptome of both cell types and / or the different techniques that
have been used to measure the protein level.
Functional effect of CAR T cells in tumour and T cell engagement
We next examined the function of the CAR T cells transduced with each of the promoter con-
structs, measuring cytokine release (IL-2 and IFN-γ), cytotoxicity and activation following
incubation of CAR T cells with the Her2+ MCF-7 breast cancer cell line. Although the expres-
sion of CD69 as an activation marker was similarly expressed among the CAR T cells with dif-
ferent promoters (Fig 4A), EF-1 and CMV CAR T cells showed optimal cytokine release after
engaging MCF-7 cells (Fig 4B & 4C). CAR T cells transduced with hPGK were less active and
those with the RPBSA construct failed to release detectable IL-2 and IFN-γ. Cytotoxicity assay
with the four constructs showed similar results with strong killing with CAR T cells expressing
under the EF-1 promoter at 24 h time points (Fig 4D).
PLOS ONE Functional analysis of promoters in CAR T cells
PLOS ONE | https://doi.org/10.1371/journal.pone.0232915 July 24, 2020 6 / 18
To functionally test the relationship between the expression level of the most distal gene
Mcl-1, and resistance to AICD, CAR T cells carrying four different promoters were challenged
with 1 μg/mL LZ-CD95L and mitochondrial depolarisation monitored by TMRE staining and
flow cytometry. In the absence of CD95L-triggering, there was little difference in cell viability
or CAR T cell yields using the four different promoters (Fig 5A and data not shown). Again,
EF-1 provided the most potent protection against CD95L-induced cell death (Fig 5). Note, the
protection against AICD observed here could reflect a contribution of both Mcl-1, as well as
Fig 2. Protein expression from four different constitutive promoters driving long mRNA. Transfected HEK293T cells were
lysed with RIPA buffer and processed for immunoblotting using antibodies to detect (a) GFP (b) c-Myc tag for Her2 CAR and (c)
Mcl-1 expression with β-actin used as a loading control for the Western blots. All representative blots above are repeated three
times and quantified and presented in the bar graph (right) using Image Studio Lite. Bar graph values represent the mean
values ± SD from three independent repeats.
https://doi.org/10.1371/journal.pone.0232915.g002
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the pro-survival effect of the CD28 domain in the CAR. For example, CD28 has been shown to
enhance the T cell survival by upregulating Bcl2-xL [25]. However, in this setting (without
CAR triggering), the presence of the CD28 domain-CAR makes only a minor contribution to
the observed protection against CD95L-induced cell death, as compared to the major anti-apo-
ptotic action of Mcl-1 (manuscript in preparation).
Promoter comparison for driving short transcripts
We compared the ability of the four promoters in transcribing GFP linked to an FMC63 CD19
CAR, the most studied CAR construct and the first CAR T cell design approved by the FDA.
The FMC63 CAR transcript is 1.2 kb shorter than the GFP-Her2CAR-Mcl1. Viral titres and
transduction efficacies were similar among all promoters driving the shorter FMC63 CAR
mRNA (Fig 6A & 6B). Protein expression of the shorter GFP-CAR constructs was enhanced in
HEK293T transduced with EF-1 and CMV constructs (Fig 6C). In primary T cells, EF-1 gave
the highest expression for GFP and CD19 CAR, while CMV gave a more heterogenous expres-
sion, but this was not statistically significantly lower than EF-1 (Fig 6D & 6E).
Although CD69 expression on antigen stimulated CAR T cells was similar for all promoter
constructs (Fig 7A), EF-1 constructs drove higher levels of CAR triggering in terms of cytokine
release and cytotoxicity. RPBSA was more effective in driving short transcripts, as compared
to performance observed earlier for long and complex RNA (Fig 7B–7D), further emphasizing
that promoter activity is dependent on the nature of the downstream transcript.
Core promoter elements, CpG island and TF binding sites are varying
between promoters
Although all four selected promoters are assumed to be constitutive and active in most cell
types, bioinformatic analysis showed that the four promoters vary in terms of core promoter
Fig 3. GFP and Her2 CAR expression of the four constructs in primary human T cells. Flow cytometry carried out to measure the expression of (a) GFP and (b) Her2
CAR (c-myc tag). Dead cells were excluded by Zombie NIR viability dye at analysis. GFP positive cells were gated and MFI assessment of CAR and GFP is shown for
three individual donors are shown in graphs. (c) Live T cells positive for GFP (Y-axis) and / or Her2 CAR (anti-c-myc; X-axis).
https://doi.org/10.1371/journal.pone.0232915.g003
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elements and potential TF binding sites. While there is no universal core promoter elements
for RNA polymerase II, the TATA box, initiator (Inr) element, TFIIB recognition element
(BRE), downstream core promoter element (DPE) and motif ten element (MTE) are well-
established core promoter elements (Fig 8A). Overall, EF-1 had more core promoter elements,
such as GC box, DPE and MTE (Fig 8B, Table 1). Except for hPGK, all promoters contain a
TATA box.
Fig 4. Comparison of anti-tumor activity using different promoters in CAR T cells. (a) Flow cytometric analysis of Her2 CAR T cells 18 h after co-culture
with Her2+ / MCF-7 cells. Data shows the MFI of CD69 expression from three different donors. Bar graphs show the secretion of (b) IL-2 and (c) IFN-γ by
different CAR T cells measured by ELISA. CAR T cells were incubated with Her-2+ MCF-7 cell line for 24 h before supernatants were collected. Cytokines
were measured in ng/mL. (d) Luciferase based cytotoxicity assay assessed 24, 48 and after 72 h after incubation of CAR T cells with MCF-7 cells stably
expressing the firefly luciferase gene. The graph shows the percent of cell viability, calculated by dividing the luciferase of the sample well over the luciferase
reading of untreated MCF-7.
https://doi.org/10.1371/journal.pone.0232915.g004
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Another feature of eukaryotic promoters is the presence of CpG islands. CpG islands could
result in hypermethylation and gene silencing. However, promoters with CpG islands contain-
ing multiple Sp1 binding sites exhibit a hypomethylated state and are typically stronger pro-
moters [26]. We therefore searched for CpG islands within our promoters using two different
programs (Table 2). Except for CMV, all promoters were expected to have at least one CpG
island. When we searched the Sp1 binding sites within the CpG islands, EF-1 and hPGK
showed the highest number of Sp1 binding sites in their CpG islands (Table 3). EMBOSS
Cpgplot program predicted two CpG island for EF-1 with 37 Sp1 binding sites. Fig 8C repre-
sents the total number of TFBS within the four promoters. Of these identified TFBS, sixteen
TFs were selected based on their function and expression in T cells [27–29] and the relative
Fig 5. TMRE assay for monitoring mitochondrial membrane potential. (a) CAR T cells expressing Mcl-1 as an anti-apoptotic gene as the most distal gene in the
cassette were challenged with 1 μg/mL (top) or 0 μg/mL (below) LZ-CD95L to mimic AICD. TMRE+ events represent intact cells with healthy mitochondria, while
TMRE- are cells with depolarised mitochondria. pCCLsin (lentivector expressing only GFP) was used as control. Graphs represent the percent of (b) TMRE and c) DAPI
positive CAR T cells.
https://doi.org/10.1371/journal.pone.0232915.g005
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enrichment of their corresponding TFBS in each promoter plotted (Fig 8D) [27–29]. Fig 8D
highlights promoters that demonstrate a specific enrichment of binding sites for T cell-associ-
ated TF, relative to the other promoters. Essentially, the graph illustrates the number of TFBS
present in each promoter, expressed as percentage of those present in all promoters. EF-1 pos-
sessed binding sites for all these TFs (Fig 8D). CMV is the next promoter enriched for T cell-
specific TFs, excluding GATA3, LEF-1, STAT5 and IF-2 (Fig 8D). It should be noted that EF-1
is almost twice the length of other promoters (>600 bp), and this length allows a greater possi-
ble enrichment of TFBS and core promoter elements.
Who should drive the CAR?
In order to have a broader view in comparing the strength of each promoter, scores from 0–10
were assigned to all functional assays carried out in primary T cells (Fig 9). Scores were calcu-
lated using the following formula:
Score ¼
Mean of each value
Mean of maximum value
� 10
Based on data from Fig 9A, the promoter strengths for short transcript were in the follow-
ing order: EF-1 > RPBSA > hPGK > CMV. For long transcripts carrying another accessory
gene (Mcl-1) in addition to GFP-CAR, the promoter strengths were as follow: EF-1 > CMV >
hPGK> RPBSA (Fig 9B). Taken together, EF-1 displayed the best function in driving both
short and long RNA transcripts. However, if the insert size between two LTR increases beyond
10 kb, other promoters could be considered to mitigate drops in the viral titre and transduc-
tion efficiency [30]. In our study, the largest insert utilised was 6.8 kb.
Fig 6. Comparison of four constructs for transcribing short RNA. The eGFP gene linked to FMC63 CD19 CAR was cloned under the control of the four promoters.
(a) Titration and (b) transduction efficacy among four constructs (c) Western blot analysis for GFP and CD19 CAR level of HEK293T cells transduced at MOI 2:1 plus
1 μg/mL polybrene (d) Quantification representation of western blot using Image Studio Lite. Bar graph values represent the mean values ± SD from three different
repeats. (e) GFP and f) CD19 CAR expression in CAR T cells by flow cytometry.
https://doi.org/10.1371/journal.pone.0232915.g006
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Fig 7. Functional analysis of CAR T cells expressing short RNA. (a) CD69 activation assay was carried out 18 hours after incubation of the four types of promoter-
driven CD19 CAR T cells with CD19+ HEK293T cells. (b, c) Cytokine release assay for secretion of (b) IL-2 and (c) IFN-γ. CAR T cells were co-cultured with CD19+
HEK239T and supernatant were collected after 24 h. (d) Luciferase based cytotoxicity assay assessed 24, 48 and 72 h after incubation of CD19 CAR T cells with CD19+
HEK293 cells stably expressing the firefly luciferase gene. The graph shows the percent of cell viability, calculated by dividing the luciferase of test wells divided by the
luciferase signal of untreated HEK293T.
https://doi.org/10.1371/journal.pone.0232915.g007
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Discussion
In this study, we compared four promoters for optimal expression of long RNA encoding mul-
tiple gene products in CAR T cells. Our results suggest that promoter requirements are strin-
gent for driving long RNA, and that EF-1 is the best choice for driving short or long RNA in
CAR T cells, similar to an early study [31]. In contrast to the poor results obtained here for
Fig 8. Structure and bioinformatic analysis of the four different promoters. (a) Structure of a typical eukaryotic core promoter and the position of core elements within
a promoter were investigated in the four different promoters (b) Total number of core promoter elements predicted by YAPP, GPMiner and ElemeNT algorithms (details
provided in Table 1) (c) The number of TF binding sites in promoters sequenced analyzed by AliBaba2.1, PROMO and GPMiner programs d) Enrichment of sixteen TFs
highly-expressed in T cells in the four promoters. The data shows the percentage of total number predicted binding sites for the four promoters.
https://doi.org/10.1371/journal.pone.0232915.g008
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hPGK and RPBSA in driving long and complex RNA, these same promoters demonstrated lit-
tle difference to the so-called strong promoters CMV and EF-1 in lentiviral based systems driv-
ing shorter RNA sequences, such as CAR and fluorescent reporter genes (see Fig 6E)–
consistent with other studies [1, 8, 9, 21, 23].
To determine the functional role of additional accessory genes expressed in long constructs,
we utilised Mcl-1, a bcl2 family member with an essential role in T cell development, mito-
chondrial function and lifespan. To our knowledge, this is the first study to demonstrate that
Mcl-1 is a suitable candidate for enhancing CAR T cell performance [15, 16]. Expression of
mcl1 in a position distal to the CAR allowed protection from CD95-induced cell death. Inter-
estingly, although protection was noted with all promoters, EF-1 driven-cassettes consistently
gave the best protection. The fact that protection was observed with Mcl-1 driven by the
weaker promoters RPBSA and hPGK contrasts with the stringent requirement for a strong
promoter to drive CAR expression for optimal cytotoxicity and cytokine release.
Our analysis of promoter motifs demonstrates clear differences in transcription factor bind-
ing sites and core promoter elements between the strong (EF-1 and CMV) and weaker (hPGK
and RPBSA) promoters. Although not all the predicted core promoter elements might be func-
tional in primary T cells, the high number of the core elements can correlate with the strength
of the promoter [26]. In addition EF-1 and CMV predominantly enriched for TFs specific or
highly expressed in T cells [27–29, 32, 33] such as GATA3, NFATc3, NF-kB, AP1 and c-Jun,
The number of transcription factor and core promoter element sites predicted within the pro-
moters may provide some explanation for the ability of the CMV and EF-1 promoters to direct
long mRNA expression (Fig 1, S1 Data). However, it should be noted that EF-1 is almost twice
the length of the other promoters, therefore has the potential to house more TFBS and core
promoter elements.
The activity of promoters with predicted ’ubiquitous’ expression, such as the four studied
here, will still depend greatly on the lineage of the host cell [34]. However, EF-1 promoter was
found to be active and resistant to silencing in cells where other viral promoters may become
silenced [35]. Therefore, future work will be required to determine if the superior performance
Table 1. The number of core promoter elements and TF binding sites predicted for four promoters with YAPP, GPMiner and ElemeNT algorithms.
Promoter Size (bp) Core prompter elements
GC box CAAT box BRE TATA box Inr MTE DPE Bridge
CMV 617 3 4 - 2 10 - 6 12
EF-1 1192 11 - 2 2 7 2 24 22
hPGK 516 8 2 3 - 3 2 12 10
RPBSA 612 3 1 1 2 3 - 10 8
https://doi.org/10.1371/journal.pone.0232915.t001
Table 2. Bioinformatic tools used for studying promoter structure and TF binding sites.
Program Promoter element CpG island TF binding sites
YAPP ✓ - -
GPMiner ✓ ✓ ✓
ElemeNT ✓ - -
AliBaba2.1 - - ✓
PROMO - - ✓
EMBOSS Cpgplot - ✓ -
CpGFinder - ✓ -
https://doi.org/10.1371/journal.pone.0232915.t002
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of EF-1 and CMV in expressing long RNA sequences can be extrapolated to other cell primary
cell types.
In our study, the lower expression of CAR within a long mRNA transcript driven by the
RPBSA and hPGK translated into lower lytic function for a Her2-expressing tumor cell line.
Given the profound effects that CAR density has on T cell activation, our results will be useful
for developing strategies to titrate CAR expression at the T cell. Promoter choice would be
expected to be a critical consideration for controlling the levels of surface expressed CAR,
which in turn would dictate the level of T cell activation, lytic function, as well as undesirable
tonic (antigen-independent) signaling [2, 36–39]. Optimal CAR expression will be critical for
minimizing tonic signaling, while optimizing signal transduction during antigen-specific sig-
naling. In addition, lowering the level of CAR expression could contribute desirable avidity
effects to T cell recognition of antigen, thereby minimizing CAR T cell activation by tumor-
associated antigen on self-tissue [14]. Interestingly, despite CMV inducing a noticeably higher
level expression of GFP, CAR and Mcl-1 in HEK293T cells, as compared to EF-1, functional
analysis showed superior activation of primary human CAR T cells driven by EF-1 in terms of
cytokine release and cytotoxicity against MCF-7. EF-1 is enriched in binding sites of TFs
expressed in T cells (Fig 8C), suggesting a mechanism for the increased EF-1 activity in T cells,
as compared to HEK293T cells. In addition functional experiments demonstrated that EF-1
Table 3. The number of CpG islands and Sp1 binding sites within selected promoters.
Promoter Number of CpG islands Position Number of Sp1 binding sites
EF-1 1 604–868 17
CMV 0 - -
hPGK 1 54–392 16
RPBSA 1 194–405 8
https://doi.org/10.1371/journal.pone.0232915.t003
Fig 9. Heat map charts representing the strength of each promoter in functional assays for a) short transcripts and b) long transcripts. Each promoter was assigned a
score from 0–10 based on the data obtained from primary T cell experiments, and values were calculated by dividing mean of each data set by mean of the maximum
value obtained in the experiment and multiplied by ten.
https://doi.org/10.1371/journal.pone.0232915.g009
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driven expression of Mcl-1 provided the best protection of CAR T cells to AICD induced by
CD95L.
A further consideration for promoter choice is possible silencing in vivo. In particular,
CMV can be silenced after a period of weeks post-transduction [34, 40]. However, the effects
of promoter silencing might be overshadowed by the long term CAR T cell downregulation
that occurs in a methylation-independent fashion following CAR triggering both in vitro and
in vivo [14, 41, 42]. In conclusion, the study of long mRNA production will improve our ability
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A B S T R A C T
Mcl-1 is a member of the Bcl-2 anti-apoptotic protein family with important roles in the development, lifespan
and metabolism of lymphocytes, as well as oncogenesis. Mcl-1 displays the shortest half-life of all Bcl-2 family
members, with miRNA interference and proteasomal degradation being major pathways for Mcl-1 down-
regulation. In this study, we have identified a previously undescribed control mechanism active at the RNA level.
A divergently transcribed lncRNA LOC107985203 (named here mcl1-AS1) negatively modulated Mcl-1 ex-
pression resulting in downregulation of Mcl-1 at both mRNA and protein level in a time-dependent manner.
Using reporter assays, we confirmed that the mcl1-AS1 lncRNA promoter was located within Mcl-1 coding
region. We next placed mcl1-AS1 under tetracycline-inducible control and demonstrated decreased viability in
HEK293 cells upon doxycycline induction. Inhibition of mcl1-AS1 with shRNA reversed drug sensitivity.
Bioinformatics surveys predicted direct mcl1-AS1 lncRNA binding to Mcl-1 transcripts, suggesting its mechanism
in Mcl-1 expression is at the transcriptional level, consistent with a common role for anti-sense transcripts. The
identification of a bi-directional promoter and lncRNA controlling Mcl-1 expression will have implications for
controlling Mcl-1 activity in cancer cells, or for the purpose of enhancing the lifespan and quality of anti-cancer T
lymphocytes.
1. Introduction
Myeloid cell leukemia factor 1 (Mcl-1) belongs to the Bcl-2 anti-
apoptotic family which inhibit apoptosis by binding and interrupting
the formation of Bak / Bax dimers on the mitochondrial outer mem-
brane (Thomas et al., 2010). Mcl-1 has tissue specific expression and
apart from other Bcl-2 family members has a unique roles in physio-
logical and pathological conditions (Thomas et al., 2010). Mcl-1 de-
regulation has been reported in both hematological (Gouill et al., 2004)
and solid cancers (Fleischer et al., 2006) and its overexpression is as-
sociated with chemotherapy resistance (Song et al., 2005). In the im-
mune system, Mcl-1 contributes to T lymphocyte viability, respiration
and memory cell formation (Kim et al., 2016; Morciano et al., 2016).
Due to the potential importance of control of Mcl-1 to activity and
lifespan of chimeric antigen receptor (CAR) T cells, we investigated
mechanisms of Mcl-1 control with a view to modulating these for en-
hanced anti-cancer responses.
Mcl-1 expression in lymphocytes is rapidly induced by T cell re-
ceptor signaling and during peak cell expansion (Wensveen et al., 2010;
Tripathi et al., 2013). However, Mcl-1 displays the lowest stability of all
Bcl-2 family members with a half-life of< 1 h (Liu et al., 2005;
Senichkin et al., 2020). Mcl-1 expression is controlled by a number of
non-coding RNA (Senichkin et al., 2020). In addition, post-translational
control is mediated by caspases and Mcl-1 PEST domains that undergo
phosphorylation to induce proteasomal degradation (Senichkin et al.,
2019).
lncRNAs are a heterogeneous class of non-coding RNAs (ncRNAs)
classified as ≥200 bp in length to distinguish them from small ncRNAs
(e.g. rRNAs, tRNAs, microRNAs (Mercer et al., 2009). lncRNAs are
normally expressed in a time and tissue-specific manner, and display a
greater tissue-specificity than mRNAs (Rutenberg-Schoenberg et al.,
2016). lncRNAs are implicated in pathological and biological processes
such as cancer, development, proliferation and immunity (Chen et al.,
2017; Rad et al., 2017; Kopp and Mendell, 2018). For example, lncRNA
MALAT1 plays an important role in normal biological and physiological
process such as RNA splicing, transcriptional regulation of genes, neural
development as well as its oncogenic role in development of various
cancers (Zhang et al., 2017).
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In addition to classification based on function, lncRNAs can also be
categorized based on their location in the genome (Laurent et al.,
2015). Long intergenic noncoding RNAs (lincRNAs) are expressed from
intergenic regions and do not overlap with neighboring coding genes.
On the other hand, natural antisense transcripts and intronic lncRNAs
are expressed from coding regions (intron or exon). Lastly, antisense
(AS) are the result of divergent transcription (Mercer et al., 2009;
Atianand et al., 2017). Large portions of lncRNAs are antisense tran-
scripts which usually exert their regulatory function on neighboring
genes at different stages of transcription and translation (Su et al., 2010;
Magistri et al., 2012). Up to 40% of human coding genes may be
regulated by antisense transcripts (Chen et al., 2004; Werner et al.,
2009). Antisense transcripts have variety of functions in biological
processes, such as development, growth, migration and apoptosis (Lin
et al., 2016).
Among the antisense transcripts, the ones derived from promoters of
coding-genes are abundant in organisms from bacteria, plant and
mammalians (Wei et al., 2011). lncRNAs are often transcribed near the
transcription start site (TSS) and appear to be a widespread feature of
active promoters (Seila et al., 2008; Sigova et al., 2013). However, the
role of most of these antisense transcripts in regulation of their neigh-
boring gene is unknown.
Several microRNAs such as miR-125b (Gong et al., 2013), miR-29
(Mott et al., 2007) and miR-101 (Su et al., 2009) target the Mcl-1 3́ UTR
and downregulate its expression at a post-transcriptional level
(Senichkin et al., 2020). However, the regulation of Mcl-1 expression by
antisense transcripts has not yet been reported.
In the current study, we demonstrate that mcl1-AS1 lncRNA (NCBI
Gene ID: 107985203) is expressed from the Mcl-1 proximal promoter
and regulates Mcl-1 expression. Quantitative and functional studies
showed that mcl1-AS1 negatively regulates Mcl-1 expression at both
mRNA and protein levels in a time dependent manner, and impacts
upon sensitivity to a chemotherapeutic agent. Using reporter assays, we
confirmed that the mcl1-AS1 lncRNA promoter is located within Mcl-1
coding region. Bioinformatics surveys predicted that mcl1-AS1 lncRNA
could bind Mcl-1 mRNA, suggesting a mechanism in Mcl-1 control at
the transcriptional level, a common feature of most AS (Mercer et al.,
2009; Werner et al., 2009; Guil and Esteller, 2012).
2. Experimental procedures
2.1. Cloning and plasmid construction
Mcl1-AS1 lncRNA (574 bp of NCBI reference sequence:
XR_001738230.2) were synthesized as a gene block (gBlock, IDT) and
cloned into a tetracycline inducible Sleeping beauty plasmid (pSBtet-
GP) using asymmetric SfiI restriction sites (Kowarz et al., 2015). For
screening of the potential promoter region for mcl1-AS1, fragments of
Mcl-1 were amplified from human genomic DNA (gDNA) of PBMCs
using primers provided in the supplementary data Table S1. These
genomic fragments were cloned into pSB-bi-RFP-luciferase or dual re-
porter pSB-GFP-RFP plasmids (developed in our laboratory from Ko-
warz et al. (Kowarz et al., 2015); see Figs. 5 and 6) using NheI and NcoI
restriction enzymes.
2.2. Short hairpin RNAs (shRNAs) design and construction
Five shRNAs were designed using three different software: shRNA1
& 2 were designed by Invitrogen Block-iT (https://rnaidesigner.
thermofisher.com/rnaiexpress/), shRNA3 & 4 via WI siRNA (http://
sirna.wi.mit.edu/) and sh-RNA5 using Sfold software (http://sfold.
wadsworth.org/cgi-bin/sirna.pl). All shRNAs were synthesized as
sense and antisense oligonucleotides (IDT) with SfiI overhangs, an-
nealed as previously described (Rad et al., 2015) and cloned into
Sleeping Beauty-based, tetracycline-inducible vector pSBtet-GP.
shRNAs sequences are listed in supplementary data Table S2.
2.3. Genomic DNA and RNA extraction, cDNA synthesis and qPCR
gDNA was extracted using QIAamp DNA Mini Kit (Qiagen) ac-
cording to the manufacturer's protocol. Total RNA was extracted using
NucleoSpin® RNA Plus kit (MACHEREY-NAGEL) and was reverse
transcribed to cDNAs by PrimeScript™ RT Reagent Kit (Takara), ac-
cording to manufactures protocols. Next, 1 µl of cDNA was used as a
template in the qPCR reaction with Luna® Universal qPCR Master Mix
(NEB). The expression levels of mcl1-AS1 and Mcl-1 (isoform L) were
measured by comparative CT (2-ΔΔct) method and normalized to β-actin
as a housekeeping gene. Primer sequences are provided in supple-
mentary data Table S1.
2.4. Cell culture and transfection
Human embryonic kidney 293 (HEK293) cells were cultured in
Dulbecco’s modified eagle’s medium (DMEM; Gibco, Auckland, NZ)
supplemented with 10% fetal bovine serum (Pan Biotech, Aidenbach,
Austria) and Pen-Strep (100 U/ml penicillin and 100 µg/ml strepto-
mycin). Cells were maintained in 5% CO2 at 37 °C.
For transfection, a total of 2 × 105 HEK293 cells were cultured per
well in a 24-well plate and transfected with Sleeping Beauty transfer
and transposase plasmids (a ratio of 5:1 SB transfer plasmid to trans-
posase plasmid) using Lipofectamine 3000 following the manufacturer’s
protocol. After 24 h of transfection, media was replaced with fresh
DMEM containing 10% FBS and cells maintained at 37 °C with 5% CO2.
For induction of mcl1-AS1, shRNAs or empty plasmid (control) cells
were treated with 5 µg/ ml of doxycycline.
2.5. Western blot
Cells were lysed using RIPA lysis buffer (0.02% azide, 150 mM
NaCl, 0.25% CHAPS, 0.5% Triton-X100, 100 mM Tris, pH 8.0 along
with freshly added complete protease inhibitor; Roche #11–697-
498–001). The total protein in the cell lysate was determined by
Pierce™ BCA Protein Assay Kit (Thermo Fisher). A total of 20 µg of the
protein was separated by Bolt 4–12% Bis-Tris Plus gels (Invitrogen) and
transferred onto Nitrocellulose membranes (Protran, Amersham,
Auckland, NZ). Membranes were blocked with 0.5% sodium caseinate
(Arotech, Wellington, NZ) / PBS (Sigma) and was probed with rabbit
anti-Mcl-1 antibody (Abcam # ab28147) at 1:1000 dilution as primary
antibody and donkey anti-rabbit IgG DyLight 800 (SA5-10044) in
1:10000 dilution was used as secondary antibody. Mouse monoclonal β-
actin at a concentration of 0.5 mg/ml was used as a primary antibody
(Sigma-Aldrich #A2228) and Goat anti-mouse IgG DyLight 680
(Thermofisher #A3274) was used as secondary antibody. The mem-
brane was scanned using an Odyssey Fc Imaging System (LI-COR
Biosciences, Germany) and was analyzed using Image Studio Lite soft-
ware.
2.6. Resazurin assay
Cell viability was measured by resazurin assay (Sigma-Aldrich).
Briefly, cells were incubated with resazurin 1/10 diluted stock and
incubated for 4 h at 37 °C. Supernatants (100 µl) were transferred to a
black 96-well plate and fluorescence measured using a Varioskan™ LUX
multimode microplate (Thermo Fisher).
2.7. Bioinformatics analysis
All the software used in this study for structure prediction, position
in genome, alignments, RNA/RNA and TF binding prediction are listed
in Table 1.
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2.8. Statistical analysis
All experiments were carried out at least three times, presented as
mean ± standard deviation (SD) and analyzed by student T test and
ANOVA test with Bonferroni post-test correction. The P values
of ≤ 0.05 were considered statistically significant. (* P < 0.05, **
P < 0.01, *** P < 0.001, **** P < 0.0001)
3. Results
3.1. Characterization of mcl1-AS1 lncRNA and Mcl-1 genes
Mcl-1 is located on chromosome 1 between two lncRNAs expressed
from its upstream (mcl1-AS1 lncRNA) and downstream (lnc-MCL1-2)
regions (Fig. 1). The proximal promoter of Mcl-1 has binding sites for
transcription factors, including STAT5, SRE, Ets, SP1, CRE-BP and NF-
ƙB (Akgul et al., 2000). The Mcl-1 TSS is either located 80 bp upstream
of the ATG translation initiation codon (ACTTC) (Akgul et al., 2000), or
according to the DBTSS, is at position 150579738 (GCGCAA) (Fig. 1).
At around exon 1 and 2, Mcl-1 gene shows enrichment for promoter
marks such as H3K4me3, H3K27Ac and DNase I hypersensitivity, sug-
gesting that mcl1-AS1 lncRNA promoter is located in the intragenic site
of the Mcl-1 open reading frame (ORF) (Supplementary Figure S1 & 2).
Mcl1-AS1 lncRNA is expressed from a primary transcript encom-
passing two fused exons to create a 574 bp transcript (joining positions
1…404 and 24305…24474, NCBI Gene ID: 107985203). RNAseq data
from normal tissue shows that mcl1-AS1 lncRNA is expressed in most
tissues at low levels, with a higher level of expression in skin cells
(Supplementary Figure S3).
3.2. mcl1-AS1 lncRNA regulates Mcl-1 expression at both mRNA and
protein level
Firstly, a gain-of-function study was carried out to see the effect of
mcl1-AS1 lncRNA up-expression on endogenous expression of Mcl-1. A
doxycycline inducible sleeping beauty system was used in this study so
that the expression of mcl1-AS1 lncRNA could be controlled accord-
ingly. The expression level of mcl1-AS1 lncRNA upon treatment with
5 µg/ml of doxycycline was measured by qPCR to ensure inducible
expression of mcl1-AS1 lncRNA (Fig. 2A). lncRNAs are involved in
regulation of gene expression both at mRNA and protein level by
binding to either transcriptional or mRNA maturation machinery. To
assess the effect of mcl1-AS1 overexpression on Mcl-1 at protein level
western blotting was performed on HEK293 cells at 24 to 72 h after
mcl1-AS1 lncRNA induction by doxycycline. Induction of mcl1-AS1 did
not alter Mcl-1 level at 24 and 48 h, but Mcl-1 levels were significantly
downregulated at 72 h post-induction (Fig. 2 B&C). Similarly, mcl1-AS1
overexpression led to a decrease in Mcl-1 mRNA levels (Fig. 2 F),
confirming negative regulation of mcl1-AS1 lncRNA of Mcl-1 expres-
sion at both mRNA and protein level.
Next, five shRNAs targeting different regions of mcl1-AS1 lncRNA
were tested (Fig. 2D). To study the effect of mcl1-AS1 downregulation
on endogenous Mcl-1 by shRNA, Mcl-1 expression was measured at
both mRNA and protein levels following 72 h doxycycline induction of
Table 1
Name, application and URL of bioinformatics software used in this study.
Name Application URL
NCBI Gene Position, sequence and gene expression https://www.ncbi.nlm.nih.gov/gene
UCSC genome Browser Position, sequence and histone mark https://genome.ucsc.edu/
DBTSS TSS prediction and histone mark https://dbtss.hgc.jp/
LNCpedia version 5.2 Position, sequence and structure https://lncipedia.org/
YAPP Promoter’s element characterization http://www.bioinformatics.org/yapp/cgi-bin/yapp.cgi
PROMO TF binding site prediction http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3
AliBaba2.1 TF binding site prediction http://gene-regulation.com/pub/programs/alibaba2/
Geneious Prime® Primer design, ClustalW sequence alignment https://www.geneious.com/academic/
RNAfold Secondary structure prediction http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi
RNAalifold Structure alignment http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAalifold.cgi
LocARNA Sequence-structure-based alignment http://rna.informatik.uni-freiburg.de/LocARNA/Input.jsp
IntaRNA RNA/RNA interaction prediction http://rna.informatik.uni-freiburg.de/IntaRNA/Input.jsp
RNAup RNA/RNA interaction prediction http://rna.tbi.univie.ac.at//cgi-bin/RNAWebSuite/RNAup.cgi
Fig. 1. Characterization of human Mcl-1 gene. Mcl-1 is located in chromosome 1 and has three exons (red boxes). The Mcl-1 proximal promoter contains a 103 bp
CpG island. Two lncRNAs are driven from Mcl-1 gene. Mcl1-AS1 lncRNA is expressed from proximal promoter of Mcl-1 (classified as an 'anti-sense promoter') and lnc-
MCL1-2 is expressed from the Mcl-1 3′ UTR and acts as ceRNA. Recently, lnc-ADAMTSL4 family which comprises 13 uncharacterized lncRNAs that may overlap the
Mcl-1 promoter and enhancer. The first exon / intron of Mcl-1 shows enrichment for promoters marks such as H3K4me3, H3K27Ac and DNase I hypersensitivity
according to DBTSS and UCSC databases. For more details please see Supplementary Figure S1 & 2. (For interpretation of the references to color in this figure legend,
the reader is referred to the web version of this article.)
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shRNA expression. As shown in Fig. 2 E & F, downregulation of mcl1-
AS1 lncRNA resulted in upregulation of endogenous Mcl-1 expression at
72 h. These results confirm that the overexpression of mcl1-AS1 lncRNA
downregulates Mcl-1. To rule out that doxycycline was affecting mcl1-
AS1 expression we tested the effect of 5 µg/ml of doxycycline on
lncRNA expression, but observed no major perturbation in the expres-
sion of mcl1-AS1 (Supplementary Figure S4).
3.3. Regulation of Mcl-1 through mcl1-AS1 lncRNA affect cell viability of
HEK293 cells
Mcl-1 is an anti-apoptotic protein that impacts on cell viability by
modulating mitochondria function, particularly through its ability to
stabilise membrane potential by interfering with Bak/ Bax- mediated
pore formation in the mitochondrial outer membrane (Morciano et al.,
2016). Previous studies have shown that downregulation of Mcl-1 by
microRNAs, such as miR-101 and miR-193b sensitized cancer cells to
doxorubicin, emphasizing on the role of Mcl-1 in cell survival (Long
et al., 2015; He et al., 2016). HEK293 cells transfected with mcl1-AS1
or sh-mcl1-AS1s were treated with 10 µg/ml of doxorubicin, equivalent
to the IC50 (Supplementary Figure S5). As shown in Fig. 3, altering Mcl-
1 levels, by either overexpression or downregulation of mcl1-AS1
lncRNA, affects cellular sensitivity to doxorubicin.
3.4. Identification and characterization of mcl1-AS1 lncRNA promoter
Since the mcl1-AS1 lncRNA is complementary to the Mcl-1 proximal
promoter, its promoter is likely present within the Mcl-1 coding region.
As discussed above, exon 1 to exon 2 of Mcl-1 shows enrichment for
promoter marks (Fig. 1). To confirm the activity of the predicted mcl1-
AS1 promoter the Mcl-1 proximal to the second intron of Mcl-1 or
fragments thereof, were cloned upstream of luciferase according to
their orientation in the genome to determine if they act as a promoter
for mcl1-AS1 or Mcl1 (Fig. 4 A). Both the Mcl-1 proximal promoter and
the exon1-intron1 fragment showed promoter activity in inducing the
luciferase gene 2-fold (P < 0.0001; Fig. 4B).
To further validate the exon1-intron1 as mcl1-AS1 lncRNA
Fig. 2. Overexpression and knockdown of mcl1-AS1 lncRNA alter Mcl-1 expression. (A) Overexpression of mcl1-AS1 lncRNA in Tet-On SB system. Doxycycline (5 µg
/ ml) was added to induce mcl1-AS1 lncRNA. (B and C) Western blot of enforced expression of mcl1-AS1 lncRNA resulting in downregulation of Mcl-1 72 h post-
induction. (D) The ability of synthetic shRNAs to inhibit mcl1-AS1 expression, as determined by qPCR assay. (E) Western blot analysis of Mcl-1 expression 72 h after
transfection of HEK293 cells with shRNAs against mcl1-AS1. (F) Mcl-1 expression level quantified by qPCR, after upregulation or downregulation of mcl1-AS1
lncRNA. shRNA2 was used in qPCR experiment as it showed the most powerful shRNA. Control in all experiments is HEK293 cells transfected with empty plasmid and
treated with 5 µg / ml of doxycycline.
Fig. 3. Modulation of endogenous level of Mcl-1 through mcl1-AS1 lncRNA
alters the sensitivity of HEK293 cells to doxorubicin. HEK293 cells were in-
duced with 5 µg / ml of doxycycline to enhance (Tet-On-expressed mcl1-AS1)
or downregulate (Tet-On expressed mcl1-AS1 shRNA-2) mcl1-AS1 lncRNA ex-
pression. HEK293 was treated with 10 µg / ml of doxorubicin at 48 h, and cell
viability measured using resazurin assay at 72 h post doxycycline induction (see
also Fig. S4).
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promoter, this region was cloned into a SB-based dual-reporter plasmid
(Fig. 5 A). This dual reporter allowed us to determine the promoter
direction according to its orientation in the genome. Therefore, if the
region has promoter activity for the sense strand in the genome, GFP
should be expressed and if activity is directed to the anti-sense strand
RFP will be expressed. As Fig. 5B & C show, the proximal promoter of
Mcl-1, located in the antisense strand, expressed RFP. The exon1-in-
tron1 fragment drove GFP expressing, confirming this region as mcl1-
AS1 lncRNA promoter. Weaker expression of GFP by the second exon
and intron could be explained by the fact that this region is either an
enhancer, or an upstream promoter element, resulting in only weak
reporter expression, rather than acting as a core promoter.
To further characterize the mcl1-AS1 lncRNA promoter, we utilized
bioinformatics tools to identify transcription factor binding sites (TFBS)
and core promoter elements (Fig. 6). UCSC genome browser and
PROMO software predicted enrichment for TFs such as STAT, C/EBP,
NF-κB, Sp1 and Ets within the first exon and intron, similar to those
binding the Mcl-1 promoter (Akgul et al., 2000). The mcl1-AS1 lncRNA
core promoter contains a TATA box motif, similar to the one has been
reported for Mcl-1 gene (Tullai et al., 2007).
3.5. mcl1-AS1 lncRNA is similar to one of the members of the lnc-
ADAMTSL4 lncRNAs family
LNCipedia browser includes a new class of lncRNAs, lnc-
ADAMTSL4, that vary in length (from 213 bp to 12066 bp) and are
expressed from the Mcl-1 regulatory region (Supplementary Table S3 &
4). This family contains 13 uncharacterized lncRNAs. ClustalW align-
ment of mcl1-AS1 lncRNA against lnc-ADAMTSL4 family revealed
mcl1-AS1 lncRNA is 100% similar to lnc-ADAMTSL4-5:1 (Table 2).
Furthermore, structure based and sequence–structure-based alignments
confirmed high similarity between mcl1-AS1 lncRNA and ADAMTSL4-
5:1 (Fig. 7 A & B). In fact, ADAMTSL4-5:1 (418 bp) is shorter version of
mcl1-AS1 lncRNA (574 bp) by 156 bps, suggesting that either both
transcripts are same transcript with small differences in length (due to
different sources of RNA-seq data) or mcl1-AS1 lncRNA is a new
member of this family. Further information about the ADAMTSL4 fa-
mily is provided in Supplementary Table S3 & 4.
3.6. mcl1-AS1 lncRNA is predicted to bind to Mcl-1 mRNA
lncRNAs can regulate genes at the transcriptional level by directly
binding to the regulatory regions of gene, TFs, chromatin remodeling
proteins and transcriptional machinery (Magistri et al., 2012; Zhang
et al., 2017). At post-transcriptional level, they can bind to various RNA
Fig. 4. Identification of the potential promoter region for mcl1-AS1 lncRNA within Mcl-1 coding regions. (A) Schematic illustration of the luciferase reporter
constructs used to investigate the promoter activity of different regions of Mcl-1 gene. The luciferase plasmids lack the minimal promoter to reduce background
expression. (B) Luciferase assay for HEK293 cells transfected with reporter plasmids carrying different Mcl-1 regions.
Fig. 5. Verification of mcl1-AS1 lncRNA promoter
using a dual-reporter system. (A) Schematic illustra-
tion of the dual-reporter promoter for determining
the promoter orientation relative to its position in the
genome. Mcl-1 expresses from anti-sense strand
while mcl1-AS1 lncRNA expresses from sense strand.
Transcription from the antisense strand will result in
RFP expression, while sense transcription results in
GFP expression. (B) Fluorescent microscopy and (C)
flow cytometric analysis of HEK293 cells transfected
with dual-reporter plasmids carrying different region
of Mcl-1 gene. Induction of GFP with the first exon-
intron region verifies this sequence as the mcl1-AS1
lncRNA promoter in the sense orientation.
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binding proteins or mRNA causing changes in stability, polyadenyla-
tion, splicing, exportation and subcellular localization of the mRNA (He
et al., 2019). We looked for a possible direct interaction between mcl1-
AS1 and Mcl-1 mRNA using two different software. IntaRNA predicted
the interaction between mcl1-AS1 has different nucleotides ranged at
position 114–176 that could bind to the Mcl-1 mRNA nucleotides from
613 to 682 (Fig. 8A). Furthermore, RNAup software predicted direct
interactions of Mcl-1 and mcl1-AS1 at different positions compared to
those predicted by IntaRNA (Fig. 8B). Secondary structure of mcl1-AS1
lncRNA predicted by RNAfold is shown in Fig. 8C (see also Fig. 9).
4. Discussion
This study has identified the regulation of Mcl-1 expression (ex-
pressed on the conventional anti-sense strand) by a divergent lncRNA
expressed from the (conventional sense strand) Mcl-1 promoter (see
Fig. 9). Activity of the mcl1-AS1 core promoter was demonstrated using
reporter genes. Inducible overexpression of the mcl1-AS1 lncRNA de-
creased the abundance of endogenous Mcl-1 transcripts, confirming a
Fig. 6. Prediction of TF-binding sites within the mcl1-AS1 lncRNA promoter. TF binding sites were predicted using PROMO and AliBaba2.1 (both using different
versions of the TRANSFAC database). The TATA box was predicted using YAPP software.
Table 2
ClustalW alignment of mcl1-AS1 lncRNA versus lnc-ADAMTSL4 family
members.
Names % Pairwise Identity
mcl1-AS1 vs lnc-ADAMTSL4-1:1 40.4%
mcl1-AS1 vs lnc-ADAMTSL4-1:2 40.5%
mcl1-AS1 vs lnc-ADAMTSL4-2:1 43.1%
mcl1-AS1 vs lnc-ADAMTSL4-4:1 42.1%
mcl1-AS1 lnc-ADAMTSL4-5:1 100%
mcl1-AS1 vs lnc-ADAMTSL4-6:1 40%
mcl1-AS1 A vs lnc-ADAMTSL4-7:1 43%
mcl1-AS1 vs lnc-ADAMTSL4-7:3 41.3%
mcl1-AS1 vs lnc-ADAMTSL4-7:4 43%
mcl1-AS1 vs lnc-ADAMTSL4-7:5 43%
mcl1-AS1 vs lnc-ADAMTSL4-7:6 43%
mcl1-AS1 vs lnc-ADAMTSL4-7:7 43%
mcl1-AS1 vs lnc-ADAMTSL4-7:8 48.5%
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functional interaction between these RNA species. Conversely, shRNA
mediated knock-down of endogenous mcl1-AS1 led to a detectable in-
crease in Mcl-1.
Mcl-1 expression in lymphocytes is rapidly induced by triggering T
cell receptor signaling 24 h after activation with CD3 and CD28 anti-
bodies followed by rapid downregulation 48 and 72 h after activation
(Wensveen et al., 2010; Tripathi et al., 2013). Consistent with these
findings, Mcl-1 and mcl1-AS1 RNA showed divergent expression in
primary T cells upon CD3 and CD28 stimulation (Supplementary Figure
S6).
It is not at this stage clear how mcl1-AS1 lncRNA influences Mcl-1
expression. Direct interaction of mcl1-AS1 with Mcl-1 mRNA was pre-
dicted with some certainty using a bioinformatics approach. It is
possible that such an interaction could lead to transcriptional stalling,
mRNA degradation or interference with the nuclear export of spliced
Mcl-1 mRNA (Kopp and Mendell, 2018; He et al., 2019). Processing and
export of mcl1-AS1 or fragments thereof, could theoretically impact
upon protein translation in the cytoplasm. Another possibility is that
mcl1-AS1 lncRNA is expressed from the Mcl-1 promoter and through its
complementarity to Mcl-1 proximal promoter, mcl1-AS1 lncRNA in-
teracts with the Mcl-1 regulatory region to interrupt Mcl-1 transcrip-
tion, or to induce alternate splicing to pro-apoptotic Mcl-1S. Like most
lncRNAs, mcl1-AS1 is predicted to form a stem-loop structure which
could bind Suz12, a core component of the polycomb repressive com-
plex 2 (PRC2). Such an RNA stem-loop sequence at the 5′ end of genes
might allow histone H3 Lys27 trimethylation (H3K27me3) to inhibit
Fig. 7. Sequence-structure alignment between mcl1-AS1 lncRNA and lnc-ADAMTSL4-5:1: (A) Visualization of the local sequence–structure-based alignment relia-
bility (STAR) between mcl1-AS1 lncRNA and lnc-ADAMTSL4-5:1 using LocARNA-P Reliability Profile (STAR Profile Plot). The profile consists of the reliabilities for
each single alignment column. The dark regions indicate structure reliability, the light regions represent sequence reliability, and the thin line shows the combined
column-reliability. The column-wise reliabilities are computed as sum-of-pairs over match probabilities, which are computed by LocARNA-P. (B) The consensus
structure of the alignment, as predicted by RNAalifold, is shown in a 2D layout. Base pairs use the same color code as in “Colour and structure annotated alignment”.
The hue demonstrates sequence conservation, while saturation shows structural conservation. If gaps are present, lower case letters are used.
Fig. 8. Possible interaction between mcl1-AS1 lncRNA and Mcl-1 mRNA. (A) Possible interaction between mcl1-AS1 lncRNA and Mcl-1 mRNA at nucleotide position
114–176 of mcl1-AS1 with 613–682 nucleotides of Mcl-1 mRNA predicted by IntaRNA software. (B) Interaction at nucleotide mcl1-AS1 RNA (1492–502) with Mcl-1
mRNA (2940–2950), as predicted by RNAup software (C) Prediction of mcl1-AS1 secondary structure using RNAfold program.
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transcription (Guil and Esteller, 2012; Senichkin et al., 2020).
One possibility to modulate the influence of AS is the use of small
activating RNA (saRNA) that target promoter regions. These typically
bind to CpG islands to upregulate gene expression. Interestingly, saRNA
are slow to act compared to siRNA or miRNA, with maximal effects on
gene expression observed at 72 h (Li et al., 2006), similar to our ob-
served kinetics of shRNA-mediated relief of Mcl-1 inhibition by mcl1-
AS1. Although theoretically designed to bind to promoter regions,
saRNA have the potential to bind to AS transcripts expressed diver-
gently from gene promoters (Portnoy et al., 2011). Not surprisingly,
when we attempted to regulate Mcl-1 expression using a series of eight
saRNA targeted to the upstream Mcl-1 promoter region, these failed to
upregulate Mcl-1 gene expression (Supplementary Figure S7). Induction
of endogenous Mcl-1 expression may require 'shRNA' to directly bind
the AS transcripts and therefore effectively act as 'saRNA'.
Next generation RNA-sequencing data provided by projects such as
ENCODE (https://www.encodeproject.org/) and FANTOM5 (http://
fantom.gsc.riken.jp/5/) have led to the identification of thousands of
ncRNAs. For instance, the ENCODE release (version 25) revealed that
coding regions only account for ~2% of human genome, while
~75–90% of human genome is transcribed to ncRNAs, with an esti-
mation of 80% of them being functional in at least one cell type
(Laurent et al., 2015; Atianand et al., 2017). Furthermore, the
FANTOM5 project led to identification of 20,000 new lncRNAs, which
so far only a fraction have been characterized. The gap between raw
RNA-sequencing data and characterization of lncRNAs is made wider by
poor evolutionary conservation and limited tools to predict and func-
tionally validate their interaction with DNA, RNA and protein (Thiel
et al., 2019).
In addition to the transcription of coding sequences, antisense
transcription is also abundant at active promoters and may drive the
expression of short-lived, non-coding RNA (Seila et al., 2008; Werner
et al., 2009). While the functions of most of these antisense transcripts
are poorly known, previous studies suggest that AS may mainly play
repressive roles (Shearwin et al., 2005). The regulatory pathway un-
covered here further highlights the potential for anti-sense regulation of
cell survival pathways and its relevance to cancer and the immune re-
sponse (Zhang et al., 2017; Chen et al., 2018).
Among the lncRNAs, PVT1 and LINC00152 have been shown to
enhance Mcl-1 expression by increasing Mcl-1 mRNA stability or act as
competitive endogenous RNAs (ceRNAs) for miRNAs (Wu et al., 2017;
Chen et al., 2018). Both PVT1 and LINCOO152 are located in different
chromosomes (chromosome 8 and 2 respectively) than Mcl-1 (chro-
mosome 1), hence they are acting in trans in Mcl-1 regulation. The only
known lncRNA acting in cis in Mcl-1 regulation is lnc-MCL-1-2. Using in
silico analysis, Ronchetti et al. suggested that lnc-MCL-1-2, which is
expressed from Mcl-1 3́ UTR region, has potential binding sites for the
miR-17 family (miR-106a, miR-18a & b, miR-20a and miR-17) and
therefore could act as competing endogenous ceRNA to enhance Mcl-1
expression (Ronchetti et al., 2016).
Mcl1-AS1 may be a newly identified member of lnc-ADAMTSL4
lncRNA family, since ADAMTSL4-5:1 (418 bp) shares 100% similarity
with mcl1-AS1 lncRNA (574 bp). Either both are transcribed as the
same transcript, with small differences in length (possibly due to dif-
ferent sources of RNA-seq data), or mcl1-AS1 lncRNA is a new member
of this family. Future investigations are necessary to validate the latter
possibility.
Due to the critical role of Mcl-1 in both cancer and for T cell activity
and lifespan, it may be possible to regulate Mcl-1 expression by mod-
ulating the level of endogenous lncRNA identified here. This has po-
tential for enhancing susceptibility of cancer cells to chemotherapy, or
enhancing the activity of anti-cancer T cells for immunotherapy.
However, the diversity of potential transcripts expressed from the Mcl-1
regulatory region (see Fig. 1) highlights the extreme complexity of
control mechanisms for Mcl-1 expression. It is also possible that the
transcripts display tissue-specific roles in Mcl-1 regulation. Further re-
search will be required to determine the potential for these transcripts
in the regulation of Mcl-1 and neighboring genes.
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Fig. 9. Possible mechanisms for mcl1-AS1 lncRNA negative regulation of Mcl-1 expression. Direct interaction of mcl-AS1 lncRNA with Mcl-1 mRNA was predicted by
two different bioinformatic tools as shown. The interaction could result in interference of mcl1-AS1 with Mcl-1 mRNA maturation and exportation. In addition, since
mcl1-AS1 is complementary to the Mcl-1 promoter it is possible it directly interacts with the Mcl-1 regulatory region to interrupts transcription. LncRNAs with stem-
loop structures have been shown to recruit the repressory complexes at regulatory regions of genes to suppress their expression.
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